https://multiplemyelomahub.com daily 1 2026-04-05T04:07:26.180Z https://multiplemyelomahub.com/types weekly 0.8 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/types/malignancies weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/types/risk weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/types/chromosomal-aberrations weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/types/mm-related-mutations weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/types/pcl-like-mm weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/types/transplant-ineligible-mm weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics weekly 0.8 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/immune-modulators weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/targeted-protein-degraders weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/nuclear-receptor-agonists weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/proteasome-inhibitors weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/t-cell-engagers weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/car-t-cell-therapy weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/cellular-therapy weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/bcl-2-inhibitors weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/conjugated-antibodies weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/nuclear-export-inhibitors weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/antibody-therapy weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/chemotherapy weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/p300cbp-inhibitors weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/hdac-inhibitors weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/peptide-drug-conjugates weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/chemokine-receptor-antagonists weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/phospholipid-drug-conjugates weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/biological-therapy weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/jak-inhibitors weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/fusion-peptides weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/antibody-recruiting-molecules weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/immunocytokines weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/kinase-inhibitors weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/biphosphonates weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/checkpoint-inhibitors weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/btk-inhibitors weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/therapeutics/vaccines weekly 0.7 2025-03-17T08:35:00.000Z https://multiplemyelomahub.com/congresses weekly 0.8 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/ims2022-1 weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/ebmt weekly 0.7 2025-04-08T11:46:00.000Z https://multiplemyelomahub.com/congresses/tct weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/car-t-meetings weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/esh weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/iach weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/soho weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/other weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/ash weekly 0.7 2026-01-12T16:20:00.000Z https://multiplemyelomahub.com/congresses/emn18-1 weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/nccn weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/american-association-for-cancer-research weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/esmo-2023 weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/imw weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/llm weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/comy weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/congresses/eha weekly 0.7 2025-07-03T09:59:00.000Z https://multiplemyelomahub.com/congresses/asco weekly 0.7 2025-03-21T18:45:00.000Z https://multiplemyelomahub.com/trials weekly 0.8 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/stomp weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cc-92480-mm-002 weekly 0.7 2025-04-23T08:28:00.000Z https://multiplemyelomahub.com/trials/ca057-003 weekly 0.7 2025-04-23T08:28:00.000Z https://multiplemyelomahub.com/trials/excaliber-rrmm weekly 0.7 2025-04-23T08:28:00.000Z https://multiplemyelomahub.com/trials/excaliber-maintenance weekly 0.7 2025-04-23T08:28:00.000Z https://multiplemyelomahub.com/trials/successor-1 weekly 0.7 2025-04-23T08:28:00.000Z https://multiplemyelomahub.com/trials/successor-2 weekly 0.7 2025-04-23T08:28:00.000Z https://multiplemyelomahub.com/trials/cc-92480-mm-001 weekly 0.7 2025-04-23T08:28:00.000Z https://multiplemyelomahub.com/trials/cc-220-mm-001 weekly 0.7 2025-04-23T08:28:00.000Z https://multiplemyelomahub.com/trials/gem-iberdarax weekly 0.7 2025-10-31T12:08:00.000Z https://multiplemyelomahub.com/trials/magnetismm-30 weekly 0.7 2025-12-03T14:10:00.000Z https://multiplemyelomahub.com/trials/emn26 weekly 0.7 2025-12-03T14:10:00.000Z https://multiplemyelomahub.com/trials/melt-mm weekly 0.7 2026-04-01T18:36:00.000Z https://multiplemyelomahub.com/trials/i2d-ifm2021-03 weekly 0.7 2026-04-01T18:36:00.000Z https://multiplemyelomahub.com/trials/imroz weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/koala weekly 0.7 2026-03-23T17:31:00.000Z https://multiplemyelomahub.com/trials/cartitude-4 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/linker-mm1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/majestec-3 weekly 0.7 2025-12-22T14:25:00.000Z https://multiplemyelomahub.com/trials/perseus weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/master weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/milestone weekly 0.7 2026-02-16T11:38:00.000Z https://multiplemyelomahub.com/trials/canova weekly 0.7 2026-02-09T13:41:00.000Z https://multiplemyelomahub.com/trials/admyre weekly 0.7 2026-02-09T14:58:00.000Z https://multiplemyelomahub.com/trials/insight-mm weekly 0.7 2026-02-03T12:43:00.000Z https://multiplemyelomahub.com/trials/lummicar-study-1 weekly 0.7 2025-11-14T13:54:00.000Z https://multiplemyelomahub.com/trials/izalco weekly 0.7 2026-01-27T14:31:00.000Z https://multiplemyelomahub.com/trials/dreamm-7 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/dreamm-8 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cartitude-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cartitude-2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/karmma weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/magnetismm-3 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/majestec-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/karmma-3 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cepheus weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/monumental-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/trimm-2 weekly 0.7 2025-09-04T09:16:00.000Z https://multiplemyelomahub.com/trials/redirectt-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/immagine-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/inmmycar weekly 0.7 2026-01-14T14:31:00.000Z https://multiplemyelomahub.com/trials/p-bcma-allo1-001 weekly 0.7 2025-12-22T11:08:00.000Z https://multiplemyelomahub.com/trials/iraklia weekly 0.7 2025-06-06T12:36:00.000Z https://multiplemyelomahub.com/trials/camma-1 weekly 0.7 2025-09-04T09:16:00.000Z https://multiplemyelomahub.com/trials/cobra weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gem-cesar weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gmmg-hd7 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/determination weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/fumanba-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/benefit weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/auriga weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/magnetismm-6 weekly 0.7 2025-06-06T12:40:00.000Z https://multiplemyelomahub.com/trials/allg-mm23 weekly 0.7 2025-12-03T14:10:00.000Z https://multiplemyelomahub.com/trials/sealand weekly 0.7 2025-12-03T14:11:00.000Z https://multiplemyelomahub.com/trials/jcog1911b-dash weekly 0.7 2025-12-03T14:11:00.000Z https://multiplemyelomahub.com/trials/andromeda weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/aquila weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/swog-s1702 weekly 0.7 2025-11-06T17:12:00.000Z https://multiplemyelomahub.com/trials/lynx weekly 0.7 2025-11-04T20:12:00.000Z https://multiplemyelomahub.com/trials/istopmm weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/midas weekly 0.7 2025-06-06T12:40:00.000Z https://multiplemyelomahub.com/trials/bellini weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/quiredex weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/e3a06 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/centaurus weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/atlas weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/maia weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gmmg-concept weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/dreamm-9 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gem-bela-vrd weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/majestec-5 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/monumental-2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/majestec-2 weekly 0.7 2025-09-04T09:16:00.000Z https://multiplemyelomahub.com/trials/alcyone weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/locommotion weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/momment weekly 0.7 2025-06-06T12:36:00.000Z https://multiplemyelomahub.com/trials/trimm-3 weekly 0.7 2025-06-06T12:40:00.000Z https://multiplemyelomahub.com/trials/forte weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/iskia weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/linker-mm2 weekly 0.7 2025-06-06T12:37:00.000Z https://multiplemyelomahub.com/trials/beladrd weekly 0.7 2025-06-06T12:40:00.000Z https://multiplemyelomahub.com/trials/boston-biomed-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cassiopeia weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cc-220-mm-002 weekly 0.7 2025-04-23T08:28:00.000Z https://multiplemyelomahub.com/trials/rest weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/kilimanjaro weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/karmma-2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/candor weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/optimismm weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/ikema weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/apollo weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/image weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/mmrf-commpass weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gem2017fit weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/alliance-a061202 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/griffin weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/camma-2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/karmma-9 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gmmg-hg7 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/alfa weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/select weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/quintessential weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cartitude-5 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cartitude-6 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/icaria-mm weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/mm-014 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/dreamm-3 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/majestec-7 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/karmma-7 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/legend-2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gem2014main weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gem2012menos65 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/ocean weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/eloquent-3 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/hpn217-3001 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/emn20 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/dreamm-2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/ifm2009 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/mylacre weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/genesis weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/magnetismm-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/magnetismm-2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/magnetismm-9 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/clover-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/eliana weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/zuma-12 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/irene-ghobrial-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/tourmaline-mm3 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/tourmaline-mm4 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cammouflage weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/mm-ep1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/pleiades weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/emn02ho95 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/emn12ho129 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gem-claridex weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/polaris weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/myeloma-xi weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/vista weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/monumental-3 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/monumental-5 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/ascent weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/mmybrave weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/emn19 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/horizon weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/lighthouse weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/ifm-2017-03 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/pollux weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/neutrodiet weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cartifan-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/freedmm weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/mrd2stop weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/vital weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/ho143 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/hovon-143 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/stamina weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/promise weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/storm weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/optimum weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/mydrug weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/universal weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/ignite weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cardamon weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/carfilzomib-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/clarion weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/endurance weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/panorama-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/castor weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/tourmaline-mm1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/lyra weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/epicovideha weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/fitness weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/bmt-ctn-1302 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/tourmaline-mm2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/calgb-100104 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/aspire weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/anchor weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/lummicar-study-2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/panorama-3 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/birma weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/swog-s0777 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/equuleus weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/sirius weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/eloquent-2 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/evolve weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/melani-01 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/swog-1211 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/dreamm-6 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/dreamm-5 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/dreamm1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/columba weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/arrow weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/endeavor weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/champion-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/solidarity weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/rv-mm-pi-209 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/emn18 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/eloquent-1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/ifm2005-02 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/tourmaline-al1 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/gen501 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/cassiopet weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/crb-401 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/keynote-023 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/keynote-183 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/trials/keynote-185 weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/expert-opinions weekly 0.8 2025-04-23T09:07:00.000Z https://multiplemyelomahub.com/drug-updates weekly 0.8 2025-04-23T09:07:00.000Z https://multiplemyelomahub.com/educational-resources weekly 0.8 2025-11-19T13:35:00.000Z https://multiplemyelomahub.com/educational-resources/editorial-themes-and-reviews weekly 0.7 2025-11-19T13:35:00.000Z https://multiplemyelomahub.com/educational-resources/drugs-approvals-in-multiple-myeloma weekly 0.7 2025-11-11T13:42:00.000Z https://multiplemyelomahub.com/educational-resources/visual-abstracts weekly 0.7 2025-11-11T13:42:00.000Z https://multiplemyelomahub.com/educational-resources/mm-hub-symposiums weekly 0.7 2025-11-11T13:42:00.000Z https://multiplemyelomahub.com/educational-resources/spotlights weekly 0.7 2025-11-11T13:42:00.000Z https://multiplemyelomahub.com/educational-resources/steering-committee-meetings weekly 0.7 2025-11-11T13:42:00.000Z https://multiplemyelomahub.com/educational-resources/masterclass weekly 0.7 2025-11-11T13:42:00.000Z https://multiplemyelomahub.com/educational-resources/diagnostic-and-treatment-guidelines weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/educational-resources/special-populations weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/educational-resources/supportive-care weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/educational-resources/risk-scores-and-prognostic-tools weekly 0.7 2025-04-22T16:15:00.000Z https://multiplemyelomahub.com/medical-information/targeting-cereblon-for-the-treatment-of-mm-rationale-and-latest-data monthly 0.9 2026-04-02T14:29:00.000Z https://multiplemyelomahub.com/medical-information/ema-chmp-approves-sc-daratumumab-for-self-or-caregiver-administration-in-mm monthly 0.9 2026-03-31T10:10:00.000Z https://multiplemyelomahub.com/medical-information/real-world-outcomes-with-dpd-vs-dkd-in-rrmm monthly 0.9 2026-03-27T13:14:00.000Z https://multiplemyelomahub.com/medical-information/imroz-post-hoc-analysis-mrd-dynamics-with-isavrdisard-for-tindmm monthly 0.9 2026-03-26T11:08:00.000Z https://multiplemyelomahub.com/medical-information/australias-tga-grants-cta-for-first-in-human-kmcar-t-cell-therapy-for-kappa-restricted-rrmm monthly 0.9 2026-03-23T17:42:00.000Z https://multiplemyelomahub.com/medical-information/cartitude-4-updated-analysis-cilta-cel-for-len-refractory-mm monthly 0.9 2026-03-20T10:42:00.000Z https://multiplemyelomahub.com/medical-information/linker-mm1-longer-term-follow-up-and-subgroup-analyses monthly 0.9 2026-03-17T14:02:00.000Z https://multiplemyelomahub.com/medical-information/al-iss-a-validated-international-staging-system-for-al-amyloidosis monthly 0.9 2026-03-13T08:00:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-sc-teclistamab-daratumumab-for-rrmm monthly 0.9 2026-03-10T17:00:00.000Z https://multiplemyelomahub.com/medical-information/optimizing-selection-of-bridging-therapies-prior-to-car-t-cell-therapy-for-mm monthly 0.9 2026-03-09T11:30:00.000Z https://multiplemyelomahub.com/medical-information/perseus-post-hoc-analysis-prognostic-value-of-ctc-in-te-ndmm monthly 0.9 2026-03-04T12:14:00.000Z https://multiplemyelomahub.com/medical-information/ash-2026-guidelines-diagnosis-of-al-amyloidosis monthly 0.9 2026-03-02T08:00:00.000Z https://multiplemyelomahub.com/medical-information/impact-of-t1114-on-mrd-dynamics-in-ndmm monthly 0.9 2026-02-26T09:11:00.000Z https://multiplemyelomahub.com/medical-information/mechanisms-of-acquired-gprc5d-resistance-following-talquetamab-in-rrmm monthly 0.9 2026-02-24T10:00:00.000Z https://multiplemyelomahub.com/medical-information/canova-vd-vs-pd-for-t1114-positive-rrmm monthly 0.9 2026-02-24T10:00:00.000Z https://multiplemyelomahub.com/medical-information/fda-accepts-new-drug-application-for-iberdomide-dd-for-rrmm monthly 0.9 2026-02-18T16:00:00.000Z https://multiplemyelomahub.com/medical-information/admyre-matched-eca-analysis-of-plitidepsin-lddxm-vs-pom-lddxm-for-rrmm monthly 0.9 2026-02-18T09:08:00.000Z https://multiplemyelomahub.com/medical-information/insight-mm-impact-of-pi-choice-plus-rd-on-real-world-outcomes-in-rrmm monthly 0.9 2026-02-16T08:00:00.000Z https://multiplemyelomahub.com/medical-information/zevor-cel-for-the-treatment-of-rrmm-5-year-follow-up-from-the-phase-i-part-of-lummicar-study-1 monthly 0.9 2026-02-13T11:27:00.000Z https://multiplemyelomahub.com/medical-information/magnetismm-30-elranatamab-iberdomide-for-rrmm monthly 0.9 2026-02-11T05:00:00.000Z https://multiplemyelomahub.com/medical-information/izalco-sc-isatuximab-via-obi-or-manual-injection-kd-for-rrmm monthly 0.9 2026-02-09T14:21:00.000Z https://multiplemyelomahub.com/medical-information/impact-of-ocular-toxicities-associated-with-belantamab-mafodotin-treatment-in-patients-with-rrmm monthly 0.9 2026-02-09T14:36:00.000Z https://multiplemyelomahub.com/medical-information/symposium-series-integrating-novel-bcma-directed-therapies-into-clinical-practice-insights-from-real-world-experience monthly 0.9 2026-02-03T06:00:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-fast-track-designation-to-investigational-bispecific-t-cell-engager-lbl-034-for-rrmm monthly 0.9 2026-02-02T17:26:00.000Z https://multiplemyelomahub.com/medical-information/the-role-of-mrd-as-an-endpoint-in-clinical-trials-for-mm monthly 0.9 2026-02-03T15:17:00.000Z https://multiplemyelomahub.com/medical-information/symposium-future-directions-with-novel-and-established-bcma-dt-in-the-multiple-myeloma-treatment-paradigm monthly 0.9 2026-02-11T09:49:00.000Z https://multiplemyelomahub.com/medical-information/symposium-practical-considerations-when-sequencing-novel-agents-and-managing-aes-with-bcma-directed-therapies monthly 0.9 2026-02-12T11:52:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-sc-daratumumab-vrd-for-ndmm monthly 0.9 2026-01-28T16:35:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-fast-track-designation-to-ibi3003-for-the-treatment-of-rrmm monthly 0.9 2026-01-30T12:45:00.000Z https://multiplemyelomahub.com/medical-information/symposium-real-world-insights-and-clinical-experience-with-bcmadirected-therapies monthly 0.9 2026-02-10T09:59:00.000Z https://multiplemyelomahub.com/medical-information/symposium-bcma-directed-therapies-in-mm-current-applications-and-the-evolving-clinical-landscape monthly 0.9 2026-02-06T14:44:00.000Z https://multiplemyelomahub.com/medical-information/redirectt-1-phase-ii-talquetamab-teclistamab-for-extramedullary-mm monthly 0.9 2026-04-01T16:04:00.000Z https://multiplemyelomahub.com/medical-information/immagine-1-phase-ii-updated-results-anito-cel-for-rrmm monthly 0.9 2026-02-02T12:58:00.000Z https://multiplemyelomahub.com/medical-information/inmmycar-phase-i-novel-in-vivo-car-t-cell-gene-therapy-for-rrmm monthly 0.9 2026-02-02T12:59:00.000Z https://multiplemyelomahub.com/medical-information/impact-of-response-to-bridging-therapy-on-outcomes-following-cilta-cel-infusion monthly 0.9 2026-01-13T10:37:00.000Z https://multiplemyelomahub.com/medical-information/majestec-3-tec-dara-vs-dara-based-soc-regimens-for-rrmm monthly 0.9 2026-01-07T09:00:00.000Z https://multiplemyelomahub.com/medical-information/anti-cd38-retreatment-in-patients-with-rrmm-real-world-data monthly 0.9 2026-01-02T09:00:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-latest-updates-from-the-phase-i-trial-of-p-bcma-allo1-for-the-treatment-of-rrmm monthly 0.9 2026-01-20T13:16:00.000Z https://multiplemyelomahub.com/medical-information/continuous-vs-fixed-duration-teclistamab-dosing-strategies-in-rrmm-real-world-evidence monthly 0.9 2025-12-23T06:00:00.000Z https://multiplemyelomahub.com/medical-information/improving-access-to-car-t-cell-therapy-for-eligible-patients-with-mm monthly 0.9 2026-03-26T14:21:00.000Z https://multiplemyelomahub.com/medical-information/ash-2025-congress-coverage-other-plasma-cell-dyscrasias monthly 0.9 2025-12-16T16:08:00.000Z https://multiplemyelomahub.com/medical-information/ash-2025-congress-coverage-relapsedrefractory-multiple-myeloma monthly 0.9 2025-12-15T07:00:00.000Z https://multiplemyelomahub.com/medical-information/ash-2025-live-congress-coverage-from-the-multiple-myeloma-hub monthly 0.9 2026-02-18T13:17:00.000Z https://multiplemyelomahub.com/medical-information/ash-2025-cartitude-4-long-term-pfs-outcomes-with-cilta-cel-for-standard-risk-rrmm monthly 0.9 2025-12-11T15:09:00.000Z https://multiplemyelomahub.com/medical-information/ash-2025-top-abstracts-whats-hot-in-multiple-myeloma monthly 0.9 2026-02-18T13:16:00.000Z https://multiplemyelomahub.com/medical-information/talquetamab-in-heavily-pretreated-patients-with-rrmm-real-world-evidence monthly 0.9 2025-12-01T02:00:00.000Z https://multiplemyelomahub.com/medical-information/dreamm-8-patient-reported-outcomes-with-belantamab-mafodotin-pd-for-rrmm monthly 0.9 2025-11-27T11:44:00.000Z https://multiplemyelomahub.com/medical-information/lummicar-study-1-a-phase-ii-trial-of-zevor-cel-in-chinese-patients-with-rrmm monthly 0.9 2025-11-26T15:34:00.000Z https://multiplemyelomahub.com/medical-information/auriga-a-post-hoc-analysis-of-post-transplant-d-r-maintenance-in-ndmm monthly 0.9 2025-11-21T11:07:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-daratumumab-vcd-for-the-treatment-of-newly-diagnosed-al-amyloidosis monthly 0.9 2025-11-20T15:01:00.000Z https://multiplemyelomahub.com/medical-information/camma-1-phase-1b-dose-expansion-results-for-cevostamab-pd-in-rrmm monthly 0.9 2025-11-18T11:05:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-daratumumab-for-the-treatment-of-high-risk-smoldering-mm monthly 0.9 2025-11-14T12:08:00.000Z https://multiplemyelomahub.com/medical-information/trimm-2-phase-ib-trial-talquetamab-daratumumab-in-rrmm monthly 0.9 2025-11-13T15:00:00.000Z https://multiplemyelomahub.com/medical-information/swog-s1702-phase-ii-trial-isatuximab-in-rr-al-amyloidosis monthly 0.9 2025-11-10T11:03:00.000Z https://multiplemyelomahub.com/medical-information/lynx-darakd-for-the-treatment-of-rrmm-with-prior-dara-exposure monthly 0.9 2025-11-10T11:06:00.000Z https://multiplemyelomahub.com/medical-information/outcomes-with-novel-celmod-agents-for-multiple-myeloma monthly 0.9 2025-11-06T15:29:00.000Z https://multiplemyelomahub.com/medical-information/magnetismm-3-impact-of-reduced-elranatamab-dosing-frequency-on-pros-in-rrmm monthly 0.9 2025-10-29T06:00:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-belantamab-mafodotin-in-combination-with-vd-for-the-treatment-of-rrmm monthly 0.9 2025-10-27T12:27:00.000Z https://multiplemyelomahub.com/medical-information/infection-risk-in-patients-with-smoldering-mm monthly 0.9 2025-10-24T06:00:00.000Z https://multiplemyelomahub.com/medical-information/clinical-experience-with-belantamab-mafodotin-management-strategies-for-ocular-toxicity monthly 0.9 2025-10-23T14:34:00.000Z https://multiplemyelomahub.com/medical-information/midas-mrd-driven-strategy-after-isa-krd-induction-in-nd-asct-eligible-mm monthly 0.9 2025-10-22T14:05:00.000Z https://multiplemyelomahub.com/medical-information/ims-imwg-recommended-consensus-genomic-staging-of-high-risk-mm monthly 0.9 2025-10-06T15:15:00.000Z https://multiplemyelomahub.com/medical-information/bellini-trial-survival-analysis-venetoclax-vs-placebo-in-rrmm monthly 0.9 2025-10-06T14:52:00.000Z https://multiplemyelomahub.com/medical-information/masterclass-high-risk-smoldering-mm-latest-updates-for-diagnostic-criteria-and-prognosis monthly 0.9 2025-11-06T15:20:00.000Z https://multiplemyelomahub.com/medical-information/how-might-the-clinical-development-of-celmods-impact-the-treatment-paradigm-for-mm monthly 0.9 2025-10-20T15:24:00.000Z https://multiplemyelomahub.com/medical-information/initial-results-from-the-phase-ii-magnetismm-6-study-part-1-dose-level-g monthly 0.9 2025-10-06T08:28:00.000Z https://multiplemyelomahub.com/medical-information/cartitude-2-cilta-cel-len-maintenance-for-mm-with-suboptimal-response-to-asct monthly 0.9 2025-10-03T12:09:00.000Z https://multiplemyelomahub.com/medical-information/administration-of-bispecific-antibodies-in-patients-with-rrmm-in-outpatient-and-community-settings-a-roadmap monthly 0.9 2025-09-20T13:42:00.000Z https://multiplemyelomahub.com/medical-information/ims-2025-other-plasma-cell-dyscrasias monthly 0.9 2025-09-25T09:29:00.000Z https://multiplemyelomahub.com/medical-information/ims-2025-relapsedrefractory-multiple-myeloma monthly 0.9 2025-09-24T10:00:00.000Z https://multiplemyelomahub.com/medical-information/ims-2025-live-congress-feed monthly 0.9 2025-09-23T11:22:00.000Z https://multiplemyelomahub.com/medical-information/evolving-diagnostic-criteria-for-high-risk-smoldering-mm monthly 0.9 2025-09-30T16:24:00.000Z https://multiplemyelomahub.com/medical-information/phase-iii-iraklia-trial-on-body-injector-sc-vs-iv-isatuximab-with-pd-for-rrmm monthly 0.9 2025-09-08T11:20:00.000Z https://multiplemyelomahub.com/medical-information/masterclass-bcma-cd3-bispecific-antibodies-in-mm-current-and-evolving-roles monthly 0.9 2025-09-15T09:16:00.000Z https://multiplemyelomahub.com/medical-information/what-combination-regimens-including-bites-are-being-evaluated-for-the-treatment-of-rrmm monthly 0.9 2025-09-17T19:49:00.000Z https://multiplemyelomahub.com/medical-information/risk-stratification-and-prognosis-in-smoldering-mm monthly 0.9 2025-09-10T10:37:00.000Z https://multiplemyelomahub.com/medical-information/soho-2025-live-congress-feed monthly 0.9 2025-09-08T09:53:00.000Z https://multiplemyelomahub.com/medical-information/what-combination-regimens-containing-bcma-directed-bispecific-antibodies-are-being-evaluated-for-mm monthly 0.9 2025-09-09T18:23:00.000Z https://multiplemyelomahub.com/medical-information/updated-recommendations-for-the-management-of-patients-with-mm-eha-emn-evidence-based-guidelines monthly 0.9 2025-08-22T14:41:00.000Z https://multiplemyelomahub.com/medical-information/outcomes-in-frail-patients-receiving-bcma-directed-bsabs-for-rrmm-a-retrospective-study monthly 0.9 2025-08-13T07:58:00.000Z https://multiplemyelomahub.com/medical-information/how-can-neurotoxicity-associated-with-car-t-cell-therapy-in-mm-be-managed monthly 0.9 2025-08-27T12:47:00.000Z https://multiplemyelomahub.com/medical-information/what-might-be-the-future-applications-for-bcma-directed-bispecific-antibodies-in-mm-and-other-plasma-cell-dyscrasias monthly 0.9 2025-08-18T09:22:00.000Z https://multiplemyelomahub.com/medical-information/visual-abstract-monumental-1-long-term-follow-up-of-talquetamab-for-the-treatment-of-rrmm monthly 0.9 2025-11-13T10:26:00.000Z https://multiplemyelomahub.com/medical-information/management-of-ocular-toxicities-associated-with-belantamab-mafodotin-in-rrmm-latin-american-expert-panel-recommendations monthly 0.9 2025-08-04T11:38:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-orphan-drug-designation-to-sar446523-for-the-treatment-of-rrmm monthly 0.9 2025-07-30T14:59:00.000Z https://multiplemyelomahub.com/medical-information/phase-ii-gmmg-concept-trial-final-analysis-of-isa-krd-in-patients-with-hr-ndmm monthly 0.9 2025-07-25T09:09:00.000Z https://multiplemyelomahub.com/medical-information/ec-grants-approval-to-belantamab-mafodotin-in-combination-with-vd-and-pd-for-rrmm monthly 0.9 2025-07-25T12:28:00.000Z https://multiplemyelomahub.com/medical-information/ec-approves-isa-vrd-for-the-treatment-of-transplant-eligible-ndmm monthly 0.9 2025-07-25T11:57:00.000Z https://multiplemyelomahub.com/medical-information/ec-approves-sc-daratumumab-for-the-treatment-of-hr-smoldering-mm monthly 0.9 2025-07-25T10:37:00.000Z https://multiplemyelomahub.com/medical-information/first-in-human-trial-of-jnj-5322-in-patients-with-rrmm-preliminary-phase-i-results monthly 0.9 2025-07-17T11:50:00.000Z https://multiplemyelomahub.com/medical-information/cgc-plasma-cell-neoplasm-working-group-recommendations-for-testing-and-reporting-cytogenetic-results-for-mm-risk-stratification monthly 0.9 2025-07-16T08:51:00.000Z https://multiplemyelomahub.com/medical-information/gmmg-hd7-final-analysis-isa-rvd-vs-rvd-in-transplant-eligible-patients-with-ndmm monthly 0.9 2025-07-10T14:52:00.000Z https://multiplemyelomahub.com/medical-information/alcyone-final-analysis-efficacy-and-safety-of-vpm-vs-d-vpm-in-transplant-ineligible-ndmm monthly 0.9 2025-07-04T10:04:00.000Z https://multiplemyelomahub.com/medical-information/linvoseltamab-granted-accelerated-approval-by-the-fda-for-patients-with-rrmm monthly 0.9 2025-07-09T14:12:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-rationale-for-early-intervention-in-high-risk-smoldering-mm monthly 0.9 2025-06-30T12:56:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-hub-spotlight-latest-data-from-the-phase-iii-cepheus-trial monthly 0.9 2025-07-09T14:08:00.000Z https://multiplemyelomahub.com/medical-information/chmp-recommends-ec-approval-of-isa-vrd-for-the-treatment-of-transplant-eligible-patients-with-ndmm monthly 0.9 2025-07-09T14:12:00.000Z https://multiplemyelomahub.com/medical-information/eha-2025-other-plasma-cell-dyscrasias monthly 0.9 2025-06-23T10:10:00.000Z https://multiplemyelomahub.com/medical-information/eha-2025-relapsedrefractory-multiple-myeloma monthly 0.9 2025-06-19T11:42:00.000Z https://multiplemyelomahub.com/medical-information/eha-2025-live-congress-coverage monthly 0.9 2025-06-19T10:02:00.000Z https://multiplemyelomahub.com/medical-information/how-are-bcma-directed-bispecific-antibodies-currently-utilized-in-real-world-practice-for-mm monthly 0.9 2025-06-17T17:15:00.000Z https://multiplemyelomahub.com/medical-information/eha-2025-top-abstracts-in-mm-and-other-plasma-cell-dyscrasias monthly 0.9 2025-06-19T10:03:00.000Z https://multiplemyelomahub.com/medical-information/mrd-in-mm-implications-for-clinical-practice-and-trial-design monthly 0.9 2025-06-16T18:37:00.000Z https://multiplemyelomahub.com/medical-information/targeting-xpo1-for-the-treatment-of-mm-real-world-evidence monthly 0.9 2025-06-09T14:02:00.000Z https://multiplemyelomahub.com/medical-information/2025-asco-annual-meeting-congress-coverage monthly 0.9 2025-06-04T16:06:00.000Z https://multiplemyelomahub.com/medical-information/sc-daratumumab-monotherapy-for-the-treatment-of-high-risk-smoldering-mm monthly 0.9 2025-05-21T06:21:00.000Z https://multiplemyelomahub.com/medical-information/how-to-incorporate-novel-therapies-into-the-treatment-paradigm-for-early-rrmm monthly 0.9 2025-06-24T10:23:00.000Z https://multiplemyelomahub.com/medical-information/belantamab-mafodotin-combinations-approved-in-japan-for-the-treatment-of-rrmm monthly 0.9 2025-07-09T14:13:00.000Z https://multiplemyelomahub.com/medical-information/cassiopeia-long-term-mrd-results-of-d-vtd-in-ndmm monthly 0.9 2025-05-15T13:53:00.000Z https://multiplemyelomahub.com/medical-information/carfilzomib-lenalidomide-and-dexamethasone-krd-in-patients-with-rrmm-realworld-evidence monthly 0.9 2025-05-12T16:28:00.000Z https://multiplemyelomahub.com/medical-information/targeting-cd38-in-mm-challenges-and-resistance-mechanisms monthly 0.9 2025-05-14T10:48:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-future-perspectives-for-anti-cd38-mabs-in-the-treatment-of-mm monthly 0.9 2025-06-03T10:40:00.000Z https://multiplemyelomahub.com/medical-information/ec-grants-conditional-marketing-authorization-to-linvoseltamab-for-rrmm monthly 0.9 2025-04-30T15:51:00.000Z https://multiplemyelomahub.com/medical-information/mrd-guided-dara-krd-induction-in-ndmm-a-phase-ii-trial monthly 0.9 2025-04-28T14:19:00.000Z https://multiplemyelomahub.com/medical-information/celmods-for-the-treatment-of-mm-latest-clinical-trial-data monthly 0.9 2025-04-25T08:13:00.000Z https://multiplemyelomahub.com/medical-information/efficacy-and-prognostic-indicators-of-isapd-in-dara-refractory-multiple-myeloma-a-real-world-study monthly 0.9 2025-04-17T15:15:00.000Z https://multiplemyelomahub.com/medical-information/uk-mhra-approves-belantamab-mafodotin-in-combination-with-vd-and-pd-for-rrmm monthly 0.9 2025-07-09T14:14:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-hub-spotlight-cd38-as-a-therapeutic-target-for-mm monthly 0.9 2025-07-09T14:07:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-rationale-for-treating-early-rrrm-with-targeted-therapies monthly 0.9 2025-06-03T10:39:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-current-treatment-recommendations-and-unmet-needs-in-early-rrmm monthly 0.9 2025-06-03T10:40:00.000Z https://multiplemyelomahub.com/medical-information/cepheus-long-term-follow-up-of-d-vrd-vs-vrd-in-transplant-ineligible-ndmm monthly 0.9 2025-04-08T11:00:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-hub-spotlight-mechanism-of-action-for-celmods-in-mm monthly 0.9 2025-07-09T14:08:00.000Z https://multiplemyelomahub.com/medical-information/ebmt monthly 0.9 2025-04-08T14:19:00.000Z https://multiplemyelomahub.com/medical-information/ec-approves-subcutaneous-daratumumab-in-combination-with-vrd-for-ndmm-regardless-of-transplant-eligibility monthly 0.9 2025-04-07T14:39:00.000Z https://multiplemyelomahub.com/medical-information/visual-abstract-or-belantamab-mafodotin-in-combination-with-pd-for-rrmm-latest-data-from-dreamm-8-1 monthly 0.9 2025-04-29T14:48:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-spotlight-latest-survival-and-efficacy-data-from-the-phase-iii-dreamm-7-trial monthly 0.9 2025-07-09T14:07:00.000Z https://multiplemyelomahub.com/medical-information/maia-long-term-results-and-patient-reported-outcomes-with-daratumumablenalidomidedexamethasone-in-transplant-ineligible-ndmm monthly 0.9 2025-03-26T09:09:00.000Z https://multiplemyelomahub.com/medical-information/visual-abstract-or-belantamab-mafodotin-in-combination-with-pd-for-rrmm-latest-data-from-dreamm-8 monthly 0.9 2025-11-13T10:25:00.000Z https://multiplemyelomahub.com/medical-information/centaurus-a-phase-ii-trial-of-daratumumab-monotherapy-for-intermediatehigh-risk-smoldering-mm monthly 0.9 2025-02-26T16:52:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-hub-spotlight-interim-data-from-the-phase-iii-imroz-trial monthly 0.9 2025-07-09T14:04:00.000Z https://multiplemyelomahub.com/medical-information/cartitude-4-mrd-negativity-analysis-cilta-cel-for-len-refractory-mm monthly 0.9 2025-12-09T11:56:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-latest-updates-from-clinical-trials-of-isatuximab-for-ndmm monthly 0.9 2025-03-11T15:09:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-impact-of-elranatamab-on-quality-of-life-in-relapsedrefractory-multiple-myeloma monthly 0.9 2025-04-29T14:36:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-clinical-experience-with-elranatamab-for-the-treatment-of-multiple-myeloma monthly 0.9 2025-02-26T10:43:00.000Z https://multiplemyelomahub.com/medical-information/auriga-daratumumab-lenalidomide-maintenance-in-newly-diagnosed-mm monthly 0.9 2025-02-17T08:56:00.000Z https://multiplemyelomahub.com/medical-information/2025-tandem-meetings-or-transplantation-and-cellular-therapy-meetings-of-astct-and-cibmtr monthly 0.9 2025-02-20T14:37:00.000Z https://multiplemyelomahub.com/medical-information/7th-european-car-t-cell-meeting-congress-coverage monthly 0.9 2025-02-17T08:56:00.000Z https://multiplemyelomahub.com/medical-information/majestec-5-latest-data-teclistamab-dr-bortezomib-for-te-ndmm monthly 0.9 2025-02-10T22:07:00.000Z https://multiplemyelomahub.com/medical-information/etentamig-combined-with-daratumumabdexamethasone-for-rr-mm-results-from-the-phase-i-kilimanjaro-trial monthly 0.9 2025-02-20T15:34:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-hub-spotlight-updated-data-from-the-phase-ii-karmma-2-trial monthly 0.9 2025-07-09T14:04:00.000Z https://multiplemyelomahub.com/medical-information/dreamm-9-updated-interim-analysis-belantamab-mafodotin-in-combination-with-soc-in-transplant-ineligible-ndmm monthly 0.9 2025-01-29T12:55:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-hub-spotlight-updated-data-from-cartitude-2 monthly 0.9 2025-07-09T14:03:00.000Z https://multiplemyelomahub.com/medical-information/immagine-1-preliminary-phase-ii-results-of-anitocabtagene-autoleucel-in-patients-with-triple-class-exposed-rrmm monthly 0.9 2025-01-23T16:37:00.000Z https://multiplemyelomahub.com/medical-information/ca057-003-mezigdomide-dexamethasone-in-novel-novel-combination-for-rrmm monthly 0.9 2026-02-18T13:19:00.000Z https://multiplemyelomahub.com/medical-information/belantamab-mafodotin-combination-therapies-in-early-rrmm monthly 0.9 2025-08-05T09:11:00.000Z https://multiplemyelomahub.com/medical-information/efficacy-of-isa-vrd-as-first-line-therapy-in-newly-diagnosed-mm monthly 0.9 2024-12-18T17:42:00.000Z https://multiplemyelomahub.com/medical-information/image-study-isatuximab-plus-pomalidomide-and-dexamethasone-for-rrmm-in-the-real-world-setting monthly 0.9 2024-12-18T12:24:00.000Z https://multiplemyelomahub.com/medical-information/ash24-other-plasma-cell-dyscrasias monthly 0.9 2024-12-18T12:23:00.000Z https://multiplemyelomahub.com/medical-information/2024-ash-annual-meeting-live-congress-feed monthly 0.9 2024-12-18T16:20:00.000Z https://multiplemyelomahub.com/medical-information/ash24-newly-diagnosed-multiple-myeloma monthly 0.9 2024-12-18T12:20:00.000Z https://multiplemyelomahub.com/medical-information/iwwm-12-what-are-the-implications-of-istopmm-for-mm-and-wm monthly 0.9 2024-12-12T00:20:00.000Z https://multiplemyelomahub.com/medical-information/ash-2024-top-abstracts-in-mm-and-other-plasma-cell-dyscrasias monthly 0.9 2024-12-04T10:49:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-panel-discussion-or-strategies-for-the-management-of-treatment-related-toxicities-in-mm monthly 0.9 2025-07-09T14:16:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-bcma-directed-adcs-for-the-treatment-of-mm monthly 0.9 2025-07-09T14:16:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-treatment-paradigm-in-early-rrmm monthly 0.9 2025-07-09T14:16:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-panel-discussion-or-how-to-sequence-bcma-directed-therapies-in-rrmm monthly 0.9 2025-07-09T14:16:00.000Z https://multiplemyelomahub.com/medical-information/iberdd-for-transplant-ineligible-patients-with-ndmm-results-from-the-phase-iii-cc-220-mm-001-trial monthly 0.9 2024-11-14T12:13:00.000Z https://multiplemyelomahub.com/medical-information/phase-i-trial-on-the-efficacy-and-safety-of-p-bcma-allo1-car-t-cell-therapy-in-rrmm monthly 0.9 2024-11-12T13:02:00.000Z https://multiplemyelomahub.com/medical-information/ixazomib-in-combination-with-pomalidomide-and-dexamethasone-in-patients-with-lenalidomide-refractory-mm-results-from-the-alliance-a061202-trial monthly 0.9 2024-11-07T12:32:00.000Z https://multiplemyelomahub.com/medical-information/real-world-efficacy-of-isa-kd-in-patients-with-rrmm monthly 0.9 2024-11-07T09:33:00.000Z https://multiplemyelomahub.com/medical-information/um171-expanded-cord-blood-transplantation-for-patients-with-high-risk-ndmm-results-from-a-phase-iii-trial monthly 0.9 2024-11-01T10:12:00.000Z https://multiplemyelomahub.com/medical-information/2024-update-on-diagnosis-risk-stratification-and-treatment-of-patients-with-multiple-myeloma monthly 0.9 2024-10-30T07:49:00.000Z https://multiplemyelomahub.com/medical-information/real-world-data-on-the-safety-and-efficacy-of-cilta-cel-in-patients-with-rrmm monthly 0.9 2024-10-24T11:03:00.000Z https://multiplemyelomahub.com/medical-information/gem-bela-vrd-belantamab-mafodotin-in-combination-with-vrd-for-transplant-eligible-ndmm monthly 0.9 2024-10-17T14:17:00.000Z https://multiplemyelomahub.com/medical-information/how-do-i-treat-patients-who-have-relapsed-after-quadruplet-regimen-in-the-first-line-in-multiple-myeloma monthly 0.9 2024-10-17T09:28:00.000Z https://multiplemyelomahub.com/medical-information/case-series-or-how-do-i-treat-patients-with-rrmm-after-failure-of-bcma-targeted-therapies monthly 0.9 2024-10-17T09:11:00.000Z https://multiplemyelomahub.com/medical-information/d-vtd-in-transplant-eligible-patients-with-ndmm-long-term-follow-up-of-cassiopeia-trial monthly 0.9 2024-10-04T12:53:00.000Z https://multiplemyelomahub.com/medical-information/ims2024-relapsedrefractory-multiple-myeloma monthly 0.9 2024-10-04T12:53:00.000Z https://multiplemyelomahub.com/medical-information/ims2024-newly-diagnosed-multiple-myeloma monthly 0.9 2024-10-04T12:52:00.000Z https://multiplemyelomahub.com/medical-information/ixazomib-in-combination-with-daratumumab-and-dexamethasone-for-the-treatment-of-rrmm monthly 0.9 2024-10-01T11:58:00.000Z https://multiplemyelomahub.com/medical-information/iach-2024-live-congress-feed monthly 0.9 2024-10-03T10:08:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-isa-vrd-for-transplant-ineligible-ndmm monthly 0.9 2024-09-23T16:37:00.000Z https://multiplemyelomahub.com/medical-information/frontline-quadruplet-therapy-for-multiple-myeloma-update-form-soho-2024 monthly 0.9 2024-09-23T09:19:00.000Z https://multiplemyelomahub.com/medical-information/management-of-complications-of-car-t-cell-therapies-in-europe monthly 0.9 2024-09-11T16:38:00.000Z https://multiplemyelomahub.com/medical-information/outpatient-administration-of-car-t-cell-therapies-in-patients-with-hematological-malignancies monthly 0.9 2024-09-25T14:01:00.000Z https://multiplemyelomahub.com/medical-information/belantamab-mafodotin-for-rrmm-real-world-data-from-the-alfa-study monthly 0.9 2024-09-03T15:02:00.000Z https://multiplemyelomahub.com/medical-information/real-world-study-on-efficacy-and-safety-of-ide-cel-in-older-patients-with-rrmm monthly 0.9 2024-09-03T15:05:00.000Z https://multiplemyelomahub.com/medical-information/soho-2024-live-congress-feed monthly 0.9 2024-09-16T12:44:00.000Z https://multiplemyelomahub.com/medical-information/safety-and-efficacy-of-teclistamab-in-patients-with-rrmm-exposed-to-anti-bcma-majestec-1-cohort-c monthly 0.9 2024-09-02T08:01:00.000Z https://multiplemyelomahub.com/medical-information/kpd-for-patients-with-early-rrmm-primary-analysis-from-the-phase-ii-select-trial monthly 0.9 2024-08-21T10:51:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-vrd-for-transplant-eligible-patients-with-ndmm-mrd-analysis-from-the-perseus-trial monthly 0.9 2024-08-15T13:45:00.000Z https://multiplemyelomahub.com/medical-information/efficacy-and-safety-of-isa-vrd-in-the-treatment-of-transplant-ineligible-patients-with-ndmm-phase-iii-benefit-trial monthly 0.9 2024-08-15T07:18:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-the-next-wave-of-immune-based-therapies-what-you-need-to-know monthly 0.9 2025-07-09T14:17:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-how-to-sequence-car-t-cell-therapy-and-bispecific-antibodies-in-relapsedrefractory-multiple-myeloma monthly 0.9 2025-07-09T14:17:00.000Z https://multiplemyelomahub.com/medical-information/camma-2-cohort-a1-cevostamab-in-patients-with-rrmm-and-prior-bcma-targeted-adc-or-car-t-cell-therapy monthly 0.9 2024-08-01T15:28:00.000Z https://multiplemyelomahub.com/medical-information/bcma-directed-immunotherapies-in-mm-the-importance-of-sequencing monthly 0.9 2024-08-13T14:17:00.000Z https://multiplemyelomahub.com/medical-information/celmods-in-multiple-myeloma monthly 0.9 2024-08-13T14:11:00.000Z https://multiplemyelomahub.com/medical-information/magnetismm-3-long-term-survival-after-elranatamab-monotherapy-in-patients-with-rrmm monthly 0.9 2024-07-31T08:38:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-subcutaneous-daratumumab-in-combination-with-vrd-for-ndmm monthly 0.9 2024-08-01T09:35:00.000Z https://multiplemyelomahub.com/medical-information/iberdomide-efficacy-and-safety-in-rrmm monthly 0.9 2024-08-13T14:09:00.000Z https://multiplemyelomahub.com/medical-information/infections-associated-with-bispecific-antibodies monthly 0.9 2025-08-06T08:14:00.000Z https://multiplemyelomahub.com/medical-information/car-t-cell-therapies-in-clinical-practice monthly 0.9 2025-08-06T08:14:00.000Z https://multiplemyelomahub.com/medical-information/talquetamab-for-patients-with-rrmm-updated-results-from-the-monumental-1-trial monthly 0.9 2024-07-08T10:53:00.000Z https://multiplemyelomahub.com/medical-information/karmma-2-cohort-2b-ide-cel-in-early-relapse-clinical-high-risk-mm monthly 0.9 2024-07-17T13:09:00.000Z https://multiplemyelomahub.com/medical-information/eha2024-2 monthly 0.9 2024-07-31T09:10:00.000Z https://multiplemyelomahub.com/medical-information/eha2024-1 monthly 0.9 2024-07-31T09:09:00.000Z https://multiplemyelomahub.com/medical-information/eha2024 monthly 0.9 2024-07-31T09:09:00.000Z https://multiplemyelomahub.com/medical-information/bvd-vs-dvd-in-patients-with-rr-mm-results-from-the-dreamm-7-trial monthly 0.9 2024-06-19T10:41:00.000Z https://multiplemyelomahub.com/medical-information/isa-vrd-for-transplant-ineligible-patients-with-ndmm-interim-results-from-the-imroz-trial monthly 0.9 2024-06-20T13:05:00.000Z https://multiplemyelomahub.com/medical-information/current-and-future-use-of-bcma-directed-car-t-cell-therapy-in-mm monthly 0.9 2024-06-19T12:10:00.000Z https://multiplemyelomahub.com/medical-information/dreamm-8-belantamab-mafodotin-in-lenalidomide-exposed-patients-with-rrmm monthly 0.9 2024-06-12T09:58:00.000Z https://multiplemyelomahub.com/medical-information/talquetamab-pomalidomide-for-the-treatment-of-rrmm-preliminary-safety-and-efficacy-from-monumental-2 monthly 0.9 2024-05-20T15:10:00.000Z https://multiplemyelomahub.com/medical-information/immune-fitness-and-teclistamab-response-majestec-1-subanalysis monthly 0.9 2024-06-11T10:59:00.000Z https://multiplemyelomahub.com/medical-information/eha-2024-abstracts-what-s-hot-in-multiple-myeloma monthly 0.9 2024-06-11T14:20:00.000Z https://multiplemyelomahub.com/medical-information/how-might-ai-be-incorporated-into-the-diagnosis-and-management-of-mm monthly 0.9 2024-05-14T16:16:00.000Z https://multiplemyelomahub.com/medical-information/karmma-9-idecabtagene-vicleucel-plus-lenalidomide-for-the-treatment-of-ndmm-with-suboptimal-response-to-asct monthly 0.9 2024-05-15T13:30:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-latest-updates-to-the-nccn-guidelines-for-the-management-of-mm monthly 0.9 2024-06-03T12:25:00.000Z https://multiplemyelomahub.com/medical-information/locommotion-final-analysis-at-2-year-follow-up monthly 0.9 2024-05-14T14:53:00.000Z https://multiplemyelomahub.com/medical-information/the-impact-of-bridging-therapy-on-outcomes-following-treatment-with-ide-cel-in-rrmm monthly 0.9 2024-05-13T10:21:00.000Z https://multiplemyelomahub.com/medical-information/auto-hct-in-newly-diagnosed-mm-with-del-17p-real-world-outcomes monthly 0.9 2024-05-03T10:54:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2024-latest-updates-from-cartitude-2-and-cartitude-4 monthly 0.9 2024-05-03T10:48:00.000Z https://multiplemyelomahub.com/medical-information/novel-bispecific-antibodies-in-mm-characteristics-and-latest-data monthly 0.9 2024-04-26T15:46:00.000Z https://multiplemyelomahub.com/medical-information/impact-of-treatment-modality-and-route-of-administration-on-rates-of-crs-in-rrmm monthly 0.9 2024-04-22T13:24:00.000Z https://multiplemyelomahub.com/medical-information/teclistamab-real-world-safety-and-efficacy monthly 0.9 2024-08-08T12:31:00.000Z https://multiplemyelomahub.com/medical-information/dual-antigen-targeting-immunotherapies-in-mm monthly 0.9 2024-04-19T10:07:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-rationale-for-t-cell-therapies-in-the-treatment-of-smoldering-mm monthly 0.9 2024-04-16T11:23:00.000Z https://multiplemyelomahub.com/medical-information/european-commission-approves-cilta-cel-for-the-treatment-of-rrmm-after-1-prior-lot monthly 0.9 2024-04-29T15:54:00.000Z https://multiplemyelomahub.com/medical-information/antigen-escape-as-a-mechanism-of-resistance-to-t-cell-engaging-therapies-in-multiple-myeloma monthly 0.9 2024-04-16T14:58:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-rationale-for-monitoring-secondary-malignancies-after-bcma-and-cd19-car-t-cell-therapy monthly 0.9 2024-04-12T12:08:00.000Z https://multiplemyelomahub.com/medical-information/magnetismm-3-trial-patient-reported-outcomes-following-treatment-with-elranatamab monthly 0.9 2024-04-12T15:43:00.000Z https://multiplemyelomahub.com/medical-information/optimismm-trial-a-subanalysis-by-frailty-and-bortezomib-dose-adjustment monthly 0.9 2024-04-09T10:41:00.000Z https://multiplemyelomahub.com/medical-information/infections-following-bispecific-antibody-therapy-in-mm-incidence-and-characteristics monthly 0.9 2024-04-03T12:16:00.000Z https://multiplemyelomahub.com/medical-information/approaches-to-measuring-frailty-in-mm-comparison-of-imwg-fi-and-prfp monthly 0.9 2024-03-26T14:31:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-looking-to-the-future-of-bispecific-antibodies-in-mm-and-panelist-qanda monthly 0.9 2024-04-08T15:24:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-practical-management-of-adverse-events-with-immunotherapies monthly 0.9 2024-04-08T15:24:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-beyond-bcma-novel-strategies-using-bispecific-antibodies monthly 0.9 2024-04-08T15:23:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-bcma-directed-bispecific-antibodies monthly 0.9 2024-04-08T15:23:00.000Z https://multiplemyelomahub.com/medical-information/symposium-or-introduction-to-t-cell-engagers-and-general-mechanism-of-action monthly 0.9 2024-04-08T10:48:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-idecabtagene-vicleucel-for-triple-class-exposed-rrmm monthly 0.9 2024-04-09T09:56:00.000Z https://multiplemyelomahub.com/medical-information/car-t-cell-therapy-in-older-patients-efficacy-and-rates-of-immune-mediated-toxicity monthly 0.9 2024-03-21T09:35:00.000Z https://multiplemyelomahub.com/medical-information/integrating-cilta-cel-into-earlier-lines-of-therapy-rationale-and-latest-data-from-cartitude-2-and-cartitude-4 monthly 0.9 2024-08-09T12:37:00.000Z https://multiplemyelomahub.com/medical-information/what-factors-contribute-to-resistance-to-bcma-targeted-car-t-cell-therapies-in-multiple-myeloma monthly 0.9 2024-03-26T11:12:00.000Z https://multiplemyelomahub.com/medical-information/factors-associated-with-unsustained-mrd-negativity-in-patients-with-mm-eligible-for-transplant monthly 0.9 2024-03-08T09:57:00.000Z https://multiplemyelomahub.com/medical-information/dermatological-toxicities-associated-with-talquetamab-in-rrmm monthly 0.9 2024-03-08T09:57:00.000Z https://multiplemyelomahub.com/medical-information/european-commission-approves-idecabtagene-vicleucel-for-the-treatment-of-triple-class-exposed-rrmm monthly 0.9 2024-03-21T15:19:00.000Z https://multiplemyelomahub.com/medical-information/panobinostat-gemcitabine-busulfan-and-melphalan-salvage-therapy-in-rrmm monthly 0.9 2024-03-08T09:56:00.000Z https://multiplemyelomahub.com/medical-information/ocean-subgroup-analysis-melflufen-in-patients-refractory-to-prior-alkylators monthly 0.9 2024-03-08T09:56:00.000Z https://multiplemyelomahub.com/medical-information/extended-maintenance-with-vrd-in-ndmm-a-15-year-follow-up monthly 0.9 2024-03-12T17:32:00.000Z https://multiplemyelomahub.com/medical-information/opportunistic-infections-in-multiple-myeloma-part-ii-prophylaxis-and-management monthly 0.9 2024-07-16T13:36:00.000Z https://multiplemyelomahub.com/medical-information/opportunistic-infections-in-multiple-myeloma-part-i-etiology-and-incidence monthly 0.9 2024-07-16T13:36:00.000Z https://multiplemyelomahub.com/medical-information/cartitude-2-cohorts-a-and-b-updated-efficacy-and-safety-results monthly 0.9 2024-03-01T16:46:00.000Z https://multiplemyelomahub.com/medical-information/gmmg-concept-trial-isa-krd-for-the-treatment-of-high-risk-newly-diagnosed-mm monthly 0.9 2024-03-05T09:12:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-management-strategies-for-crs-and-icans-in-mm monthly 0.9 2024-03-01T09:35:00.000Z https://multiplemyelomahub.com/medical-information/elopd-for-the-treatment-of-rrmm-real-world-efficacy-and-safety-data monthly 0.9 2024-02-27T11:40:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-latest-updates-on-trispecific-antibodies-for-the-treatment-of-mm monthly 0.9 2024-02-05T12:17:00.000Z https://multiplemyelomahub.com/medical-information/outcomes-of-patients-with-ndmm-transplanted-with-vel-mel-or-mel200-conditioning-regimens monthly 0.9 2024-02-22T18:10:00.000Z https://multiplemyelomahub.com/medical-information/vte-prophylaxis-real-world-practices-and-ifm-clinical-guidelines monthly 0.9 2024-02-20T10:42:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-real-world-outcomes-following-treatment-with-teclistamab-in-rrmm monthly 0.9 2024-02-02T12:22:00.000Z https://multiplemyelomahub.com/medical-information/elderly-fit-ndmm-latest-updates-from-ash-2023 monthly 0.9 2024-02-02T11:50:00.000Z https://multiplemyelomahub.com/medical-information/how-do-response-rates-observed-in-clinical-trials-translate-into-real-world-outcomes-in-mm monthly 0.9 2024-01-29T21:41:00.000Z https://multiplemyelomahub.com/medical-information/karmma-3-trial-updates-from-ash-2023 monthly 0.9 2024-01-29T21:21:00.000Z https://multiplemyelomahub.com/medical-information/extramedullary-mm-understanding-predictors-of-development-and-treatment-outcomes monthly 0.9 2024-07-16T13:37:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-an-overview monthly 0.9 2025-11-13T10:23:00.000Z https://multiplemyelomahub.com/medical-information/are-car-t-cell-therapies-effective-in-the-treatment-of-extramedullary-mm monthly 0.9 2024-01-29T21:12:00.000Z https://multiplemyelomahub.com/medical-information/istopmm-study-a-revised-definition-for-lc-mgus-in-patients-with-preserved-kidney-function monthly 0.9 2024-01-29T15:30:00.000Z https://multiplemyelomahub.com/medical-information/fda-issues-new-boxed-warning-for-car-t-cell-therapies monthly 0.9 2024-01-30T11:10:00.000Z https://multiplemyelomahub.com/medical-information/how-does-treatment-with-ide-cel-impact-quality-of-life-in-rrmm monthly 0.9 2024-06-25T15:49:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-impact-of-dexamethasone-dose-strength-on-outcomes-in-ndmm monthly 0.9 2024-01-17T10:52:00.000Z https://multiplemyelomahub.com/medical-information/perseus-primary-efficacy-and-safety-results monthly 0.9 2024-01-03T12:03:00.000Z https://multiplemyelomahub.com/medical-information/iberdomide-maintenance-after-asct-in-ndmm-results-from-the-phase-ii-emn26-trial monthly 0.9 2024-01-02T13:15:00.000Z https://multiplemyelomahub.com/medical-information/iskia-trial-isa-krd-vs-krd-for-pretransplant-induction-and-posttransplant-consolidation-in-ndmm monthly 0.9 2023-12-21T11:11:00.000Z https://multiplemyelomahub.com/medical-information/uvea-ixa-efficacy-and-safety-of-ixazomib-based-therapy-outside-a-clinical-trial-setting monthly 0.9 2023-12-18T17:28:00.000Z https://multiplemyelomahub.com/medical-information/dreamm-2-long-term-analysis-of-efficacy-and-safety-of-belamaf-in-patients-with-rrmm monthly 0.9 2023-12-18T17:18:00.000Z https://multiplemyelomahub.com/medical-information/majestec-1-incidence-and-management-of-infections-in-patients-with-rrmm-treated-with-teclistamab monthly 0.9 2023-12-12T10:51:00.000Z https://multiplemyelomahub.com/medical-information/patient-case-discussion-on-treating-with-celmods monthly 0.9 2025-08-05T09:16:00.000Z https://multiplemyelomahub.com/medical-information/maintenance-therapy-in-mm-continuing-therapy-vs-discontinuation-according-to-mrd-status monthly 0.9 2023-11-30T18:02:00.000Z https://multiplemyelomahub.com/medical-information/ash-2023-top-abstracts-in-mm-and-other-plasma-cell-dyscrasias monthly 0.9 2023-11-30T16:03:00.000Z https://multiplemyelomahub.com/medical-information/the-impact-of-physical-activity-on-functional-performance-in-multiple-myeloma monthly 0.9 2023-11-09T21:08:00.000Z https://multiplemyelomahub.com/medical-information/for-a-triple-class-refractory-patient-entering-4l-therapy-how-would-you-sequence-bcmaxcd3-and-gprc5dxcd3-bispecifics monthly 0.9 2023-11-10T10:09:00.000Z https://multiplemyelomahub.com/medical-information/impact-of-diabetes-on-multiple-myeloma-survival-outcomes-across-different-racial-groups monthly 0.9 2023-11-21T09:18:00.000Z https://multiplemyelomahub.com/medical-information/ikema-trial-isa-kd-versus-kd-for-relapsedrefractory-multiple-myeloma-final-overall-survival-analysis monthly 0.9 2023-11-20T09:31:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-rationale-for-combination-venetoclax-kd-treatment-in-patients-with-t-1114-rrmm monthly 0.9 2023-10-24T17:03:00.000Z https://multiplemyelomahub.com/medical-information/considerations-when-comparing-car-t-cells-and-bispecific-antibodies-for-rrmm monthly 0.9 2023-10-24T16:37:00.000Z https://multiplemyelomahub.com/medical-information/how-might-ivig-therapy-be-used-to-treat-infection-after-bcma-targeted-therapies-in-mm monthly 0.9 2023-11-07T09:05:00.000Z https://multiplemyelomahub.com/medical-information/autologous-stem-cell-transplantation-in-newly-diagnosed-multiple-myeloma-real-world-results monthly 0.9 2023-10-25T08:21:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-pros-and-cons-of-bispecific-antibodies-and-car-t-cell-therapies-in-myeloma monthly 0.9 2023-10-24T08:39:00.000Z https://multiplemyelomahub.com/medical-information/personalized-treatment-strategies-for-older-and-frail-patients-with-mm monthly 0.9 2023-12-08T22:06:00.000Z https://multiplemyelomahub.com/medical-information/results-of-the-phase-iii-optimismm-trial-of-pomalidomide-bortezomib-and-dexamethasone monthly 0.9 2023-10-25T12:58:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-latest-updates-to-the-portuguese-mm-treatment-guidelines monthly 0.9 2023-10-24T08:06:00.000Z https://multiplemyelomahub.com/medical-information/what-factors-influence-the-adoption-rates-of-novel-mm-therapies-in-latin-america monthly 0.9 2023-10-10T10:29:00.000Z https://multiplemyelomahub.com/medical-information/european-medicines-agency-recommends-marketing-authorization-for-elranatamab monthly 0.9 2023-10-16T14:25:00.000Z https://multiplemyelomahub.com/medical-information/outcomes-in-patients-with-mm-achieving-mrd-negativity-after-treatment-with-cilta-cel-cartitude-1 monthly 0.9 2023-10-11T08:29:00.000Z https://multiplemyelomahub.com/medical-information/what-impact-does-osseous-vs-hematogenous-extramedullary-mm-have-on-patient-outcomes monthly 0.9 2023-10-06T13:12:00.000Z https://multiplemyelomahub.com/medical-information/mezigdomide-dexamethasone-for-the-treatment-of-rrmm monthly 0.9 2023-09-20T08:55:00.000Z https://multiplemyelomahub.com/medical-information/patient-outcomes-in-mm-global-disparities monthly 0.9 2023-10-12T10:58:00.000Z https://multiplemyelomahub.com/medical-information/how-to-select-maintenance-therapies-post-asct-for-patients-with-high-risk-mm monthly 0.9 2023-09-18T08:09:00.000Z https://multiplemyelomahub.com/medical-information/efficacy-and-safety-of-car-t-cell-therapies-produced-in-academic-centers monthly 0.9 2023-09-08T09:24:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-motixafortide-plus-filgrastim-for-hematopoietic-stem-cell-mobilization monthly 0.9 2023-09-14T09:04:00.000Z https://multiplemyelomahub.com/medical-information/should-risk-adapted-mm-treatment-be-informed-by-age-or-frailty-status monthly 0.9 2023-09-12T12:26:00.000Z https://multiplemyelomahub.com/medical-information/isatuximab-vrd-in-auto-hsct-ineligible-ndmm-phase-ib-trial monthly 0.9 2023-09-08T11:55:00.000Z https://multiplemyelomahub.com/medical-information/final-analysis-from-phase-iii-candor-trial-in-adult-patients-with-relapsedrefractory-mm monthly 0.9 2023-09-04T11:24:00.000Z https://multiplemyelomahub.com/medical-information/how-does-linvoseltamab-differ-from-other-bispecific-antibodies monthly 0.9 2023-09-04T09:07:00.000Z https://multiplemyelomahub.com/medical-information/recommendations-for-the-management-of-multiple-myeloma-related-renal-impairment-international-myeloma-working-group monthly 0.9 2024-07-16T13:33:00.000Z https://multiplemyelomahub.com/medical-information/ema-chmp-recommends-conditional-marketing-authorization-for-talquetamab monthly 0.9 2023-10-01T09:13:00.000Z https://multiplemyelomahub.com/medical-information/visual-abstract-or-real-world-treatment-patterns-in-third-line-therapies-for-rrmm-across-europe monthly 0.9 2024-07-16T13:19:00.000Z https://multiplemyelomahub.com/medical-information/novel-treatment-strategies-for-light-chain-amyloidosis-updates-from-eha-2023 monthly 0.9 2023-07-28T15:02:00.000Z https://multiplemyelomahub.com/medical-information/how-can-we-better-predict-early-relapse-in-multiple-myeloma monthly 0.9 2023-08-15T10:02:00.000Z https://multiplemyelomahub.com/medical-information/the-impact-of-second-primary-and-second-hematological-malignancies-on-survival-outcomes-of-mm-after-auto-hsct monthly 0.9 2023-10-10T12:09:00.000Z https://multiplemyelomahub.com/medical-information/how-to-treat-advanced-refractory-mm monthly 0.9 2023-08-01T12:34:00.000Z https://multiplemyelomahub.com/medical-information/bcma-targeted-therapies-for-multiple-myeloma-part-ii-car-t-cells monthly 0.9 2023-10-01T09:16:00.000Z https://multiplemyelomahub.com/medical-information/bcma-targeted-therapies-for-mm-part-i-adcs-and-bsab monthly 0.9 2023-08-02T08:00:00.000Z https://multiplemyelomahub.com/medical-information/tailoring-first-line-therapy-to-mrd-status-the-master-trial-final-analysis monthly 0.9 2023-07-20T14:51:00.000Z https://multiplemyelomahub.com/medical-information/answering-the-common-challenges-facing-real-world-car-t-cell-therapies monthly 0.9 2023-07-28T08:53:00.000Z https://multiplemyelomahub.com/medical-information/elranatamab-for-rrmm-updates-from-the-magnetismm-trials monthly 0.9 2023-08-24T11:26:00.000Z https://multiplemyelomahub.com/medical-information/real-world-patient-cases-car-t-cell-therapy monthly 0.9 2023-07-26T11:09:00.000Z https://multiplemyelomahub.com/medical-information/biomarkers-and-patient-eligibility-for-car-t-cell-therapies-in-mm monthly 0.9 2023-07-28T08:52:00.000Z https://multiplemyelomahub.com/medical-information/emn-recommendations-prevention-and-management-of-car-t-and-bispecific-antibody-related-adverse-events-in-mm monthly 0.9 2024-07-16T13:33:00.000Z https://multiplemyelomahub.com/medical-information/is-upfront-auto-sct-still-the-preferred-option-for-eligible-patients monthly 0.9 2023-07-11T10:20:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-orphan-drug-designation-to-isb-2001 monthly 0.9 2023-07-11T10:17:00.000Z https://multiplemyelomahub.com/medical-information/are-car-t-cell-therapies-safe-for-patients-with-impaired-renal-function monthly 0.9 2023-07-11T14:21:00.000Z https://multiplemyelomahub.com/medical-information/patient-treatment-preferences-for-the-management-of-mm monthly 0.9 2023-07-07T09:43:00.000Z https://multiplemyelomahub.com/medical-information/latest-updates-on-cilta-cel-from-cartitude-1-and-cartitude-4 monthly 0.9 2024-04-24T11:41:00.000Z https://multiplemyelomahub.com/medical-information/iopofosine-i-131-for-the-treatment-of-rrmm-interim-data-from-clover-1 monthly 0.9 2023-06-30T15:39:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-fast-track-designation-to-inobrodib-for-rrmm monthly 0.9 2023-07-04T09:26:00.000Z https://multiplemyelomahub.com/medical-information/redirectt-1-talquetamab-teclistamab-in-rr-mm monthly 0.9 2023-06-12T10:14:00.000Z https://multiplemyelomahub.com/medical-information/long-term-outcomes-following-car-t-cell-therapy-in-b-cell-malignancies monthly 0.9 2023-06-06T19:22:00.000Z https://multiplemyelomahub.com/medical-information/emn-recommendations-for-the-management-of-mm-and-covid-19-in-the-post-pandemic-era monthly 0.9 2024-07-16T13:33:00.000Z https://multiplemyelomahub.com/medical-information/current-rationale-for-the-use-of-mrd-driven-therapy-in-mm monthly 0.9 2023-06-05T15:59:00.000Z https://multiplemyelomahub.com/medical-information/eha-2023 monthly 0.9 2023-06-11T06:00:00.000Z https://multiplemyelomahub.com/medical-information/eha2023-abstracts-what-s-hot-in-multiple-myeloma-and-other-plasma-cell-dyscrasias monthly 0.9 2023-06-06T07:56:00.000Z https://multiplemyelomahub.com/medical-information/asco23 monthly 0.9 2023-05-31T10:53:00.000Z https://multiplemyelomahub.com/medical-information/mm-risk-influences-of-diet-and-the-microbiome monthly 0.9 2024-07-16T13:27:00.000Z https://multiplemyelomahub.com/medical-information/cartitude-2-cohort-c-efficacy-and-safety-of-cilta-cel-in-patients-with-relapsedrefractory-mm monthly 0.9 2023-05-18T12:28:00.000Z https://multiplemyelomahub.com/medical-information/car-t-cell-therapy-associated-hlh-like-syndrome monthly 0.9 2023-05-11T11:55:00.000Z https://multiplemyelomahub.com/medical-information/infection-incidence-with-car-t-cell-and-bispecific-antibody-therapies monthly 0.9 2023-05-19T09:25:00.000Z https://multiplemyelomahub.com/medical-information/definition-and-clinical-significance-of-the-mgus-like-phenotype-in-patients-with-monoclonal-gammopathies monthly 0.9 2023-05-11T10:17:00.000Z https://multiplemyelomahub.com/medical-information/etiologies-and-management-of-cytopenias-following-car-t-cell-infusion monthly 0.9 2023-05-09T11:29:00.000Z https://multiplemyelomahub.com/medical-information/comy-2023 monthly 0.9 2023-05-09T09:57:00.000Z https://multiplemyelomahub.com/medical-information/resistance-mechanisms-to-car-t-cell-therapy monthly 0.9 2023-05-19T10:42:00.000Z https://multiplemyelomahub.com/medical-information/prognostic-impact-of-mrd-dynamics-during-maintenance-therapy-for-patients-with-ndmm monthly 0.9 2023-04-27T15:36:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-fast-track-designation-to-cb-011-for-the-treatment-of-rrmm monthly 0.9 2023-04-27T13:45:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2023 monthly 0.9 2023-04-19T14:22:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-orphan-drug-designation-to-om-301-for-the-treatment-of-patients-with-mm-and-aml monthly 0.9 2023-04-20T13:48:00.000Z https://multiplemyelomahub.com/medical-information/molecular-oriented-therapy-approaches-in-patients-with-rr-mm monthly 0.9 2023-04-24T15:18:00.000Z https://multiplemyelomahub.com/medical-information/common-genomic-diagnostic-tests monthly 0.9 2023-04-05T13:34:00.000Z https://multiplemyelomahub.com/medical-information/final-results-from-the-pleiades-and-equuleus-trials-daratumumab-carfilzomib-and-dexamethasone-in-rrmm monthly 0.9 2023-04-04T15:28:00.000Z https://multiplemyelomahub.com/medical-information/u-s-fda-grants-orphan-drug-designation-to-isb-1442-for-the-treatment-of-rrmm monthly 0.9 2023-03-28T16:17:00.000Z https://multiplemyelomahub.com/medical-information/ims-workshop-2023 monthly 0.9 2023-03-24T11:37:00.000Z https://multiplemyelomahub.com/medical-information/identifying-pcl-like-mm monthly 0.9 2023-03-16T09:20:00.000Z https://multiplemyelomahub.com/medical-information/krd-as-maintenance-therapy-results-from-the-atlas-trial monthly 0.9 2023-05-04T16:03:00.000Z https://multiplemyelomahub.com/medical-information/chronic-opioid-use-following-auto-hsct-in-patients-with-mm monthly 0.9 2023-03-09T15:34:00.000Z https://multiplemyelomahub.com/medical-information/latest-updates-on-idecabtagene-vicleucel-results-from-the-karmma-2-and-karmma-3-trials monthly 0.9 2023-07-28T14:59:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-combination-therapy-granted-full-marketing-authorization-in-the-uk monthly 0.9 2023-03-10T14:36:00.000Z https://multiplemyelomahub.com/medical-information/gprc5d-directed-car-t-cell-therapy-and-bispecific-antibodies-for-patients-with-rr-mm-latest-updates-from-ash-2022 monthly 0.9 2023-04-24T15:18:00.000Z https://multiplemyelomahub.com/medical-information/latest-updates-on-the-myeloma-xi-trial-from-ash-2022 monthly 0.9 2023-02-24T09:31:00.000Z https://multiplemyelomahub.com/medical-information/editorial-theme-peripheral-neuropathy monthly 0.9 2024-07-16T13:23:00.000Z https://multiplemyelomahub.com/medical-information/talquetamab-in-rr-mm-updates-from-the-monumental-1-3-and-5-trials monthly 0.9 2023-02-22T14:46:00.000Z https://multiplemyelomahub.com/medical-information/isatuximab-based-quadruplet-induction-achieves-high-mrd-negative-rates-in-patients-with-newly-diagnosed-mm monthly 0.9 2023-02-09T16:25:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-regenerative-medicine-advanced-therapy-and-fast-track-designation-to-equecabtagene-autoleucel-for-rrmm monthly 0.9 2023-02-17T10:04:00.000Z https://multiplemyelomahub.com/medical-information/current-status-and-future-directions-in-the-diagnosis-and-treatment-of-patients-with-primary-pcl monthly 0.9 2023-02-09T11:27:00.000Z https://multiplemyelomahub.com/medical-information/smoldering-mm-management-in-2022-and-beyond monthly 0.9 2023-01-31T16:11:00.000Z https://multiplemyelomahub.com/medical-information/car-t-2023 monthly 0.9 2023-02-16T10:11:00.000Z https://multiplemyelomahub.com/medical-information/how-is-the-immune-reconstitution-in-patients-who-stop-therapy-after-achieving-mrd-negativity monthly 0.9 2023-01-25T11:49:00.000Z https://multiplemyelomahub.com/medical-information/development-of-a-novel-bispecific-t-cell-engager-targeting-ilt3 monthly 0.9 2023-01-27T11:28:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-main-discrepancies-between-mm-treating-centers-in-brazil monthly 0.9 2023-01-25T11:26:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-initial-data-of-dara-cybord-in-patients-with-extramedullary-disease monthly 0.9 2023-01-25T10:46:00.000Z https://multiplemyelomahub.com/medical-information/ema-and-fda-licensing-of-melphalan-flufenamide-for-rrmm monthly 0.9 2023-01-19T11:27:00.000Z https://multiplemyelomahub.com/medical-information/initial-results-of-daratumumab-lenalidomide-in-frail-patients-the-ifm-2017-03-trial monthly 0.9 2024-07-16T12:57:00.000Z https://multiplemyelomahub.com/medical-information/why-should-frailty-be-considered-a-dynamic-factor-in-mm-and-when-should-it-be-assessed monthly 0.9 2024-07-16T12:57:00.000Z https://multiplemyelomahub.com/medical-information/selecting-the-best-regimen-at-first-relapse monthly 0.9 2025-08-06T08:14:00.000Z https://multiplemyelomahub.com/medical-information/the-imwg-revised-international-staging-system-for-multiple-myeloma-proposed-second-revision monthly 0.9 2023-01-23T16:56:00.000Z https://multiplemyelomahub.com/medical-information/how-can-we-identify-early-the-best-responders-to-ide-cel monthly 0.9 2023-01-03T15:07:00.000Z https://multiplemyelomahub.com/medical-information/managing-thrombosis-in-multiple-myeloma-expert-recommendations monthly 0.9 2023-01-09T17:14:00.000Z https://multiplemyelomahub.com/medical-information/identifying-and-treating-high-risk-patients-in-2023 monthly 0.9 2025-08-06T08:14:00.000Z https://multiplemyelomahub.com/medical-information/the-neutrodiet-trial-is-a-protective-diet-necessary-after-sct monthly 0.9 2023-01-09T16:20:00.000Z https://multiplemyelomahub.com/medical-information/how-can-the-unique-structure-of-the-bispecific-abbv-383-impact-its-safety-and-efficacy monthly 0.9 2023-01-11T17:27:00.000Z https://multiplemyelomahub.com/medical-information/cartifan-1-initial-results-of-the-phase-ii-clinical-trial monthly 0.9 2023-01-04T15:41:00.000Z https://multiplemyelomahub.com/medical-information/what-is-bloodflow-and-how-can-it-improve-mrd-assessment-in-mm monthly 0.9 2023-01-03T14:51:00.000Z https://multiplemyelomahub.com/medical-information/risk-stratification-of-newly-diagnosed-multiple-myeloma-using-chromosome-1 monthly 0.9 2023-01-03T14:45:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-main-improvements-in-next-generation-car-t-cell-products monthly 0.9 2022-12-20T14:14:00.000Z https://multiplemyelomahub.com/medical-information/monoclonal-gammopathy-of-renal-significance-current-classification-diagnosis-and-management monthly 0.9 2022-12-20T10:29:00.000Z https://multiplemyelomahub.com/medical-information/how-to-treat-patients-with-al-amyloidosis-relapsing-from-dara-cybord monthly 0.9 2022-12-15T15:34:00.000Z https://multiplemyelomahub.com/medical-information/real-world-access-to-mm-clinical-trials-international-and-national-disparities-in-equity-and-access monthly 0.9 2022-12-15T15:35:00.000Z https://multiplemyelomahub.com/medical-information/after-ash-2022-are-we-closer-to-using-mrd-guided-treatment-decisions-in-mm monthly 0.9 2022-12-20T13:59:00.000Z https://multiplemyelomahub.com/medical-information/immunotherapies-and-a-future-outlook-on-clinical-trial-designs monthly 0.9 2022-12-15T15:31:00.000Z https://multiplemyelomahub.com/medical-information/is-birtamimab-an-option-for-patients-with-advanced-al-amyloidosis-at-high-risk-for-early-death monthly 0.9 2022-12-14T11:45:00.000Z https://multiplemyelomahub.com/medical-information/ash-congress-2022 monthly 0.9 2022-12-06T16:55:00.000Z https://multiplemyelomahub.com/medical-information/implementing-a-holistic-pain-treatment-plan-in-advanced-multiple-myeloma monthly 0.9 2024-04-25T03:12:00.000Z https://multiplemyelomahub.com/medical-information/dos-and-donts-in-pain-management-in-multiple-myeloma monthly 0.9 2024-04-25T03:12:00.000Z https://multiplemyelomahub.com/medical-information/understanding-pain-in-early-multiple-myeloma monthly 0.9 2024-04-25T03:11:00.000Z https://multiplemyelomahub.com/medical-information/ash-2022-top-abstracts-in-mm-and-other-plasma-cell-dyscrasias monthly 0.9 2023-02-09T09:58:00.000Z https://multiplemyelomahub.com/medical-information/abbv-383-a-novel-bcmacd3-bispecific-antibody-for-the-treatment-of-rrmm monthly 0.9 2022-11-23T17:42:00.000Z https://multiplemyelomahub.com/medical-information/withdrawal-of-belantamab-mafodotin-for-rrmm-in-the-us monthly 0.9 2022-11-23T12:14:00.000Z https://multiplemyelomahub.com/medical-information/safety-and-efficacy-of-the-gprc5d-targeted-car-t-cell-therapy-mcarh109 monthly 0.9 2022-11-18T17:16:00.000Z https://multiplemyelomahub.com/medical-information/quality-of-life-in-patients-with-multiple-myeloma-after-car-t-cell-therapy monthly 0.9 2022-11-23T17:43:00.000Z https://multiplemyelomahub.com/medical-information/elranatamab-receives-breakthrough-therapy-designation-for-the-treatment-of-rrmm monthly 0.9 2022-11-08T10:21:00.000Z https://multiplemyelomahub.com/medical-information/incidence-of-cytopenias-and-infections-in-patients-with-rr-mm-after-treatment-with-idecabtagene-vicleucel monthly 0.9 2022-11-02T15:59:00.000Z https://multiplemyelomahub.com/medical-information/irene-g-a-prospective-rct-of-nutritional-support-following-allo-hsct monthly 0.9 2022-10-31T09:51:00.000Z https://multiplemyelomahub.com/medical-information/teclistamab-cqyv-granted-accelerated-approval-by-the-fda monthly 0.9 2022-10-27T13:01:00.000Z https://multiplemyelomahub.com/medical-information/cd3-t-cells-as-biomarkers-of-frailty-in-elderly-patients-with-hematologic-malignancies monthly 0.9 2022-10-25T10:40:00.000Z https://multiplemyelomahub.com/medical-information/visual-abstract-or-key-updates-to-the-classification-of-plasma-cell-neoplasms-and-paraprotein-disorders-the-5th-who-classification monthly 0.9 2022-10-21T08:53:00.000Z https://multiplemyelomahub.com/medical-information/t-cell-apheresis-for-the-manufacture-of-car-t-cell-therapies-current-challenges-and-future-perspectives monthly 0.9 2022-10-21T14:20:00.000Z https://multiplemyelomahub.com/medical-information/ide-cel-in-rrmm-real-world-experience-and-biomarkers-of-response monthly 0.9 2022-10-12T11:35:00.000Z https://multiplemyelomahub.com/medical-information/mezigdomide-with-bortezomib-or-carfilzomib-for-rrmm monthly 0.9 2022-10-12T09:10:00.000Z https://multiplemyelomahub.com/medical-information/monitoring-immune-dysfunction-and-reconstitution-in-multiple-myeloma monthly 0.9 2022-10-06T08:33:00.000Z https://multiplemyelomahub.com/medical-information/which-patients-might-benefit-the-most-from-isatuximab-based-combinations-in-the-relapsed-setting monthly 0.9 2022-11-14T10:25:00.000Z https://multiplemyelomahub.com/medical-information/visual-abstract-or-rehabilitation-strategies-for-patients-undergoing-car-t-cell-therapy monthly 0.9 2024-07-16T13:19:00.000Z https://multiplemyelomahub.com/medical-information/cd43-as-an-adverse-prognostic-marker-for-mm-and-other-hematologic-malignancies monthly 0.9 2022-09-26T13:08:00.000Z https://multiplemyelomahub.com/medical-information/living-with-mm-understanding-patient-and-caregiver-perceptions-to-improve-hcp-patient-communication monthly 0.9 2022-09-16T16:13:00.000Z https://multiplemyelomahub.com/medical-information/is-it-possible-to-use-different-bcma-targeted-agents-successively monthly 0.9 2022-09-28T12:18:00.000Z https://multiplemyelomahub.com/medical-information/esmo-2022 monthly 0.9 2022-12-07T10:45:00.000Z https://multiplemyelomahub.com/medical-information/current-perspectives-on-circulating-tumor-cells-in-newly-diagnosed-mm-eligible-for-transplant monthly 0.9 2022-09-06T08:52:00.000Z https://multiplemyelomahub.com/medical-information/epidemiological-update-on-the-incidence-of-multiple-myeloma-and-mortality-up-to-2020 monthly 0.9 2022-09-01T16:52:00.000Z https://multiplemyelomahub.com/medical-information/teclistamab-receives-ema-conditional-marketing-authorization monthly 0.9 2022-08-26T12:48:00.000Z https://multiplemyelomahub.com/medical-information/ims-congress-2022 monthly 0.9 2022-09-14T21:55:00.000Z https://multiplemyelomahub.com/medical-information/karmma-3-trial-of-ide-cel-vs-soc-in-rrmm-meets-its-primary-endpoint monthly 0.9 2024-06-25T15:48:00.000Z https://multiplemyelomahub.com/medical-information/rg2634-a-novel-bispecific-antibody-targeting-gprc5d-for-the-treatment-of-rrmm monthly 0.9 2023-03-21T13:44:00.000Z https://multiplemyelomahub.com/medical-information/identifying-and-managing-ocular-toxicities-in-patients-with-mm monthly 0.9 2022-08-11T12:46:00.000Z https://multiplemyelomahub.com/medical-information/high-risk-cytogenetics-in-patients-with-ndmm-treated-with-dara-krd-and-tandem-asct-results-of-the-ifm-2018-04-trial monthly 0.9 2022-08-18T03:46:00.000Z https://multiplemyelomahub.com/medical-information/efficacy-of-oricar-017-a-gprc5d-directed-car-t-cell-therapy-in-patients-with-rr-mm-findings-from-the-polaris-study monthly 0.9 2022-08-09T15:00:00.000Z https://multiplemyelomahub.com/medical-information/results-from-the-cartbcma-hcb-01-clinical-trial-assessing-the-efficacy-and-safety-of-ari0002h-an-academic-bcma-directed-car-t-cell-therapy-for-rrmm monthly 0.9 2023-09-15T23:32:00.000Z https://multiplemyelomahub.com/medical-information/weighing-up-pfs-and-os-in-the-determination-trial-re-evaluating-the-role-of-transplant-in-myeloma monthly 0.9 2022-07-28T14:53:00.000Z https://multiplemyelomahub.com/medical-information/classification-and-treatment-of-frail-and-ultra-frail-patients-with-multiple-myeloma-challenges-and-future-perspectives monthly 0.9 2024-07-16T12:58:00.000Z https://multiplemyelomahub.com/medical-information/eha-2022 monthly 0.9 2022-08-10T10:44:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-pros-and-cons-of-bispecific-antibodies-for-multiple-myeloma monthly 0.9 2022-07-28T12:40:00.000Z https://multiplemyelomahub.com/medical-information/teclistamab-for-relapsedrefractory-multiple-myeloma-updated-phase-iii-majestec-1-results monthly 0.9 2022-07-26T12:57:00.000Z https://multiplemyelomahub.com/medical-information/results-of-a-phase-iii-study-investigating-belantamab-mafodotin-in-combination-with-lenalidomide-and-dexamethasone-as-frontline-therapy monthly 0.9 2022-07-25T14:05:00.000Z https://multiplemyelomahub.com/medical-information/discussion-2-integrating-bcma-directed-agents-in-the-treatment-landscape-for-relapsedrefractory-mm monthly 0.9 2025-08-06T08:15:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-combined-with-vd-receives-european-marketing-authorization-for-rrmm monthly 0.9 2022-07-22T16:06:00.000Z https://multiplemyelomahub.com/medical-information/discussion-1-the-role-of-consolidation-after-autologous-stem-cell-transplantation monthly 0.9 2025-08-06T08:15:00.000Z https://multiplemyelomahub.com/medical-information/the-gem-pethema-score-for-assessing-the-risk-of-early-severe-infection monthly 0.9 2022-07-13T09:15:00.000Z https://multiplemyelomahub.com/medical-information/is-experience-with-ide-cel-car-t-in-the-real-world-setting-comparable-to-the-karmma-trial-results monthly 0.9 2022-07-05T15:09:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-initial-results-of-adc-based-combinations monthly 0.9 2022-07-05T15:12:00.000Z https://multiplemyelomahub.com/medical-information/talquetamab-receives-breakthrough-therapy-designation-from-the-fda monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/delving-into-the-prospects-of-mass-spectrometry-in-multiple-myeloma monthly 0.9 2022-07-01T10:27:00.000Z https://multiplemyelomahub.com/medical-information/comy-22 monthly 0.9 2022-08-12T14:18:00.000Z https://multiplemyelomahub.com/medical-information/initial-data-from-the-phase-i-study-of-cart-ddbcma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-promise-study-what-have-we-learnt-about-mgus-prevalence-and-clinical-implications monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/recommendations-for-transplantation-in-mm-from-the-american-society-for-transplantation-and-cellular-therapy monthly 0.9 2022-06-17T09:04:00.000Z https://multiplemyelomahub.com/medical-information/how-to-manage-bridging-therapies-prior-to-car-t-cells-in-multiple-myeloma monthly 0.9 2023-04-27T09:03:00.000Z https://multiplemyelomahub.com/medical-information/cartitude-2-cohort-b-results-of-cilta-cel-in-patients-with-early-relapsed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/which-targets-are-being-explored-in-myeloma-with-bispecific-antibodies monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-current-and-future-strategies-for-maintenance-therapy-after-autologous-transplant monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2022 monthly 0.9 2022-09-02T08:47:00.000Z https://multiplemyelomahub.com/medical-information/eha2022-abstracts-what-s-hot-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/supportive-care-in-multiple-myeloma-managing-fatigue-cognitive-impairment-and-psychological-wellbeing monthly 0.9 2024-07-16T12:55:00.000Z https://multiplemyelomahub.com/medical-information/how-might-the-mass-score-aid-treatment-decisions-for-newly-diagnosed-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/conditional-approval-granted-to-cilta-cel-by-the-ec monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/defining-relapsed-and-refractory-mm-the-challenges-and-controversies monthly 0.9 2022-05-27T08:27:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-key-considerations-of-the-updated-guidelines-for-early-relapsed-multiple-myeloma monthly 0.9 2024-07-16T13:30:00.000Z https://multiplemyelomahub.com/medical-information/how-is-the-definition-of-high-risk-mm-evolving monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/bhv-1100-a-bispecific-antibody-recruiting-molecule monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/in-the-era-of-upfront-quadruplets-is-there-still-a-role-for-tandem-transplant monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2022 monthly 0.9 2022-08-12T14:00:00.000Z https://multiplemyelomahub.com/medical-information/novel-risk-score-for-predicting-early-relapse-in-patients-with-multiple-myeloma monthly 0.9 2024-07-16T13:27:00.000Z https://multiplemyelomahub.com/medical-information/challenges-and-future-directions-for-access-to-cell-therapies-a-global-perspective monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/combining-bispecific-antibodies-with-monoclonal-antibodies-to-treat-relapsedrefractory-mm monthly 0.9 2022-11-14T10:26:00.000Z https://multiplemyelomahub.com/medical-information/what-factors-correlate-with-a-better-response-to-bcma-directed-car-t-cell-products monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/initial-results-in-rrmm-with-modakafusp-alfa-a-first-in-class-cd38-targeted-immunocytokine monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-can-mrd-assessment-help-when-treating-patients-with-high-risk-mm-after-transplantation monthly 0.9 2024-07-16T13:27:00.000Z https://multiplemyelomahub.com/medical-information/the-phase-iii-trial-of-at-01-a-radiotracer-for-amyloidosis-deposits monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-might-be-the-advantages-and-disadvantages-of-treating-with-daratumumab-upfront monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/management-of-pain-understanding-the-current-needs-of-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-ema-chmp-provide-positive-opinion-on-cilta-cel-for-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/management-of-short-medium-and-long-term-complications-in-patients-receiving-car-t-cell-therapy monthly 0.9 2022-03-29T16:27:00.000Z https://multiplemyelomahub.com/medical-information/first-in-human-study-of-regn5458-a-novel-bcma-bispecific-antibody monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/access-and-future-prospects-of-advanced-immunotherapies-for-multiple-myeloma-in-europe monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-supportive-care-is-needed-for-patients-receiving-car-t-cell-therapy monthly 0.9 2024-07-16T12:56:00.000Z https://multiplemyelomahub.com/medical-information/precision-medicine-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/imwg-recommendations-for-infections-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/cevostamab-for-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-21 monthly 0.9 2022-08-12T14:39:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-ciltacabtagene-autoleucel-for-the-treatment-of-patients-with-rrmm monthly 0.9 2024-07-16T13:13:00.000Z https://multiplemyelomahub.com/medical-information/venetoclax-with-carfilzomib-and-dexamethasone-in-patients-with-relapsed-or-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-do-car-t-cell-recipients-respond-to-covid-19-vaccination monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/update-from-the-griffin-trial-of-dara-rvd-in-newly-diagnosed-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-of-the-icaria-mm-trial-of-isatuximab-pomalidomide-and-dexamethasone-in-patients-with-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/elranatamab-a-subcutaneous-bcmacd3-bispecific-antibody-in-patients-with-rrmm-findings-from-the-magnetismm-1-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/incorporating-pet-imaging-in-a-new-risk-stratification-system-for-ndmm monthly 0.9 2024-07-16T13:28:00.000Z https://multiplemyelomahub.com/medical-information/mrd-guided-consolidation-and-treatment-de-escalation-results-from-the-master-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-iceland-screens-treats-or-prevents-multiple-myeloma-istopmm-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/visual-abstract-venetoclax-in-patients-with-multiple-myeloma-who-are-receiving-bortezomib-and-dexamethasone-as-standard-therapy-bellini monthly 0.9 2022-10-28T16:02:00.000Z https://multiplemyelomahub.com/medical-information/results-of-treatment-with-ixazomib-daratumumab-in-intermediate-fit-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/isatuximab-with-rvd-in-patients-with-newly-diagnosed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/response-to-anti-bcma-car-t-therapy-in-patients-with-renal-dysfunction monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/in-which-scenarios-a-pi-added-to-rd-maintenance-could-benefit-patients-with-mm-after-auto-hsct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-ao-176-orphan-drug-designation-for-the-treatment-of-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-can-we-achieve-with-novel-mass-spectrometry-techniques monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-as-maintenance-therapy-for-transplant-eligible-patients-with-ndmm-what-have-we-learned-from-griffin-and-cassiopeia-trials monthly 0.9 2022-01-14T14:07:00.000Z https://multiplemyelomahub.com/medical-information/updated-efficacy-and-safety-analysis-from-the-phase-iii-candor-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dara-c-vrd-pre-and-post-asct-for-ultra-high-risk-mm-and-primary-plasma-cell-leukemia monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-lifts-clinical-hold-on-allogeneic-car-t-cell-therapy-trials monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/forte-trial-update-carfilzomib-based-induction-and-maintenance-therapy-for-patients-with-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/life-after-car-t-clinical-outcomes-of-patients-with-mm-who-relapse-after-bcma-targeted-car-t-cell-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/emn-recommendations-for-covid-19-vaccination-in-patients-with-mm monthly 0.9 2024-07-16T13:34:00.000Z https://multiplemyelomahub.com/medical-information/carfilzomib-as-maintenance-therapy-after-upfront-and-salvage-asct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/humoral-and-cellular-responses-in-patients-with-lymphoid-malignancies-receiving-sars-cov-2-vaccination monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-there-still-a-role-in-mm-for-auto-sct-after-induction-with-a-quadruplet-combination monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/where-does-carfilzomib-fit-in-the-current-mm-treatment-landscape monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-should-chromosome-1-abnormalities-be-assessed-in-all-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/could-ctcs-and-tumor-dna-be-more-sensitive-than-a-bm-aspirate-to-assess-treatment-response-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2021-abstracts-what-s-hot-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-withdrawal-of-panobinostat-for-the-treatment-of-rr-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-approval-of-subcutaneous-daratumumab-carfilzomib-and-dexamethasone-for-rr-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/continuous-versus-fixed-duration-therapy-in-multiple-myeloma-the-great-debate monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/orphan-drug-designation-granted-to-a-fastcar-dual-targeting-car-t-cell-gc012f-for-the-treatment-of-rr-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/covid-19-lessons-learnt-in-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/treatment-pathways-and-patient-attrition-across-lines-of-therapy-the-french-experience monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/a-comprehensive-guide-on-when-and-how-to-treat-early-relapsed-multiple-myeloma monthly 0.9 2024-07-16T13:31:00.000Z https://multiplemyelomahub.com/medical-information/editorial-theme-or-neurotoxicity-and-anti-bcma-agents monthly 0.9 2024-07-16T13:23:00.000Z https://multiplemyelomahub.com/medical-information/vactosertib-plus-pomalidomide-without-corticosteroids-for-relapsed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-assessing-t-1114-can-be-the-first-step-towards-personalized-therapy-in-mm-2 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/managing-infections-with-novel-immunotherapies-prevention-treatment-and-impact-on-the-qol-of-patients-with-mm monthly 0.9 2021-11-16T11:14:00.000Z https://multiplemyelomahub.com/medical-information/editorial-theme-or-mechanisms-of-resistance-to-immunotherapies monthly 0.9 2024-07-16T13:23:00.000Z https://multiplemyelomahub.com/medical-information/maintenance-therapy-following-second-auto-hsct-a-cibmtr-analysis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-safety-and-efficacy-of-a-reduced-toxicity-regimen-in-frail-patients-with-ndmm monthly 0.9 2024-07-16T12:58:00.000Z https://multiplemyelomahub.com/medical-information/withdrawal-of-melflufen-in-combination-with-dexamethasone-for-patients-with-rrmm-in-the-u-s monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/geriatric-hematology-in-low-resource-settings-improving-care-for-older-people-through-the-implementation-of-geriatric-hematology-programs monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/a-generic-version-of-lenalidomide-capsules-has-been-approved-by-the-fda-for-mds-and-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/after-the-cardamon-trial-update-what-do-we-know-about-the-role-of-asct-and-k-maintenance-in-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-places-a-clinical-hold-on-allogeneic-car-t-cell-trials monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/end-of-the-lyra-study-dara-vcd-induction-therapy-followed-by-dara-maintenance monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-might-the-iberdomide-safety-profile-be-critical-for-its-future-implications monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/editorial-theme-or-carfilzomib-and-cardiovascular-adverse-events monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/after-the-latest-follow-up-of-the-master-trial-can-we-safely-implement-mrd-guided-frontline-treatment-in-the-clinic monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/racial-health-disparities-in-patients-with-multiple-myeloma-a-population-based-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/isatuximab-pd-in-the-frail-population-icaria-mm-subgroup-analysis monthly 0.9 2024-07-16T12:58:00.000Z https://multiplemyelomahub.com/medical-information/identifying-sensitivity-to-venetoclax-high-response-rates-reported-with-vendd-in-t-1114-relapsedrefractory-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-challenges-of-monitoring-organ-response-in-al-amyloidosis-what-has-been-achieved-so-far monthly 0.9 2021-09-24T10:29:00.000Z https://multiplemyelomahub.com/medical-information/my-top-5-communications-from-the-18th-imw monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/clonal-hematopoiesis-and-car-t-cell-therapy-outcomes monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-the-initial-efficacy-observed-with-melflufen-dexamethasone-has-not-translated-into-improved-overall-survival-os-in-the-ocean-phase-iii-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/imwg-clinical-practice-guidelines-for-the-treatment-of-multiple-myeloma-related-bone-disease monthly 0.9 2024-07-16T13:31:00.000Z https://multiplemyelomahub.com/medical-information/does-current-reporting-on-car-t-cell-therapy-in-clinical-trials-overestimate-efficacy-why-the-distinction-between-itt-and-mitt-populations-is-important monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/p-bcma-allo1-receives-clearance-of-investigational-new-drug-application-by-fda-for-the-treatment-of-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ct103a-improving-persistence-of-car-t-cell-therapy-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/epicovideha-registry-epidemiology-and-outcomes-in-patients-with-hematologic-malignancies-infected-with-covid-19 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ikema-isatuximab-in-combination-with-the-standard-of-care-regimen-carfilzomib-dexamethasone-for-the-treatment-of-rr-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/extended-follow-up-from-the-dreamm-2-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/severity-of-sars-cov-2-infection-and-the-safety-of-covid-19-vaccination-in-patients-receiving-hsct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/karmma-long-term-follow-up-and-subgroup-analysis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-regenerative-medicine-advanced-therapy-designation-to-allo-715-for-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/teclistamab-a-bcmacd3-bispecific-antibody-for-patients-with-rrmm-phase-i-majestec-1-trial-results monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/are-we-nearer-to-effective-care-in-the-elderly-mm-population monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/carfilzomib-bendamustine-and-dexamethasone-in-patients-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fungal-superinfections-and-covid-19-in-the-icu monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/preclinical-data-support-in-human-studies-of-cd38-t-cell-engager-isb-1342-for-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/interim-analysis-on-the-isa-krd-quadruplet-regimen-for-patients-with-high-risk-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/cilta-cel-for-relapsedrefractory-mm-updated-results-from-the-cartitude-1-and-cartitude-2-trials monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-to-identify-and-mitigate-neurologic-aes-when-treating-with-car-t-and-t-cell-engagers monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-to-treat-first-relapse-in-lenalidomide-refractory-mm monthly 0.9 2021-07-19T11:32:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-pomalidomide-and-dexamethasone-for-the-treatment-of-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dara-rd-for-patients-with-ndmm-ineligible-for-transplant-5-year-follow-up-of-the-maia-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-subcutaneous-daratumumab-pd-for-the-treatment-of-rr-mm monthly 0.9 2024-07-16T13:14:00.000Z https://multiplemyelomahub.com/medical-information/outcomes-of-triple-class-exposedrefractory-disease-in-real-world-care-what-is-the-current-soc monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/evaluating-the-addition-of-elotuzumab-to-krd-by-mrd-assessment-the-future-of-mrd-guided-treatment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/key-considerations-when-treating-patients-with-newly-diagnosed-high-risk-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-impact-of-car-t-cell-therapy-on-quality-of-life-of-patients-with-triple-class-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/when-sequencing-therapies-for-rrmm-how-can-we-identify-which-patients-may-benefit-most-from-car-t monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-main-challenges-for-treating-mm-in-brazil monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/with-the-unprecedented-results-seen-with-novel-therapies-what-is-needed-to-overcome-the-poor-prognosis-of-high-risk-mm monthly 0.9 2021-06-30T10:43:00.000Z https://multiplemyelomahub.com/medical-information/how-do-mm-cells-develop-resistance-to-bcma-targeted-agents-can-it-be-overcome-in-the-clinic monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/which-patients-could-benefit-most-from-post-hsct-maintenance-therapy-with-daratumumab-single-agent monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-maintenance-therapy-in-patients-with-ndmm-findings-from-cassiopeia-part-2 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-can-mrd-kinetics-assessment-help-with-treatment-decisions-during-maintenance-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/initial-results-of-cilta-cel-a-car-t-cell-therapy-in-earlier-lines-of-treatment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-major-advances-for-the-triple-class-exposed-population monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ide-cel-in-triple-class-rrmm-key-efficacy-and-safety-data-from-the-karmma-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-ec-has-extended-approval-for-sc-daratumumab-vcd-for-al-amyloidosis-based-on-updated-results-from-the-phase-iii-andromeda-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-krd-hsct-overcome-the-poor-prognosis-of-harboring-a-high-risk-cytogenetic-aberration monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-ec-has-extended-marketing-authorization-for-sc-daratumumab-pd-for-the-treatment-of-rr-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-isa-krd-achieve-deep-responses-in-high-risk-ndmm-regardless-of-transplant-eligibility monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-daratumumab-vrd-cyclophosphamide-might-be-an-option-to-consider-for-high-risk-ndmm monthly 0.9 2021-07-21T15:07:00.000Z https://multiplemyelomahub.com/medical-information/does-allo-hsct-still-have-a-role-in-high-risk-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/attenuated-responses-to-covid-19-vaccination-in-patients-with-hematologic-malignancies monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-challenges-and-possibilities-of-ctdna-to-monitor-response-and-relapse-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-you-need-to-know-about-keratopathy-management-with-belamaf monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha2021-abstracts-what-s-hot-in-multiple-myeloma-and-al-amyloidosis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/3-things-you-should-consider-when-treating-frail-patients monthly 0.9 2024-07-16T12:58:00.000Z https://multiplemyelomahub.com/medical-information/positive-topline-results-of-the-phase-iii-ocean-study-of-melflufen-for-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ixazomib-lenalidomide-and-dexamethasone-as-first-line-therapy-tourmaline-mm2-trial-update monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-i-treat-patients-with-mrd-after-transplantation monthly 0.9 2023-04-27T09:03:00.000Z https://multiplemyelomahub.com/medical-information/when-is-the-optimal-time-to-start-talking-with-your-patient-about-car-t-cells monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/when-bcma-directed-therapy-is-not-an-option-how-should-we-treat-late-relapse monthly 0.9 2021-05-24T08:14:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-hub-satellite-symposium-highlights-should-cure-be-the-goal-for-mm monthly 0.9 2024-07-16T13:21:00.000Z https://multiplemyelomahub.com/medical-information/how-will-studying-the-mm-immune-system-and-microenvironment-help-us-understand-drug-resistance monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-could-mass-spectrometry-substitute-ife-in-diagnosis-and-monitoring-of-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/roundtable-discussionmultiple-myeloma-hub-satellite-symposium-should-cure-be-the-goal-for-mm monthly 0.9 2024-07-16T13:21:00.000Z https://multiplemyelomahub.com/medical-information/treating-elderly-and-frail-patients-with-mm-cure-versus-disease-control monthly 0.9 2024-07-16T12:58:00.000Z https://multiplemyelomahub.com/medical-information/is-transplantation-still-relevant-if-yes-in-which-context monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-the-treatment-of-high-risk-smm-the-way-for-achieving-the-cure monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/does-cure-have-a-different-meaning-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/covid-19-vaccination-for-hematopoietic-stem-cell-transplant-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/3-things-to-remember-when-diagnosing-patients-with-mgus monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-major-challenges-for-car-t-cell-therapies-in-europe-during-the-covid-19-pandemic monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/efficacy-and-feasibility-of-doseschedule-adjusted-rd-r-in-elderly-intermediate-fit-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/which-actionable-mutations-in-mm-are-the-mmrf-testing-in-their-mydrug-initiative monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-should-we-perform-pet-ct-in-a-patient-with-smm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/5-things-you-need-to-know-when-diagnosing-and-treating-monoclonal-gammopathy-of-renal-significance monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/positive-topline-results-from-phase-iii-genesis-trial-of-motixafortide-g-csf-for-hematopoietic-stem-cell-mobilization monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/mass-fix-for-m-protein-measurement-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/key-concepts-when-talking-about-cure-of-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/moving-beyond-car-t-cell-therapy-why-is-everyone-talking-about-nk-cell-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/results-from-the-karmma-trial-on-ide-cel-in-patients-with-relapsedrefractory-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-clears-investigational-new-drug-application-for-allo-605-for-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ec-approves-isatuximab-combined-with-carfilzomib-and-dexamethasone-for-the-treatment-of-relapsed-mm monthly 0.9 2024-07-16T13:14:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-plus-vrd-vs-vrd-in-newly-diagnosed-mm-griffin-trial-updated-analysis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/editorial-theme-or-how-multiple-myeloma-cells-develop-resistance-toescape-from-bcma-directed-novel-agents monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/which-novel-agents-will-benefit-frail-patients monthly 0.9 2024-07-16T12:58:00.000Z https://multiplemyelomahub.com/medical-information/car-t-versus-bispecific-antibodies-and-bites-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-clears-investigational-new-drug-application-for-aclx-001-for-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dart4mm-study-can-daratumumab-consolidation-achieve-mrd-negativity-after-frontline-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-do-we-need-better-myeloablative-conditioning-regimens-and-what-alternatives-are-being-explored monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-key-additions-to-the-new-nccn-guidelines-for-multiple-myeloma monthly 0.9 2024-07-16T13:31:00.000Z https://multiplemyelomahub.com/medical-information/which-therapies-are-most-frequently-used-in-triple-exposed-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/salvage-auto-hct-outcomes-with-remobilized-stem-cells-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/updating-the-nccn-guidelines-for-the-diagnosis-and-treatment-of-mgus-and-smm monthly 0.9 2024-07-16T13:31:00.000Z https://multiplemyelomahub.com/medical-information/advances-of-cell-therapies-in-china-reducing-manufacturing-time-with-fast-dual-car-t-cells monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/if-maintenance-after-induction-reduces-therapy-options-at-relapse-is-it-still-worth-it monthly 0.9 2021-04-01T16:10:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-dexamethasone-receives-conditional-marketing-authorization-from-the-european-commission-for-rr-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-isatuximab-combined-with-carfilzomib-and-dexamethasone-for-the-treatment-of-rrmm monthly 0.9 2024-07-16T13:14:00.000Z https://multiplemyelomahub.com/medical-information/when-is-the-optimal-time-to-use-bispecific-antibodies-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-is-there-to-know-about-the-ebmt-gocart-coalition monthly 0.9 2021-04-01T11:06:00.000Z https://multiplemyelomahub.com/medical-information/approval-of-idecabtagene-vicleucel-by-the-u-s-food-and-drug-administration monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-advantages-of-car-t-cells-derived-from-pluripotent-stem-cells monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-key-differences-between-bispecific-antibodies-and-car-t-cells monthly 0.9 2021-04-01T11:05:00.000Z https://multiplemyelomahub.com/medical-information/european-myeloma-network-vaccine-recommendations-for-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-can-patterns-of-immune-reconstitution-guide-treatment-early-after-transplant monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/nice-overturns-previous-decision-on-carfilzomib-lenalidomide-and-dexamethasone-for-the-treatment-of-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha-esmo-clinical-practice-guidelines-for-the-diagnosis-treatment-and-follow-up-of-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-it-safe-to-perform-asct-in-patients-with-renal-insufficiency monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-isa-kd-efficacious-in-patients-who-have-received-prior-asct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/nccn-covid-19-vaccination-recommendations-for-patients-with-hematologic-malignancies monthly 0.9 2024-07-16T13:34:00.000Z https://multiplemyelomahub.com/medical-information/orphan-drug-designation-granted-to-cc-99712-for-the-treatment-of-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/sustained-mrd-in-patients-with-newly-diagnosed-and-relapsedrefractory-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-lenalidomide-maintenance-be-given-to-patients-with-mm-and-covid-19-infection monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/where-are-we-on-anti-bcma-car-t-cell-therapies-for-mm monthly 0.9 2021-04-01T19:11:00.000Z https://multiplemyelomahub.com/medical-information/nice-recommends-lenalidomide-maintenance-after-auto-sct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/iberdomide-and-dexamethasone-with-bortezomib-or-daratumumab-for-relapsed-and-refractory-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/positive-ema-s-chmp-opinion-announced-for-isatuximab-with-carfilzomib-and-dexamethasone-in-relapsed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-approval-of-melflufen-in-combination-with-dexamethasone-for-rr-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-the-phase-iii-emn02ho95-study-in-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/phase-iia-trial-initiated-for-descartes-11-a-mrna-car-t-cell-therapy-for-patients-with-newly-diagnosed-high-risk-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/allogeneic-car-t-cell-therapy-for-relapsed-or-refractory-multiple-myeloma-results-from-the-universal-trial monthly 0.9 2023-03-09T22:20:00.000Z https://multiplemyelomahub.com/medical-information/ash-2020-discussion-looking-for-the-best-partner-for-lenalidomide-maintenance-after-auto-sct monthly 0.9 2021-02-22T17:13:00.000Z https://multiplemyelomahub.com/medical-information/preliminary-results-of-phase-i-trials-on-safety-and-tolerability-of-bispecific-antibodies-and-bites-for-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fast-track-designation-and-phase-ii-trial-initiation-with-elranatamab-a-bcmacd3-bispecific-antibody monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/new-findings-on-the-role-of-the-immune-microenvironment-presented-at-ash-2020 monthly 0.9 2021-04-01T11:18:00.000Z https://multiplemyelomahub.com/medical-information/survival-rates-and-impact-of-mrd-using-mfc-and-ngs-in-newly-diagnosed-multiple-myeloma-patients-results-from-the-forte-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-do-i-manage-the-risk-of-infection-in-patients-treated-with-immunotherapies monthly 0.9 2021-04-01T11:05:00.000Z https://multiplemyelomahub.com/medical-information/results-from-the-lummicar-2-study-of-ct053-a-human-bcma-specific-car-t-therapy-for-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/hdp-101-an-antibody-targeted-amanitin-conjugate-to-advance-to-phase-iiia-testing monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/phase-i-results-of-medi2228-an-anti-bcma-antibodydrug-conjugate-in-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/should-we-still-use-high-dose-melphalan-in-the-era-of-novel-agents monthly 0.9 2021-02-09T14:58:00.000Z https://multiplemyelomahub.com/medical-information/accelerated-assessment-of-cilta-cel-announced-by-the-ema monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/panorama-3-panobinostat-can-be-safely-combined-with-subcutaneous-bortezomib monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/positive-opinion-from-ema-s-chmp-on-selinexor-with-dexamethasone-for-patients-with-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-unmet-needs-in-al-amyloidosis-in-europe monthly 0.9 2021-02-02T08:59:00.000Z https://multiplemyelomahub.com/medical-information/should-we-use-melflufen-to-treat-relapsed-patients-with-poor-prognosis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2020-discussion-the-role-of-upfront-transplant-consolidation-in-the-era-of-novel-agents monthly 0.9 2021-01-28T09:21:00.000Z https://multiplemyelomahub.com/medical-information/how-does-bite-r-amg-701-compare-to-other-immunotherapies-for-heavily-pretreated-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/birma-trial-is-braf-and-mek-inhibition-successful-in-relapsed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-the-bsab-teclistamab-safe-and-effective-in-patients-with-relapsedrefractory-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/cft7455-receives-clearance-of-investigational-new-drug-application-by-fda-for-the-treatment-of-multiple-myeloma-and-non-hodgkin-lymphoma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/talquetamab-for-relapsedrefractory-multiple-myeloma-results-from-a-phase-i-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/anchor-melflufen-triplet-regimens-for-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/accelerated-approval-granted-by-fda-for-daratumumab-sc-vcd-for-al-amyloidosis-in-light-of-the-phase-iii-andromeda-trial-updated-results monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/vrd-alone-or-followed-by-asct-in-ndmm-ifm-2009-long-term-results monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/orphan-drug-designation-granted-for-hpn217-a-bcma-targeting-trispecific-t-cell-engager-for-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/redefining-pet-response-criteria-for-complete-metabolic-response-in-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/cartitude-1-results-indicate-deep-and-durable-responses-with-cilta-cel-for-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/racial-differences-in-clinical-trial-enrollment-treatment-and-survival-outcomes-in-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/thrombosis-and-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prognostic-biomarkers-and-staging-in-al-amyloidosis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-single-cell-sequencing-help-to-better-define-and-monitor-mm monthly 0.9 2021-02-01T16:47:00.000Z https://multiplemyelomahub.com/medical-information/venetoclax-bortezomib-and-dexamethasone-in-mm-updated-results-from-bellini-trial-and-t-1114-subgroup-analysis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/a-real-world-analysis-on-the-importance-of-treating-mm-with-best-available-therapy-in-earlier-lines monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/apollo-trial-results-addition-of-daratumumab-to-pomalidomide-dexamethasone-in-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-in-combination-with-bortezomib-and-dexamethasone-approved-for-relapsedrefractory-multiple-myeloma monthly 0.9 2024-07-16T13:14:00.000Z https://multiplemyelomahub.com/medical-information/why-gprc5d-is-a-promising-target-for-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/should-krd-r-become-standard-of-care-for-high-risk-smm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-is-ct053-different-from-other-bcma-directed-car-t-cell-therapies monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-does-the-ifm2009-trial-impact-the-current-treatment-of-transplant-eligible-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-can-palliative-care-improve-the-outcomes-of-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/cartitude-1-study-are-responses-with-cilta-cel-deep-and-durable monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-we-use-circulating-tumor-cells-to-identify-high-risk-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/does-dw-mri-replace-or-complement-mrd-for-response-assessment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-circulating-tumor-cell-assessment-by-flow-replace-bone-marrow-aspirates-to-monitor-smm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/editorial-theme-or-incidence-and-diagnosis-of-al-amyloidosis monthly 0.9 2024-07-16T13:23:00.000Z https://multiplemyelomahub.com/medical-information/towards-ash-2020-highlights-on-smoldering-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-imwg-22020-risk-stratification-model-for-smoldering-multiple-myeloma monthly 0.9 2024-07-16T13:28:00.000Z https://multiplemyelomahub.com/medical-information/latest-advances-in-al-amyloidosis-treatment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/maintenance-therapy-with-ixazomib-an-in-depth-analysis-of-tourmaline-mm4-results monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/request-for-approval-of-daratumumab-plus-pomalidomide-and-dexamethasone-submitted-to-ema-and-fda monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/editorial-theme-or-what-you-need-to-know-about-high-risk-multiple-myeloma monthly 0.9 2024-07-16T13:24:00.000Z https://multiplemyelomahub.com/medical-information/mortality-risk-and-clinical-outcomes-in-patients-with-mm-admitted-to-hospital-with-sars-cov-2covid-19-infection monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-re-treatment-possible-with-anti-cd38-therapies monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/my-experience-with-novel-immunotherapies monthly 0.9 2020-11-12T09:24:00.000Z https://multiplemyelomahub.com/medical-information/how-to-achieve-the-best-results-in-patients-with-high-risk-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-orphan-drug-status-to-an-investigational-nk-cell-based-therapy-for-the-treatment-of-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/predictive-factors-of-mortality-in-patients-with-hematological-malignancies-diagnosed-with-covid-19 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/primary-refractory-multiple-myeloma-real-world-experience-and-recommendations monthly 0.9 2024-07-16T13:34:00.000Z https://multiplemyelomahub.com/medical-information/should-smoldering-multiple-myeloma-be-treated monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/mobilizing-autologous-stem-cells-after-monoclonal-antibody-and-immunomodulatory-drug-based-induction-therapy-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/suggested-update-to-current-imwg-complete-response-criteria-for-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-compared-with-the-current-standard-of-care-in-penta-treated-triple-class-refractory-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/tourmaline-mm2-trial-ixazomib-with-rd-versus-rd-in-newly-diagnosed-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/second-part-of-the-phase-iii-cassiopeia-study-meets-its-primary-endpoint monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/nice-recommends-isatuximab-in-combination-with-pomalidomide-and-dexamethasone-for-the-treatment-of-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-do-we-need-to-harmonize-the-use-of-mrd-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/do-s-and-don-ts-when-diagnosing-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/lymphodepletion-optimization-for-car-t-cell-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-there-an-optimal-time-to-deploy-immunotherapies-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-high-dose-therapy-plus-auto-sct-still-plays-a-role-in-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/which-patients-with-smoldering-multiple-myeloma-would-you-enrol-in-a-clinical-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/should-all-patients-with-mm-receive-maintenance-therapy-after-transplantation monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-orphan-drug-designation-to-universal-off-the-shelf-nk-cell-therapy-product-for-the-treatment-of-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-to-use-mrd-status-to-treat-high-risk-multiple-myeloma monthly 0.9 2024-07-16T13:28:00.000Z https://multiplemyelomahub.com/medical-information/bispecific-antibodies-and-bites-currently-in-development-in-2020-for-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/suvmax-is-a-new-prognostic-indicator-for-patients-with-newly-diagnosed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/new-slamf7-targeted-car-t-cell-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/at-what-point-should-allo-sct-or-auto-allo-sct-be-considered-for-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/priority-review-for-ide-cel-granted-by-the-fda monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/krd-plus-auto-sct-induces-high-quality-durable-responses-in-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-microbiome-and-its-effects-on-the-immune-system monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/exploring-the-optimal-dose-for-lenalidomide-maintenance-after-auto-sct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-to-treat-triple-class-refractory-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/encouraging-results-for-clr-131-in-triple-class-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/use-of-ruxolitinib-in-patients-with-severe-covid-19 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-can-we-predict-responses-to-car-t-cell-therapies-such-as-bb2121 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/changing-practice-patterns-in-autologous-transplantation-at-ebmt-centers monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-clinical-significance-of-chromosome-1-abnormalities-in-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/a-novel-composite-scoring-system-to-predict-mortality-after-auto-hsct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/international-consensus-for-mrd-assessment-in-mm-clinical-trials monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/priority-review-of-melflufen-for-patients-with-triple-class-refractory-mm-by-fda monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/maria-victoria-mateos-s-top-3-breakthroughs-in-transplant-for-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-dara-vtd-the-best-induction-treatment-for-high-risk-patients-with-newly-diagnosed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/why-do-we-not-see-curative-car-t-cell-therapy-in-mm-compared-to-dlbcl-and-all monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-should-we-monitor-risk-of-progression-in-patients-achieving-mrd-negativity-after-auto-sct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-european-commission-approves-belantamab-mafodotin-for-the-treatment-of-patients-with-rrmm monthly 0.9 2024-07-16T13:14:00.000Z https://multiplemyelomahub.com/medical-information/the-impact-of-sarcopenia-in-patients-with-multiple-myeloma-undergoing-auto-hct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-daratumumab-plus-carfilzomib-and-dexamethasone-for-the-treatment-of-rrmm monthly 0.9 2024-07-16T13:14:00.000Z https://multiplemyelomahub.com/medical-information/tandem-stem-cell-transplantation-for-newly-diagnosed-high-risk-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/car-t-cell-therapy-or-bispecific-t-cell-engagers-for-the-treatment-of-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-you-identify-high-risk-mm-more-effectively monthly 0.9 2024-07-16T13:29:00.000Z https://multiplemyelomahub.com/medical-information/is-there-an-increased-risk-of-second-primary-malignancies-in-older-patients-treated-with-lenalidomide monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/differences-in-safety-profiles-of-panobinostat-ixazomib-elotuzumab-and-daratumumab-in-real-world-settings-versus-randomized-controlled-clinical-trials monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/belantamab-mafodotin-has-been-approved-by-the-fda-for-the-treatment-of-patients-with-rrmm monthly 0.9 2024-07-16T13:14:00.000Z https://multiplemyelomahub.com/medical-information/positive-topline-results-from-phase-iii-apollo-study-of-daratumumab-plus-pomalidomide-and-dexamethasone-in-the-treatment-of-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/predicting-early-relapse-in-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/results-from-the-tourmaline-mm4-trial-ixazomib-for-maintenance monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-clinical-value-of-adding-daratumumab-to-cybord-in-the-treatment-of-light-chain-amyloidosis-results-from-phase-iii-andromeda-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/belantamab-mafodotin-gets-positive-recommendations-from-both-ema-and-fda-to-be-approved-for-the-treatment-of-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/pomalidomide-vd-for-rrmm-latest-updates-on-the-optimismm-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-vrd-or-rad-induction-more-efficacious-for-patients-with-ndmm-undergoing-risk-adapted-auto-sct monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/evolve-trial-can-innovative-orva-cel-technology-be-a-new-option-for-patients-with-relapsedrefractory-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-combined-with-bortezomib-dexamethasone-the-boston-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-triplets-for-relapsedrefractory-multiple-myelomaan-alternative-to-imid-based-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/should-anti-cd38-antibodies-be-used-in-all-patients-as-induction-therapy-prior-to-transplant monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/longer-term-follow-up-of-the-phase-iii-trial-swog-s0777-vrd-for-patients-with-previously-untreated-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-daratumumab-overcome-the-negative-prognostic-impact-of-high-risk-cytogenetics-i monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/long-term-outcomes-of-lenalidomide-maintenance-after-the-stamina-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/frontline-treatment-regimens-for-patients-with-multiple-myeloma-and-renal-impairment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-can-we-use-the-microbiome-to-improve-cancer-immunotherapy-and-alleviate-side-effect-such-as-graft-versus-host-disease monthly 0.9 2020-08-26T13:01:00.000Z https://multiplemyelomahub.com/medical-information/practice-changing-abstracts-at-asco-and-eha-2020 monthly 0.9 2022-09-02T13:38:00.000Z https://multiplemyelomahub.com/medical-information/fda-places-a-clinical-hold-on-the-melani-01-study-in-patients-with-rr-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/melphalan-flufenamide-melflufen-novel-agents-for-rrmm monthly 0.9 2020-08-26T12:59:00.000Z https://multiplemyelomahub.com/medical-information/review-or-latest-updates-on-quadruplet-therapy-for-newly-diagnosed-mm monthly 0.9 2024-07-16T13:24:00.000Z https://multiplemyelomahub.com/medical-information/the-role-of-consolidation-in-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-interim-analysis-results-of-the-phase-iii-ikema-trial-or-isatuximab-kd-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/defining-the-significance-of-mgus-the-bone-marrow-microenvironment-is-compromised-from-an-early-stage-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/updates-from-the-karmma-trial monthly 0.9 2020-09-23T13:21:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-key-biological-and-clinical-characteristics-of-patients-with-ultra-low-risk-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/novel-approaches-in-multiple-myeloma-what-is-unique-about-celmods monthly 0.9 2020-08-26T12:59:00.000Z https://multiplemyelomahub.com/medical-information/isatuximab-plus-krd-for-high-risk-ndmm monthly 0.9 2020-08-26T12:59:00.000Z https://multiplemyelomahub.com/medical-information/hot-topics-in-mm-quadruplets-and-anti-bcma-therapy monthly 0.9 2020-08-26T12:58:00.000Z https://multiplemyelomahub.com/medical-information/genomics-of-high-risk-myeloma monthly 0.9 2020-08-26T12:58:00.000Z https://multiplemyelomahub.com/medical-information/the-association-between-the-diversity-of-the-oral-microbiome-and-pfs monthly 0.9 2020-08-26T12:57:00.000Z https://multiplemyelomahub.com/medical-information/can-daratumumab-overcome-the-negative-prognostic-impact-of-high-risk-cytogenetics monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-to-decide-between-bispecific-antibodies-or-car-t-cell-therapies monthly 0.9 2023-04-27T09:06:00.000Z https://multiplemyelomahub.com/medical-information/nk-cell-therapy-for-the-treatment-of-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-to-diagnose-and-treat-high-risk-multiple-myeloma-after-eha-2020 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-dreamms-at-asco-updates-on-belantamab-mafodotin-added-to-mm-backbone-therapies monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/novel-approaches-in-multiple-myeloma-bfcr4350a monthly 0.9 2020-08-26T12:57:00.000Z https://multiplemyelomahub.com/medical-information/the-dreamms-at-asco-updates-on-belantamab-mafodotin-as-a-single-agent monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-to-treat-elderly-patients-with-multiple-myeloma-in-2020 monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/how-to-diagnose-and-treat-smoldering-myeloma-in-2020 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/updates-from-dreamm-6-or-belantamab-mafodotin-in-combination-with-vd-in-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/endurance-phase-iii-results-krd-is-not-superior-to-vrd-for-newly-diagnosed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-potential-of-selinexor-combinations-for-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/preparing-for-the-eha25-highlights-from-2019-and-abstracts-to-watch-in-2020 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/subcutaneous-formulation-of-daratumumab-approved-by-the-european-commission monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-i-treat-elderly-patients-with-ndmm monthly 0.9 2020-08-26T12:53:00.000Z https://multiplemyelomahub.com/medical-information/understanding-resistance-mechanisms-to-current-standard-of-care-and-how-to-overcome-them monthly 0.9 2020-08-26T12:52:00.000Z https://multiplemyelomahub.com/medical-information/what-is-plasma-cell-leukemia-and-what-are-the-latest-advances-in-treatment monthly 0.9 2020-08-26T12:52:00.000Z https://multiplemyelomahub.com/medical-information/update-from-cartitude-1-or-what-s-new-since-ash monthly 0.9 2020-08-26T12:56:00.000Z https://multiplemyelomahub.com/medical-information/can-belantamab-mafodotin-be-used-in-patients-with-renal-impairment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-vrd-induction-suitable-for-patients-with-ndmm-and-renal-impairment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/novel-approaches-in-multiple-myeloma-tak-079 monthly 0.9 2020-08-26T12:56:00.000Z https://multiplemyelomahub.com/medical-information/should-we-use-krd-or-vrd-for-patients-with-ndmm monthly 0.9 2020-11-18T14:38:00.000Z https://multiplemyelomahub.com/medical-information/isatuximab-combination-therapy-approved-by-the-european-commission monthly 0.9 2024-07-16T13:15:00.000Z https://multiplemyelomahub.com/medical-information/comy-2020-or-sequencing-treatments-for-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-optimal-treatment-for-bone-lesions-including-patients-with-renal-insufficiency monthly 0.9 2020-08-26T12:54:00.000Z https://multiplemyelomahub.com/medical-information/results-of-the-phase-iii-emn02ho95-study-in-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/recent-advances-in-our-understanding-of-myeloma-progression monthly 0.9 2020-08-26T12:54:00.000Z https://multiplemyelomahub.com/medical-information/quadruplet-combinations-in-transplant-ineligible-ndmm-isatuximab-vd-cyclo-or-len monthly 0.9 2020-08-26T12:53:00.000Z https://multiplemyelomahub.com/medical-information/gem2012menos65-trial-or-detection-of-measurable-residual-disease-in-mm-using-the-next-generation-flow-cytometry monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/diagnosis-of-myeloma-in-complex-clinical-scenarios monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/bispecific-antibodies-for-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/highlights-from-the-first-virtual-comy-meeting monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-clears-ft538-the-first-crispr-edited-ipsc-derived-cell-therapy-for-investigation-as-a-new-drug-in-aml-and-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/comy-2020-or-highlights-from-the-oral-abstract-session monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-key-diagnostic-criteria-for-confirming-mgus monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-gold-standard-for-imaging-and-how-can-this-be-implemented-globally monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/phase-ib-final-analysis-isatuximab-carfilzomib monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-t-1416-an-independent-prognostic-factor-in-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/long-term-outcomes-of-patients-with-mm-after-bortezomib-lenalidomide-and-dexamethasone-induction-therapy monthly 0.9 2021-04-05T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-potential-impact-of-curate-ai-on-clinical-practice-in-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/safety-of-trial-participants-is-fda-s-top-priority-in-ongoing-clinical-trials-during-the-covid-19-outbreak monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/effect-of-ecog-performance-status-on-real-life-outcomes-of-patients-with-relapsedrefractory-multiple-myeloma-treated-with-daratumumab monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/educational-theme-or-monoclonal-antibodies-for-the-treatment-of-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-plus-vrd-in-transplant-eligible-patients-with-newly-diagnosed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/isatuximab-combination-therapy-for-relapsed-and-refractory-multiple-myeloma-or-results-from-the-phase-iii-ikema-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/reduced-intensity-vmp-with-lenalidomide-plus-dexamethasone-consolidation-and-lenalidomide-maintenance-for-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-the-imwg-frailty-index-an-adequate-tool-for-defining-transplant-eligibility-in-elderly-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/covid-heme-forum-supports-hematologists-during-covid-19-pandemic monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/subcutaneous-daratumumab-receives-positive-opinion-from-ema-chmp-and-approval-from-the-fda monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/management-of-covid-19-outbreak-on-transplant-wards monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/melflufen-for-triple-class-refractory-multiple-myeloma-or-final-topline-results-from-the-phase-ii-horizon-study-released monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/frequently-asked-questions-or-treating-patients-with-multiple-myeloma-during-the-covid-19-pandemic monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/monitoring-of-multi-drug-resistance-and-disease-burden-in-patients-with-mm-using-liquid-biopsy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/melflufen-plus-dexamethasone-for-relapsedrefractory-multiple-myeloma-results-from-a-phase-iii-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/results-of-the-safety-run-in-phase-of-the-andromeda-trial-in-patients-with-newly-diagnosed-al-amyloidosis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prognostic-factors-for-survival-in-tandem-vs-single-auto-sct-a-retrospective-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/outcomes-of-long-term-survivors-after-hematopoietic-stem-cell-transplantation monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/real-life-experience-of-elotuzumab-lenalidomide-and-dexamethasone-as-treatment-for-patients-with-relapsed-or-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/carfilzomib-dosing-in-patients-with-relapsed-or-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/caring-for-patients-with-hematological-malignancies-during-the-covid-19-pandemic-recommendations-from-iach-eha-and-ebmt monthly 0.9 2024-07-16T13:34:00.000Z https://multiplemyelomahub.com/medical-information/the-impact-of-targeted-treatment-and-immunotherapies-on-the-role-of-hematopoietic-stem-cell-transplantation-in-the-treatment-of-blood-cancers monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/network-meta-analysis-of-first-line-treatments-in-transplant-ineligible-multiple-myeloma-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/mor202-for-patients-with-rr-multiple-myeloma-results-from-a-phase-iiia-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/carfilzomib-cyclophosphamide-and-dexamethasone-for-the-treatment-of-transplant-ineligible-patients-with-high-risk-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/expert-opinion-or-mohamad-mohty-covid-19-and-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/results-from-a-phase-i-study-of-vlx1570-for-patients-with-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/recommendations-for-the-management-of-patients-with-multiple-myeloma-in-the-united-states-during-the-covid-19-pandemic monthly 0.9 2024-07-16T13:35:00.000Z https://multiplemyelomahub.com/medical-information/isatuximab-combination-therapy-receives-positive-opinion-from-ema-chmp-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/covid-19-and-ebmt-recommendations-for-patients-with-hematological-malignancies monthly 0.9 2024-07-16T13:35:00.000Z https://multiplemyelomahub.com/medical-information/long-term-treatment-approaches-for-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-impact-of-covid-19-on-the-management-of-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/optimal-dosing-of-bortezomib-in-multiple-myeloma-based-on-the-results-of-an-exposure-response-analysis-a monthly 0.9 2024-06-24T10:21:00.000Z https://multiplemyelomahub.com/medical-information/could-bendamustine-plus-dexamethasone-be-a-viable-treatment-option-for-rr-systemic-light-chain-amyloidosis monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-for-smoldering-multiple-myeloma-results-from-the-phase-ii-centaurus-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/improving-frontline-therapies-for-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/analysis-of-long-term-post-auto-sct-outcomes monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eloquent-1-and-tourmaline-mm2-studies-report-no-improvement-in-pfs-in-patients-with-newly-diagnosed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/gmmg-mm5-or-response-adapted-lenalidomide-maintenance-in-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/carlzomib-bendamustine-and-dexamethasone-cbd-combination-for-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dual-targeting-car-t-cell-therapy-for-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-isatuximab-plus-pomalidomide-and-dexamethasone-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/cytopenia-associated-with-car-t-cell-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dose-escalation-study-of-abbv-838-an-antibodydrug-conjugate-in-patients-with-relapsed-and-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/long-term-follow-up-from-pollux-or-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-relapsed-or-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/implementation-of-car-t-cell-therapy-in-the-real-world-a-round-table-discussion monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-and-jacie-recommendations-for-the-management-of-car-t-cell-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/sub-analysis-of-east-asian-patients-from-the-alcyone-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/efficacy-of-autologous-stem-cell-transplantation-in-patients-aged-70-years-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/car-t-cell-therapies-in-clinical-development-in-china monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/circulating-tumor-plasma-cells-as-an-independent-prognostic-marker-for-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dreamm-2-or-belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/mutated-lymphopoiesis-and-b-cell-oligoclonality-can-precede-the-pathogenesis-of-multiple-myeloma-and-persist-in-patients-with-negative-measurable-residual-disease monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-does-the-ebmt-support-the-development-of-car-t-therapies monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-impact-does-car-t-therapy-have-on-patient-quality-of-life monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-new-technologies-are-available-in-the-field-of-car-t-manufacturing monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-data-are-expected-this-year-within-the-field-of-car-t-for-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-to-overcome-resistance-to-car-t-in-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-latest-advances-in-car-t-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-advances-in-car-t-for-multiple-myeloma-have-occurred-since-last-year-s-meeting monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/tourmaline-al1-or-ixazomib-dexamethasone-for-relapsedrefractory-systemic-al-amyloidosis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ongoing-trials-of-chimeric-antigen-receptor-car-therapy-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ema-approves-quadruplet-combination-of-dara-vtd-for-newly-diagnosed-transplant-eligible-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/interim-results-from-the-first-study-of-cc-93269-in-patients-with-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/high-mrd-negativity-rates-observed-with-wkrd-d-for-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/bb21217-an-anti-bcma-car-t-cell-therapy-in-patients-with-rr-mm-updated-results-from-phase-i-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/overview-of-new-immunotherapies-in-myeloma-treatment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/monthly-educational-theme-or-car-t-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/monoclonal-antibody-based-quadruplet-regimen-with-daratumumab-carfilzomib-lenalidomide-and-dexamethasone-with-mrdbased-response-adapted-therapy-in-patients-with-newly-diagnosed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-the-alcyone-study-demonstrate-overall-survival-benefit-with-d-vmp-versus-vmp-in-patients-with-transplant-ineligible-newly-diagnosed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/u-s-fda-approves-investigational-new-drug-ind-application-for-nexi-002 monthly 0.9 2021-04-05T13:33:00.000Z https://multiplemyelomahub.com/medical-information/legend-2-and-cartitude-1-car-t-for-relapsedrefractory-multiple-myeloma monthly 0.9 2021-04-05T13:33:00.000Z https://multiplemyelomahub.com/medical-information/pooled-analysis-of-long-term-data-from-studies-of-tandem-autologous-versus-autologous-allogeneic-hsct-for-newly-diagnosed-multiple-myeloma monthly 0.9 2020-11-16T15:41:00.000Z https://multiplemyelomahub.com/medical-information/phase-iii-candor-study-or-primary-analysis monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/comparison-of-transplant-strategies-in-multiple-myeloma-lessons-from-a-large-ebmt-registry-study monthly 0.9 2021-04-05T13:35:00.000Z https://multiplemyelomahub.com/medical-information/ema-chmp-grants-positive-opinion-to-dara-vtd-combination-for-patients-with-newly-diagnosed-transplant-eligible-multiple-myeloma monthly 0.9 2021-04-05T13:35:00.000Z https://multiplemyelomahub.com/medical-information/is-venetoclax-in-combination-with-dexamethasone-efficacious-for-patients-with-t-1114-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/candor-study-should-dara-kd-become-the-new-soc-for-len-refractory-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-value-of-mrd-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/hovon-143-ixazomib-daratumumab-and-low-dose-dexamethasone-for-unfit-and-frail-patients-with-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-mission-and-vision-of-the-ikmg-research-group monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-most-promising-car-t-therapies-in-development-for-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-significant-is-the-role-of-mrd-status-in-mm-and-how-can-we-best-utilize-this-information monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/fih-results-of-tak-169-in-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/could-radiotherapeutic-approaches-be-a-promising-new-treatment-option-for-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/have-early-mortality-trends-in-myeloma-changed-over-the-last-40-years monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/does-the-vendd-bortezomib-combination-represent-a-new-treatment-option-for-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-non-cellular-immunotherapies-are-in-development-for-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-has-our-understanding-of-the-initiation-of-mm-changed-over-recent-years monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/what-are-the-latest-advances-in-treating-high-risk-smoldering-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/cartitude-1-trial-is-jnj-4528-safe-and-efficacious-for-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-should-we-treat-smoldering-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-cc-93269-a-novel-bcma-t-cell-engager-safe-and-efficacious-for-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/two-major-highlights-from-ash-for-patients-with-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-patient-quality-of-life-superior-with-car-t-or-stem-cell-transplant monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/is-auto-allo-superior-to-auto-auto-tandem-transplant-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-mrd-guide-treatment-of-post-transplant-dara-krd-consolidation monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-do-you-think-transplant-eligible-high-risk-multiple-myeloma-should-be-managed-after-induction monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/when-should-mrd-status-be-used-in-clinical-decision-making-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/practice-changing-abstracts-in-multiple-myeloma-presented-at-ash-2019 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/highlights-from-ash-2019-for-transplant-eligible-patients-with-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/has-the-gem-cesar-study-demonstrated-that-early-intervention-in-smm-should-be-a-new-soc monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/overall-survival-analysis-from-the-alcyone-trial-in-patients-with-transplant-ineligible-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/cassiopet-study-is-pet-ct-a-surrogate-prognostic-marker-in-transplant-eligible-patients-with-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/can-lenalidomide-maintenance-lead-to-increased-rates-of-mrd-negativity monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/how-do-mrd-negativity-rates-with-dara-krd-compare-to-other-treatment-options-in-patients-with-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/update-from-the-karmma-study-of-car-t-cell-product-bb2121-ide-cel monthly 0.9 2021-04-05T13:43:00.000Z https://multiplemyelomahub.com/medical-information/the-u-s-fda-grants-jnj-4528-breakthrough-therapy-designation monthly 0.9 2021-04-05T13:43:00.000Z https://multiplemyelomahub.com/medical-information/maia-study-second-interim-analysis-results monthly 0.9 2021-04-05T13:43:00.000Z https://multiplemyelomahub.com/medical-information/ixazomib-thalidomide-and-dexamethasone-for-relapsedrefractory-multiple-myeloma monthly 0.9 2021-04-05T13:44:00.000Z https://multiplemyelomahub.com/medical-information/lenalidomide-versus-observation-in-patients-with-smoldering-multiple-myeloma-a-randomized-trial monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/expert-commentary-or-the-impact-of-extramedullary-disease-on-transplantation-outcomes-in-multiple-myeloma monthly 0.9 2021-04-05T13:44:00.000Z https://multiplemyelomahub.com/medical-information/response-adapted-intensification-with-cyclophosphamide-bortezomib-and-dexamethasone-compared-with-no-intensification-in-patients-with-newly-diagnosed-multiple-myeloma-subgroup-analysis-of-the-myeloma-xi-trial monthly 0.9 2021-04-05T13:44:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-overview-of-novel-cellular-therapies-in-mm monthly 0.9 2021-04-05T13:45:00.000Z https://multiplemyelomahub.com/medical-information/tourmaline-mm4-trial-of-ixazomib-maintenance-meets-primary-endpoint monthly 0.9 2021-04-05T13:45:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-management-of-elderly-patients-with-multiple-myeloma monthly 0.9 2021-04-05T13:46:00.000Z https://multiplemyelomahub.com/medical-information/tnb-383b-receives-orphan-drug-designation-from-the-u-s-fda monthly 0.9 2021-04-05T13:46:00.000Z https://multiplemyelomahub.com/medical-information/monthly-educational-theme-or-transplant-in-myeloma monthly 0.9 2022-11-14T10:19:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-regenerative-medicine-advanced-therapy-rmat-designation-for-car-t-cell-therapy-ct053 monthly 0.9 2021-04-05T13:47:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-results-from-the-phase-ii-pleiades-trial-mmy2040-dara-sc-combination-therapy monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-lenalidomide-and-dexamethasone-granted-positive-opinion-by-ema-chmp monthly 0.9 2021-04-05T13:48:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-optimismm-subgroup-analysis-by-prior-exposure-to-bortezomib monthly 0.9 2021-04-05T13:48:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-a-r-r-o-w-subgroup-analysis-by-frailty-score monthly 0.9 2021-04-05T13:49:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-icaria-mm-cytogenetic-subgroup-analysis monthly 0.9 2021-04-05T13:49:00.000Z https://multiplemyelomahub.com/medical-information/vrd-induction-for-asct-results-from-the-phase-iii-gem2012menos65-trial monthly 0.9 2021-04-05T13:49:00.000Z https://multiplemyelomahub.com/medical-information/bispecific-antibodies-in-lymphoma-myeloma-and-acute-myeloid-leukemia monthly 0.9 2021-04-05T13:50:00.000Z https://multiplemyelomahub.com/medical-information/tj202-mor202-granted-investigational-new-drug-ind-application-in-china monthly 0.9 2021-04-05T13:50:00.000Z https://multiplemyelomahub.com/medical-information/ct103a-for-relapsedrefractory-multiple-myeloma monthly 0.9 2021-04-05T13:51:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-mrd-negativity-after-tandem-autologous-allogeneic-hsct-with-bortezomib-maintenance monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/soho-and-imw-2019-or-induction-therapies-for-multiple-myeloma monthly 0.9 2021-04-05T13:52:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-eloquent-2-final-overall-survival-results monthly 0.9 2021-04-05T13:52:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-subgroup-analysis-of-patients-with-high-risk-multiple-myeloma-and-measurable-residual-disease-assessment-in-the-cassiopeia-cohort monthly 0.9 2021-04-05T13:53:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-smoldering-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-great-debates-in-myeloma monthly 0.9 2021-04-05T13:53:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-dara-vtd-for-transplant-eligible-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-05T13:53:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-mrd-in-myeloma monthly 0.9 2021-04-05T13:54:00.000Z https://multiplemyelomahub.com/medical-information/imw-2019-or-diagnostic-work-up-and-treatment-decisions-in-multiple-myeloma monthly 0.9 2021-04-05T13:55:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-for-refractory-myeloma monthly 0.9 2021-04-05T13:55:00.000Z https://multiplemyelomahub.com/medical-information/orphan-drug-designation-granted-to-gbr-1342 monthly 0.9 2021-04-05T13:56:00.000Z https://multiplemyelomahub.com/medical-information/phase-iii-candor-study-meets-primary-endpoint monthly 0.9 2021-04-05T13:56:00.000Z https://multiplemyelomahub.com/medical-information/how-should-we-treat-al-amyloidosis-in-2019 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/soho-2019-or-which-classes-of-drugs-are-used-for-non-antibody-based-immunotherapies-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/soho-2019-or-how-should-we-treat-bone-disease-in-2019 monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/soho-2019-or-are-we-ready-to-use-mrd-for-treatment-decisions-in-patients-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/educational-theme-measurable-residual-disease-mrd monthly 0.9 2022-11-14T10:19:00.000Z https://multiplemyelomahub.com/medical-information/regulatory-updates monthly 0.9 2021-04-05T13:58:00.000Z https://multiplemyelomahub.com/medical-information/what-is-the-familial-risk-of-developing-a-hematological-malignancy monthly 0.9 2021-04-05T13:59:00.000Z https://multiplemyelomahub.com/medical-information/european-commission-approves-elotuzumab-plus-pomalidomide-and-low-dose-dexamethasone-for-relapsed-and-refractory-multiple-myeloma monthly 0.9 2021-04-05T13:59:00.000Z https://multiplemyelomahub.com/medical-information/relapsedrefractory-multiple-myeloma-what-can-we-target-next monthly 0.9 2021-04-05T13:59:00.000Z https://multiplemyelomahub.com/medical-information/primary-objective-met-in-the-dreamm-2-trial-of-belantamab-mafodotin-in-relapsedrefractory-multiple-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-granted-approval-for-frontline-use-in-japan monthly 0.9 2021-04-05T13:59:00.000Z https://multiplemyelomahub.com/medical-information/palliative-care-in-patients-with-multiple-myeloma monthly 0.9 2021-04-05T14:00:00.000Z https://multiplemyelomahub.com/medical-information/meta-analysis-and-systematic-review-of-plerixafor-for-stem-cell-mobilization-for-autologous-stem-cell-transplant-asct monthly 0.9 2021-04-05T14:00:00.000Z https://multiplemyelomahub.com/medical-information/impact-of-acquired-del-17p-in-multiple-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/medicare-announces-coverage-of-chimeric-antigen-receptor-car-t-cell-therapy-in-the-united-states-us monthly 0.9 2021-04-05T14:01:00.000Z https://multiplemyelomahub.com/medical-information/are-surrogate-endpoints-a-suitable-alternative-to-survival-in-clinical-trials monthly 0.9 2021-04-05T14:02:00.000Z https://multiplemyelomahub.com/medical-information/monthly-theme-or-an-introduction-to-patient-reported-outcomes-pros-and-quality-of-life-qol-assessments-in-multiple-myeloma monthly 0.9 2021-04-05T14:02:00.000Z https://multiplemyelomahub.com/medical-information/cytogenetic-prognostic-index-for-survival-in-multiple-myeloma monthly 0.9 2021-04-09T12:30:00.000Z https://multiplemyelomahub.com/medical-information/pembrolizumab-plus-lenalidomide-and-dexamethasone-for-the-treatment-of-multiple-myeloma-results-from-keynote-183-keynote-185-and-keynote-023 monthly 0.9 2021-04-07T12:36:00.000Z https://multiplemyelomahub.com/medical-information/ema-chmp-recommends-elotuzumab-in-combination-with-pomalidomide-and-dexamethasone-for-relapsedrefractory-multiple-myeloma monthly 0.9 2021-04-07T12:37:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-based-therapies-in-rr-mm-age-based-subgroup-analysis-of-castor-and-pollux-studies monthly 0.9 2021-04-07T12:37:00.000Z https://multiplemyelomahub.com/medical-information/risk-stratification-in-smoldering-multiple-myeloma-smm monthly 0.9 2021-02-19T19:24:00.000Z https://multiplemyelomahub.com/medical-information/genomics-of-smoldering-multiple-myeloma-smm monthly 0.9 2021-04-07T12:58:00.000Z https://multiplemyelomahub.com/medical-information/siltuximab-for-high-risk-smoldering-multiple-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/smoldering-multiple-myeloma-smm-an-introduction-to-this-month-s-educational-theme-on-the-multiple-myeloma-mm-hub monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/phase-ii-griffin-study-topline-results-released monthly 0.9 2021-04-07T12:37:00.000Z https://multiplemyelomahub.com/medical-information/fda-accelerated-approval-granted-to-selinexor-for-relapsedrefractory-multiple-myeloma monthly 0.9 2021-04-07T12:38:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-selinexor-plus-daratumumab-for-rrmm-a-phase-ibii-trial monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-results-of-the-phase-ii-carfi-trial-carfilzomib-for-asct-induction-and-maintenance-in-rrmm monthly 0.9 2021-04-07T12:38:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-triplet-of-d-rd-for-patients-with-ndmm-who-are-not-eligible-for-asct monthly 0.9 2021-04-07T12:39:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-molecular-subgroup-analysis-of-the-myeloma-xi-phase-iii-trial monthly 0.9 2021-04-07T12:39:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-updated-analysis-of-the-horizon-phase-ii-trial-melflufen-dexamethasone-for-rrmm monthly 0.9 2021-06-09T16:38:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-regulatory-updates-june-2019 monthly 0.9 2021-04-07T12:40:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-results-of-the-phase-iii-bellini-trial-venbd-for-rrmm monthly 0.9 2021-04-07T12:40:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-gem-cesar-shows-promise-for-smoldering-mm-krd-hdt-asct-therapy monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-icaria-mm-efficacy-and-safety-of-isatuximab-pomalidomide-and-dexamethasone-in-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-mechanisms-of-resistance-to-imids-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-updated-analysis-from-the-horizon-study-of-melflufen-in-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-how-does-the-microenvironment-play-a-role-in-mm-progression monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-novel-agents-for-ndmm-eha-updates monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-results-from-forte-trial-of-krd-in-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-myeloma-xi-subgroup-analysis-of-kcrd-induction-by-molecular-risk monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha-2019-or-the-role-of-autologous-transplant-in-the-future-treatment-of-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-e3a06-lenalidomide-versus-observation-for-high-risk-smoldering-multiple-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-phase-i-study-of-iberdomide-iber-in-relapsedrefractory-multiple-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-amg-420-first-in-human-phase-i-dose-escalation-study-results monthly 0.9 2021-04-07T12:51:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-icaria-mm-isatuximab-pomalidomide-dexamethasone-for-relapsedrefractory-multiple-myeloma-phase-iii-results monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-risk-subgroup-analysis-from-the-forte-trial monthly 0.9 2021-04-07T12:51:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-columba-trial-intravenous-versus-subcutaneous-daratumumab monthly 0.9 2021-04-07T12:52:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-discussion-intensive-treatment-strategies-at-what-stage-should-these-be-deployed-in-smm-and-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-cassiopeia-part-1-trial-results monthly 0.9 2021-04-07T12:52:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-safety-and-efficacy-of-d-rd-in-rr-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-octogenarians-with-multiple-myeloma-different-biology-and-different-treatment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-overview-of-the-prommis-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-immunotherapeutic-approaches-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-induction-regimens-in-ndmm-my-clinical-experience monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-how-would-you-pick-an-induction-regimen-based-on-disease-risk monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-evolving-paradigms-in-untreated-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-highlights-of-the-randomized-phase-iii-columba-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-forte-trial-updated-efficacy-analysis-by-risk-status monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-phase-ibiia-study-of-iberdomide-in-combination-with-dexamethasone-in-patients-with-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-phase-iii-trial-of-lenalidomide-versus-observation-alone-in-patients-with-asymptomatic-high-risk-smm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-what-is-the-role-of-geriatric-assessment-in-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-how-would-you-manage-high-risk-myeloma-in-older-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-disparities-in-multiple-myeloma-care monthly 0.9 2021-04-07T13:00:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-how-do-racial-disparities-affect-multiple-myeloma-treatment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-is-immunotherapy-toxicity-associated-with-improved-overall-survival-among-older-adults-with-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2019-or-what-are-the-disparities-in-multiple-myeloma-care monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-plus-carfilzomib-and-dexamethasone-for-patients-with-rrmm monthly 0.9 2021-04-07T13:00:00.000Z https://multiplemyelomahub.com/medical-information/comy-2019-or-debate-should-smoldering-myeloma-be-treated-very-early monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/results-from-the-optimismm-phase-iii-trial-pomalidomide-for-lenalidomide-refractory-patients monthly 0.9 2021-04-07T13:01:00.000Z https://multiplemyelomahub.com/medical-information/comy-2019-or-debate-are-we-ready-to-personalize-therapy-in-multiple-myeloma monthly 0.9 2021-04-07T13:01:00.000Z https://multiplemyelomahub.com/medical-information/comy-2019-or-debate-car-t-cell-therapy-in-first-relapse monthly 0.9 2021-04-07T13:01:00.000Z https://multiplemyelomahub.com/medical-information/european-commission-approves-lenalidomide-and-pomalidomide-triplets-for-multiple-myeloma monthly 0.9 2021-04-07T13:46:00.000Z https://multiplemyelomahub.com/medical-information/nice-approves-lenalidomide-in-front-line-multiple-myeloma-treatment monthly 0.9 2021-04-07T13:02:00.000Z https://multiplemyelomahub.com/medical-information/autologous-stem-cell-transplantation-in-multiple-myeloma-the-big-questions monthly 0.9 2021-04-07T13:05:00.000Z https://multiplemyelomahub.com/medical-information/autologous-stem-cell-transplant-in-multiple-myeloma-optimal-regimens monthly 0.9 2021-04-07T13:06:00.000Z https://multiplemyelomahub.com/medical-information/allogeneic-stem-cell-transplantation-in-multiple-myeloma monthly 0.9 2021-04-07T13:06:00.000Z https://multiplemyelomahub.com/medical-information/p-bcma-101-granted-orphan-drug-designation-in-relapsedrefractory-multiple-myeloma monthly 0.9 2021-03-05T15:52:00.000Z https://multiplemyelomahub.com/medical-information/clr-131-receives-fda-fast-track-designation-in-relapsedrefractory-multiple-myeloma monthly 0.9 2021-04-07T13:07:00.000Z https://multiplemyelomahub.com/medical-information/phase-i-results-for-anti-bcma-car-t-cell-therapy-bb2121 monthly 0.9 2021-04-07T13:07:00.000Z https://multiplemyelomahub.com/medical-information/phase-ii-carthadex-study-carfilzomib-thalidomide-and-dexamethasone-for-newly-diagnosed-transplant-eligible-multiple-myeloma monthly 0.9 2021-04-07T13:07:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2019-or-the-role-of-renal-impairment-in-patients-with-multiple-myeloma-undergoing-autologous-stem-cell-transplantation monthly 0.9 2021-04-07T13:08:00.000Z https://multiplemyelomahub.com/medical-information/allogeneic-versus-patient-derived-car-t-therapies-in-multiple-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/esh-2019-or-bone-disease-in-multiple-myeloma-continuous-versus-personalized-treatment monthly 0.9 2021-04-07T13:09:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2019-or-outcome-of-second-allogeneic-stem-cell-transplant-in-patients-with-multiple-myeloma monthly 0.9 2021-04-07T13:09:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2019-or-real-world-clinical-experience-of-multiple-myeloma-induction-regimens-subgroup-analysis-from-the-emmos-study monthly 0.9 2021-04-07T13:10:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2019-or-the-evolution-of-induction-regimens-in-multiple-myeloma monthly 0.9 2021-04-07T13:12:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2019-or-high-expansion-level-and-long-term-persistence-of-bcma-car-t-cells-contribute-to-potent-anti-tumor-activity-in-heavily-treated-multiple-myeloma-patients monthly 0.9 2021-04-07T14:25:00.000Z https://multiplemyelomahub.com/medical-information/ema-grants-anti-bcma-car-t-jnj-4528-prime-designation-in-multiple-myeloma monthly 0.9 2021-04-07T14:26:00.000Z https://multiplemyelomahub.com/medical-information/francesca-gay-or-esh-mm-2019-or-management-of-non-aggressive-relapse-24-months-post-transplant monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2019-or-dual-targeting-car-t-cells-with-autologous-stem-cell-transplant-for-high-risk-multiple-myeloma monthly 0.9 2021-04-07T14:26:00.000Z https://multiplemyelomahub.com/medical-information/angela-dispenzieri-or-esh-mm-2019-or-monoclonal-gammopathy-of-clinical-significance monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/karthik-ramasamy-or-esh-mm-2019-or-treatment-of-first-relapse-in-patients-ineligible-for-transplant-factors-to-consider monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/sonja-zweegman-or-esh-mm-2019-or-the-impact-of-age-on-clinical-decision-making monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/sagar-lonial-or-esh-mm-2019-or-the-potential-of-car-t-therapy-to-replace-autologous-stem-cell-transplantation monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/charlotte-pawlyn-or-esh-mm-2019-or-personalized-treatment-for-patients-with-bone-disease-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/elena-zamagni-or-esh-mm-2019-or-the-use-of-imaging-techniques-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/jonathan-keats-or-esh-mm-2019-or-defining-high-risk-disease-and-treatment-strategies-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/gareth-morgan-or-esh-mm-2019-or-the-impact-of-double-hit-genetics-on-patient-outcomes-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2019-or-targeting-nkg2d-ligands-in-patients-with-multiple-myeloma monthly 0.9 2021-01-19T02:31:00.000Z https://multiplemyelomahub.com/medical-information/positive-ema-chmp-opinion-for-two-new-triplet-regimens-in-multiple-myeloma monthly 0.9 2021-04-07T14:28:00.000Z https://multiplemyelomahub.com/medical-information/us-food-and-drug-administration-and-european-medicines-agency-approvals-sought-for-new-combined-drug-regimens-in-multiple-myeloma monthly 0.9 2021-04-07T14:49:00.000Z https://multiplemyelomahub.com/medical-information/paul-richardson-or-ebmt-2019-or-treatment-options-for-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/stefan-knop-or-ebmt-2019-or-rad-versus-vrd-in-transplant-eligible-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/chengcheng-fu-or-ebmt-19-or-car-t-cell-therapy-in-the-front-line-treatment-of-patients-with-high-risk-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/nico-gagelmann-or-ebmt-2019-or-outcomes-of-patients-with-high-risk-cytogenetics-undergoing-sct-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/hermann-einsele-or-ebmt-2019-or-car-t-therapy-versus-targeted-antibodies-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/paul-richardson-or-ebmt-2019-or-treatment-of-relapsedrefractory-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/mohamad-mohty-or-ebmt-2019-or-optimal-induction-regimen-for-autologous-stem-cell-transplant-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/maria-mateos-or-ebmt-2019-or-the-use-of-mrd-in-clinical-decision-making-for-maintenance-therapy-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/karthik-ramasamy-or-ebmt-2019-or-clinical-decisions-based-on-patient-quality-of-life-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/response-outcomes-in-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:30:00.000Z https://multiplemyelomahub.com/medical-information/patient-outcomes-in-multiple-myeloma-refractory-to-cd38-monoclonal-antibodies monthly 0.9 2021-04-07T14:30:00.000Z https://multiplemyelomahub.com/medical-information/fda-places-partial-clinical-hold-on-trials-involving-venetoclax-in-multiple-myeloma monthly 0.9 2021-04-07T14:30:00.000Z https://multiplemyelomahub.com/medical-information/carfilzomib-melphalan-prednisone-versus-bortezomib-melphalan-prednisone-for-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:31:00.000Z https://multiplemyelomahub.com/medical-information/impact-of-abnormal-pulmonary-function-on-outcomes-in-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:31:00.000Z https://multiplemyelomahub.com/medical-information/results-from-the-lyra-study-daratumumab-bortezomib-cyclophosphamide-and-dexamethasone-for-newly-diagnosed-or-relapsed-multiple-myeloma monthly 0.9 2021-04-07T14:31:00.000Z https://multiplemyelomahub.com/medical-information/nice-to-make-daratumumab-bortezomib-and-dexamethasone-triplet-available-in-england-via-the-cancer-drugs-fund monthly 0.9 2021-04-07T14:31:00.000Z https://multiplemyelomahub.com/medical-information/tct-meeting-2019-or-nicotinamide-expanded-related-donor-natural-killer-cells-for-the-treatment-of-relapsedrefractory-multiple-myeloma-and-non-hodgkin-lymphoma-results-from-the-first-in-human-phase-i-study monthly 0.9 2021-04-07T14:31:00.000Z https://multiplemyelomahub.com/medical-information/a-sub-group-analysis-from-the-endeavor-study-health-related-quality-of-life-in-relapsedrefractory-multiple-myeloma monthly 0.9 2021-04-07T14:32:00.000Z https://multiplemyelomahub.com/medical-information/the-impact-of-pre-existing-monoclonal-gammopathy-on-patient-outcome-in-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:32:00.000Z https://multiplemyelomahub.com/medical-information/clarithromycin-pomalidomide-and-dexamethasone-in-patients-with-relapsed-or-refractory-multiple-myeloma-results-from-a-phase-ii-study monthly 0.9 2021-04-07T14:32:00.000Z https://multiplemyelomahub.com/medical-information/results-of-the-phase-iii-vcat-study-subcutaneous-bortezomib-thalidomide-and-prednisolone-consolidation monthly 0.9 2021-04-07T14:32:00.000Z https://multiplemyelomahub.com/medical-information/top-line-results-from-the-phase-ii-study-of-clr-131-clover-1 monthly 0.9 2021-04-07T14:32:00.000Z https://multiplemyelomahub.com/medical-information/update-from-the-phase-iii-columba-mmy3012-study monthly 0.9 2021-04-07T14:32:00.000Z https://multiplemyelomahub.com/medical-information/update-fda-odac-delays-approval-of-selinexor-until-more-data-are-available monthly 0.9 2021-04-07T14:33:00.000Z https://multiplemyelomahub.com/medical-information/carfilzomib-and-dexamethasone-kd-therapy-in-patients-with-newly-diagnosed-multiple-myeloma-results-from-a-phase-ii-study monthly 0.9 2021-04-07T14:34:00.000Z https://multiplemyelomahub.com/medical-information/targeted-re-sensitization-of-lenalidomide-resistant-cell-lines-using-cereblon-replacement-inhibition-of-stat3-or-irf4-molecular-targeting monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/current-landscape-of-fda-approval-requests-and-trial-updates-in-multiple-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/the-status-of-anti-bcma-car-t-cell-therapy-in-multiple-myeloma-or-an-interview-with-dr-james-kochenderfer monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/car-t-cell-meeting-2019-or-car-t-in-multiple-myeloma-when-to-use-car-t monthly 0.9 2021-04-07T14:35:00.000Z https://multiplemyelomahub.com/medical-information/car-t-cell-meeting-2019-or-car-t-cell-therapy-in-multiple-myeloma-the-latest-clinical-data monthly 0.9 2021-04-07T14:36:00.000Z https://multiplemyelomahub.com/medical-information/long-term-follow-up-of-myeloma-x-a-phase-iii-trial-investigating-the-impact-of-cytogenetics-in-patients-with-relapsed-multiple-myeloma monthly 0.9 2021-04-07T14:36:00.000Z https://multiplemyelomahub.com/medical-information/results-from-a-pooled-analysis-comparing-once-weekly-with-twice-weekly-carfilzomib-therapy-in-elderly-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:38:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-split-dosing-of-daratumumab-for-patients-with-multiple-myeloma monthly 0.9 2021-04-07T14:38:00.000Z https://multiplemyelomahub.com/medical-information/patients-with-multiple-myeloma-with-a-high-sub-clonal-fraction-of-17p-deletion-have-poor-prognosis monthly 0.9 2021-04-07T14:38:00.000Z https://multiplemyelomahub.com/medical-information/analysis-of-cereblon-binding-protein-expression-in-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:38:00.000Z https://multiplemyelomahub.com/medical-information/long-term-follow-up-of-ixazomib-lenalidomide-and-dexamethasone-in-combination-with-ixazomib-maintenance-in-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2021-03-05T15:44:00.000Z https://multiplemyelomahub.com/medical-information/clinical-advances-in-myeloma-2019-or-overview-part-ii monthly 0.9 2021-04-07T14:39:00.000Z https://multiplemyelomahub.com/medical-information/clinical-advances-in-myeloma-2019-or-overview-part-1 monthly 0.9 2021-04-07T14:39:00.000Z https://multiplemyelomahub.com/medical-information/clinical-characteristics-and-the-pattern-of-progression-are-important-prognostic-factors-for-post-progression-survival-in-multiple-myeloma monthly 0.9 2021-04-07T14:40:00.000Z https://multiplemyelomahub.com/medical-information/psychological-distress-and-mental-health-related-quality-of-life-is-similar-between-patients-with-precursor-disease-and-active-myeloma monthly 0.9 2021-04-07T14:40:00.000Z https://multiplemyelomahub.com/medical-information/monoallelic-deletion-of-the-whole-locus-of-immunoglobulin-heavy-chain-gene-confers-better-prognosis-than-t-414-and-t-1416-translocations-in-newly-diagnosed-patients-with-multiple-myeloma monthly 0.9 2021-04-07T14:41:00.000Z https://multiplemyelomahub.com/medical-information/lenalidomide-doxorubicin-and-dexamethasone-induction-therapy-affects-bone-remodeling-and-angiogenesis-in-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:41:00.000Z https://multiplemyelomahub.com/medical-information/results-from-a-phase-iii-trial-evaluating-autologous-transplantation-consolidation-and-maintenance-therapy-in-multiple-myeloma monthly 0.9 2021-04-07T14:41:00.000Z https://multiplemyelomahub.com/medical-information/incb052793-a-selective-jak1-inhibitor-alone-and-in-combination-in-vitro-and-in-vivo-in-patients-with-multiple-myeloma monthly 0.9 2021-04-07T14:41:00.000Z https://multiplemyelomahub.com/medical-information/phase-i-results-of-the-legend-2-trial-lcar-b38m-car-t-therapy-for-patients-with-relapsed-or-refractory-multiple-myeloma monthly 0.9 2021-04-07T14:42:00.000Z https://multiplemyelomahub.com/medical-information/lenalidomide-maintenance-compared-to-observation-in-patients-with-newly-diagnosed-multiple-myeloma-sub-group-results-from-the-myeloma-xi-trial monthly 0.9 2021-04-07T14:42:00.000Z https://multiplemyelomahub.com/medical-information/subgroup-analysis-of-the-endeavor-trial-carfilzomib-versus-bortezomib-for-patients-with-multiple-myeloma-and-renal-impairment monthly 0.9 2021-04-07T14:42:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-ixazomib-maintenance-for-patients-with-newly-diagnosed-multiple-myeloma-results-from-the-tourmaline-mm3-trial monthly 0.9 2021-04-07T14:42:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-results-of-a-phase-iii-study-for-elderly-intermediate-fit-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:42:00.000Z https://multiplemyelomahub.com/medical-information/marc-andrea-baertsch-or-ash-2018-or-update-on-the-results-of-the-relapse-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-clinical-trials-for-high-risk-smoldering-multiple-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/sonja-zweegman-or-ash-2018-or-identification-and-treatment-of-frail-patients-with-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-triplet-combination-of-venetoclax-carfilzomib-and-dexamethasone-for-relapsedrefractory-multiple-myeloma monthly 0.9 2021-04-07T14:43:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-daratumumab-triplet-regimen-as-a-frontline-treatment-for-multiple-myeloma-patients-non-eligible-for-asct-interim-results-of-the-maia-trial monthly 0.9 2021-04-07T14:43:00.000Z https://multiplemyelomahub.com/medical-information/niccolo-bolli-or-ash-2018-or-the-pathogenic-significance-of-structural-genomic-variations-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ola-landgren-or-ash-2018-or-results-from-the-prospective-commpass-study-for-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/constantine-mitsiades-or-ash-2018-or-current-trends-in-pre-clinical-studies-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-long-term-follow-up-of-the-gem05menos65-clinical-trial-for-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:44:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-ixazomib-all-oral-triplet-as-consolidation-treatment-for-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:44:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-long-term-follow-up-of-double-vs-single-asct-in-patients-with-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:44:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-car-t-cell-clinical-trial-for-patients-with-relapsedrefractory-multiple-myeloma-using-bb21217 monthly 0.9 2021-04-07T14:45:00.000Z https://multiplemyelomahub.com/medical-information/jonathan-keats-or-ash-2018-or-development-of-genomic-approaches-to-understand-genetic-variability-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/graham-jackson-or-ash-2018-or-update-on-the-efficacy-and-safety-of-the-myeloma-xi-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/paola-neri-or-ash-2018-or-enhancer-deregulation-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/nikhil-munshi-or-ash-2018-or-biological-significance-of-non-coding-mutations-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2018-or-update-on-the-forte-trial-a-phase-iii-clinical-trial-for-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:45:00.000Z https://multiplemyelomahub.com/medical-information/shaji-kumar-or-ash-2018-or-ash-2018-some-key-highlights monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/bruno-paiva-or-ash-2018-or-the-clinical-significance-of-mrd-for-high-risk-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/lawrence-boise-or-ash-2018-or-the-prognostic-value-of-immunoglobulin-lambda-translocations-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/gareth-j-morgan-or-ash-2018-or-what-are-chromothripsis-and-chromoplexy-and-how-do-they-relate-to-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/elena-zamagni-or-ash-2018-or-new-criteria-for-determining-the-role-of-petct-in-mrd-detection-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/the-gap-between-clinical-trial-and-real-world-practice-outcomes-in-multiple-myeloma monthly 0.9 2021-04-07T14:47:00.000Z https://multiplemyelomahub.com/medical-information/fda-regenerative-medicine-advanced-therapy-designation-for-p-bcma-car-t-cell-therapy monthly 0.9 2021-03-05T15:49:00.000Z https://multiplemyelomahub.com/medical-information/association-of-subclonal-tp53-deletions-with-multiple-myeloma-prognosis monthly 0.9 2021-04-07T14:47:00.000Z https://multiplemyelomahub.com/medical-information/long-term-results-from-the-hovon-50-trial-on-the-use-of-thalidomide-for-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:47:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-elotuzumab-in-combination-with-pomalidomide-and-dexamethasone-for-relapsedrefractory-multiple-myeloma monthly 0.9 2021-04-07T14:48:00.000Z https://multiplemyelomahub.com/medical-information/esh-mm-2018-or-assessment-of-response-in-multiple-myeloma monthly 0.9 2021-04-07T14:49:00.000Z https://multiplemyelomahub.com/medical-information/esh-mm-2018-or-continuous-or-fixed-duration-therapy-in-multiple-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/esh-mm-2018-or-how-to-treat-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:49:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-orphan-drug-designation-to-stro-001-for-the-treatment-of-multiple-myeloma monthly 0.9 2021-04-07T14:50:00.000Z https://multiplemyelomahub.com/medical-information/supportive-care-managing-infection-in-myeloma-or-an-interview-with-heinz-ludwig monthly 0.9 2021-04-07T14:51:00.000Z https://multiplemyelomahub.com/medical-information/robert-hills-or-esh-mm-2018-or-how-to-judge-the-value-of-a-clinical-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-granted-fda-priority-review monthly 0.9 2021-04-07T14:51:00.000Z https://multiplemyelomahub.com/medical-information/kenneth-anderson-or-esh-mm-2018-or-future-combinations-for-the-treatment-of-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/herve-avet-loiseau-or-esh-mm-2018-or-genetics-and-risk-assessment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/shaji-kumar-or-esh-mm-2018-or-new-end-points-and-new-design-for-clinical-trials monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/saad-usmani-or-esh-mm-2018-or-progress-in-mm-with-monoclonal-antibodies monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/jesus-berdeja-or-esh-mm-2018-or-adoptive-cell-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/david-avignan-or-esh-mm-2018-or-vaccines-in-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/maria-victoria-mateos-or-esh-mm-2018-or-recent-results-of-clinical-trials-in-smm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/madhav-dhodapkar-or-esh-mm-2018-or-progression-from-mgus-to-mm-do-all-clones-take-the-same-road monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/kwee-yong-or-esh-mm-2018-or-options-for-frontline-treatment-when-new-drugs-are-not-available monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/annemiek-broijl-or-esh-mm-2018-or-managing-high-risk-patients-and-how-to-cure-them monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/niels-van-de-donk-or-esh-mm-2018-or-plasma-cell-leukemia-and-extramedullary-disease monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/irene-ghobrial-or-esh-mm-2018-or-optimizing-liquid-biopsies-for-use-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/sonja-zweegman-or-esh-mm-2018-or-european-guidelines-for-front-line-therapy monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/once-weekly-dosing-of-carfilzomib-approved-by-fda monthly 0.9 2021-04-07T14:53:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-ngs-based-test-to-detect-mrd monthly 0.9 2021-04-07T14:53:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-the-pollux-clinical-trial monthly 0.9 2021-04-07T14:53:00.000Z https://multiplemyelomahub.com/medical-information/a-dummies-guide-to-social-media-in-myeloma monthly 0.9 2021-04-07T14:54:00.000Z https://multiplemyelomahub.com/medical-information/mgus-prevalence-among-family-members-of-patients-with-mm monthly 0.9 2021-04-07T14:54:00.000Z https://multiplemyelomahub.com/medical-information/how-first-generation-novel-regimens-affect-the-risk-of-death-in-mm monthly 0.9 2021-04-07T14:54:00.000Z https://multiplemyelomahub.com/medical-information/galinpepimut-s-granted-orphan-drug-designation-by-the-ema monthly 0.9 2021-04-07T14:54:00.000Z https://multiplemyelomahub.com/medical-information/clarithromycin-the-antibiotic-of-choice-for-osteonecrosis-of-the-jaw-in-mm monthly 0.9 2021-04-07T14:55:00.000Z https://multiplemyelomahub.com/medical-information/plerixafor-as-a-mobilization-agent-prior-to-asct-in-mm monthly 0.9 2021-04-07T14:55:00.000Z https://multiplemyelomahub.com/medical-information/april-regulates-immunosuppression-via-taci-in-the-mm-bone-marrow monthly 0.9 2021-04-07T14:55:00.000Z https://multiplemyelomahub.com/medical-information/evaluation-of-cell-free-dna-as-a-biomarker-in-rrmm monthly 0.9 2021-04-07T14:56:00.000Z https://multiplemyelomahub.com/medical-information/comparison-of-three-staging-systems-for-newly-diagnosed-mm-patients-undergoing-asct monthly 0.9 2021-04-07T14:56:00.000Z https://multiplemyelomahub.com/medical-information/dot1l-is-a-potential-new-target-in-mm monthly 0.9 2021-04-07T14:58:00.000Z https://multiplemyelomahub.com/medical-information/panobinostat-as-a-maintenance-treatment-for-mm-results-from-the-muk-six-trial monthly 0.9 2021-04-07T14:59:00.000Z https://multiplemyelomahub.com/medical-information/the-european-commission-approves-daratumumab-as-front-line-treatment-in-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T14:59:00.000Z https://multiplemyelomahub.com/medical-information/fda-approval-sought-for-once-weekly-carfilzomib monthly 0.9 2021-04-07T14:59:00.000Z https://multiplemyelomahub.com/medical-information/pvx-410-vaccine-alone-or-with-lenalidomide-for-patients-with-smoldering-multiple-myeloma monthly 0.9 2021-04-07T17:04:00.000Z https://multiplemyelomahub.com/medical-information/elotuzumab-combo-granted-fda-priority-review monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/autologous-transplantation-using-a-simple-method-to-store-peripheral-blood-stem-cells monthly 0.9 2021-04-07T14:59:00.000Z https://multiplemyelomahub.com/medical-information/metabolomic-profile-of-myeloma-patients-reveals-potential-new-therapeutic-targets monthly 0.9 2021-04-07T15:00:00.000Z https://multiplemyelomahub.com/medical-information/evaluation-of-ixazomib-with-cyclophosphamide-and-dexamethasone-for-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T15:00:00.000Z https://multiplemyelomahub.com/medical-information/tigit-a-potential-target-for-checkpoint-inhibition-in-multiple-myeloma monthly 0.9 2021-04-07T15:00:00.000Z https://multiplemyelomahub.com/medical-information/multiple-myeloma-diagnosis-in-primary-care monthly 0.9 2021-04-07T15:00:00.000Z https://multiplemyelomahub.com/medical-information/what-is-monoclonal-gammopathy-of-clinical-significance monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/a-triplet-regimen-that-includes-ixazomib-twice-a-week-for-newly-diagnosed-multiple-myeloma monthly 0.9 2021-04-07T15:00:00.000Z https://multiplemyelomahub.com/medical-information/psmb5-mutations-described-for-the-first-time-in-multiple-myeloma-patients monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/health-related-quality-of-life-results-from-the-mrc-myeloma-ix-clinical-trial monthly 0.9 2021-04-07T15:01:00.000Z https://multiplemyelomahub.com/medical-information/prognostic-factors-for-smoldering-multiple-myeloma-progression monthly 0.9 2021-04-07T17:04:00.000Z https://multiplemyelomahub.com/medical-information/srf231-is-granted-orphan-designation-status-for-the-treatment-of-multiple-myeloma monthly 0.9 2021-04-07T15:01:00.000Z https://multiplemyelomahub.com/medical-information/a-retrospective-study-of-early-onset-multiple-myeloma monthly 0.9 2021-04-07T15:02:00.000Z https://multiplemyelomahub.com/medical-information/double-hit-a-subgroup-of-high-risk-newly-diagnosed-multiple-myeloma-patients monthly 0.9 2021-04-07T15:02:00.000Z https://multiplemyelomahub.com/medical-information/the-chmp-recommends-daratumumab-as-front-line-treatment monthly 0.9 2021-04-07T15:02:00.000Z https://multiplemyelomahub.com/medical-information/fast-track-designation-granted-for-galinpepimut-s monthly 0.9 2021-04-07T15:02:00.000Z https://multiplemyelomahub.com/medical-information/nice-rejects-daratumumab-darzalex-for-use-second-line-with-bortezomib-and-dexamethasone monthly 0.9 2022-10-31T11:37:00.000Z https://multiplemyelomahub.com/medical-information/eha-2018-or-pomalidomidedexamethasone-with-or-without-elotuzumab-the-eloquent-3-trial monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/eha-2018-or-preclinical-study-to-assess-dual-bcl-2-and-mcl-1-inhibition-in-mm monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/eha-2018or-phase-iiia-study-of-mor202-used-in-combination-treatments monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/eha-2018-or-preclinical-data-for-bcmaxcd3-bi-specific-antibody-jnj-957 monthly 0.9 2021-04-07T15:04:00.000Z https://multiplemyelomahub.com/medical-information/eha-2018-or-phase-ib-study-of-isatuximab-in-combination-with-pomalidomide-and-dexamethasone monthly 0.9 2021-04-07T15:05:00.000Z https://multiplemyelomahub.com/medical-information/eha-2018-or-the-phase-iii-optimismm-study-of-pomalidomide-bortezomib-and-dexamethasone monthly 0.9 2021-04-07T15:05:00.000Z https://multiplemyelomahub.com/medical-information/eha-2018-or-interim-analysis-of-the-phase-iii-emn02hovon-95-mm-trial-to-assess-vrd-consolidation-with-lenalidomide-maintenance monthly 0.9 2021-04-07T15:05:00.000Z https://multiplemyelomahub.com/medical-information/eha-2018-or-final-analysis-of-the-phase-iii-gimema-trial monthly 0.9 2021-04-07T15:05:00.000Z https://multiplemyelomahub.com/medical-information/katja-weisel-or-eha-2018-or-turning-the-tide-after-relapse-managing-relapsed-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/hermann-einsele-or-eha-2018-or-new-concepts-in-consolidation-for-patients-with-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/charlotte-pawlyn-or-eha-2018-or-results-from-myeloma-xi-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/jesus-berdeja-or-eha-2018-or-the-crb-401-phase-i-bb2121-car-t-cell-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/enrique-ocio-or-eha-2018-or-pipeline-therapies-for-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/sonja-zweegman-or-eha-2018-or-the-issue-of-frailty-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/paola-neri-or-eha-2018-or-the-basis-for-immunotherapy-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/niels-van-de-donk-or-eha-2018-or-immunotherapy-in-myeloma-why-when-and-how monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2018-or-updated-results-from-the-crb-401-phase-i-study-of-bb2121-car-t-cells monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/asco-2018-or-what-happened-with-pembrolizumab-in-mm-clinical-trials monthly 0.9 2021-04-07T15:07:00.000Z https://multiplemyelomahub.com/medical-information/francesca-gay-or-asco-2018-or-update-on-the-forte-trial-according-to-risk-status-in-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2018-or-phase-i-trial-of-ruxolitinib-lenalidomide-and-methylprednisolone-for-rrmm monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/rafael-fonseca-or-asco-2018-or-value-and-cost-of-myeloma-therapy-we-can-afford-it monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/vincent-rajkumar-or-asco-2018-or-value-and-cost-of-myeloma-therapy-we-cannot-afford-it monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/philippe-moreau-or-asco-2018-or-critical-trials-in-mm-that-could-change-clinical-practice monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ajai-chari-or-asco-2018-or-subgroup-analysis-of-the-mmy1001-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/nina-shah-or-asco-2018-or-phase-ii-study-of-ex-vivo-expanded-cord-blood-nk-cells-for-the-treatment-of-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/niels-van-de-donk-or-asco-2018-or-what-to-do-when-antibodies-fail-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/timothy-rebbeck-or-asco-2018-or-myeloma-outcomes-and-disparities-in-african-americans monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/asco-2018-or-phase-iii-arrow-study-once-weekly-carfilzomib-plus-dexamethasone-in-rrmm monthly 0.9 2021-04-07T15:09:00.000Z https://multiplemyelomahub.com/medical-information/elena-zamagni-or-asco-2018-or-is-skeletal-survey-dead-in-mm-what-imaging-to-use-and-when monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/luciano-costa-or-asco-2018-or-phase-ii-study-of-venetoclax-carfilzomib-and-dexamethasone-in-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/faith-davies-or-asco-2018-or-future-monoclonal-antibodies-bcma-and-beyond monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/shaji-kumar-or-asco-2018-or-the-multifaceted-nature-of-the-multiple-myelomas monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/g-david-roodman-or-asco-2018-or-optimal-treatment-of-bone-disease-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/comy-2018-or-affordable-and-effective-strategies-in-myeloma-do-they-exist monthly 0.9 2021-04-07T15:11:00.000Z https://multiplemyelomahub.com/medical-information/ravi-vij-or-asco-2018-or-practical-use-of-imaging-from-mgus-to-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/maria-victoria-mateos-or-asco-2018-or-highlights-of-the-randomized-phase-iii-arrow-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/comy-2018-or-cytogenetics-and-genetics monthly 0.9 2021-04-07T15:12:00.000Z https://multiplemyelomahub.com/medical-information/comy-2018-or-quality-of-life-considerations-in-myeloma monthly 0.9 2021-04-07T15:12:00.000Z https://multiplemyelomahub.com/medical-information/phase-iii-study-of-vorinostat-based-quadruplet-to-treat-rrmm-patients monthly 0.9 2021-04-07T15:12:00.000Z https://multiplemyelomahub.com/medical-information/comy-2018-or-an-overview monthly 0.9 2021-04-07T15:13:00.000Z https://multiplemyelomahub.com/medical-information/galinpepimut-s-granted-fda-orphan-drug-designation monthly 0.9 2021-04-07T15:13:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-approved-by-fda-for-frontline-use monthly 0.9 2021-04-07T15:13:00.000Z https://multiplemyelomahub.com/medical-information/time-to-plateau-shows-prognostic-value-in-ndmm monthly 0.9 2021-04-07T15:13:00.000Z https://multiplemyelomahub.com/medical-information/kdm1a-is-first-identified-germline-mm-predisposition-gene monthly 0.9 2021-04-07T15:13:00.000Z https://multiplemyelomahub.com/medical-information/safety-of-90-minute-daratumumab-infusion monthly 0.9 2021-04-07T15:14:00.000Z https://multiplemyelomahub.com/medical-information/microfluidic-device-improves-detection-of-genetic-abnormalities-and-treatment-outcome-in-mm monthly 0.9 2021-04-07T15:16:00.000Z https://multiplemyelomahub.com/medical-information/risk-of-progression-to-mm-a-long-term-follow-up-of-mgus-patients monthly 0.9 2021-04-07T15:17:00.000Z https://multiplemyelomahub.com/medical-information/new-imaging-methodology-enables-rapid-assessment-of-transplant-success-in-hematologic-malignancies monthly 0.9 2021-04-07T15:17:00.000Z https://multiplemyelomahub.com/medical-information/the-concept-of-a-cure-in-mm-a-comparison-of-survival-outcomes monthly 0.9 2021-04-07T15:24:00.000Z https://multiplemyelomahub.com/medical-information/validation-of-the-r-iss-for-stratification-of-transplant-eligible-mm-patients monthly 0.9 2021-04-07T15:24:00.000Z https://multiplemyelomahub.com/medical-information/detection-of-mm-associated-translocations-and-mutations-in-igll5 monthly 0.9 2021-04-07T15:24:00.000Z https://multiplemyelomahub.com/medical-information/treatment-to-suppression-of-focal-lesions-in-ndmm-is-an-important-therapeutic-goal monthly 0.9 2021-04-07T15:24:00.000Z https://multiplemyelomahub.com/medical-information/selinexor-receives-fda-fast-track-designation monthly 0.9 2021-04-07T15:25:00.000Z https://multiplemyelomahub.com/medical-information/high-bmi-in-early-and-late-adulthood-is-a-risk-factor-for-mm monthly 0.9 2021-04-07T15:25:00.000Z https://multiplemyelomahub.com/medical-information/denosumab-approved-for-mm-in-europe monthly 0.9 2022-10-28T16:22:00.000Z https://multiplemyelomahub.com/medical-information/response-kinetics-and-treatment-outcomes-in-rrmm monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2018-or-pre-transplant-induction-in-mm monthly 0.9 2021-04-07T17:04:00.000Z https://multiplemyelomahub.com/medical-information/embt-2018-or-therapies-for-fit-elderly-mm-patients monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/following-nice-guidelines-or-an-interview-with-ceri-bygrave monthly 0.9 2021-04-07T15:26:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2018-or-galinpepimut-s-gps-vaccine-in-high-risk-mm monthly 0.9 2021-04-07T15:26:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2018-or-efficacy-and-safety-of-bortezomib-in-allogeneic-transplant-for-high-risk-relapsed-mm monthly 0.9 2021-04-07T15:26:00.000Z https://multiplemyelomahub.com/medical-information/prof-mohamad-mohty-or-ebmt-2018-or-role-of-double-auto-transplant-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2018-or-efficacy-of-allogeneic-stem-cell-transplantation-in-amyloidosis-patients monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2018-or-haploidentical-transplantation-in-patients-with-high-risk-or-multiply-relapsed-mm monthly 0.9 2021-04-07T15:26:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2018-or-impact-of-cytogenetics-on-transplant-outcome-in-mm-patients-with-emd monthly 0.9 2021-04-07T15:26:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2018-or-cost-effectiveness-of-modern-mm-therapies monthly 0.9 2021-04-07T15:27:00.000Z https://multiplemyelomahub.com/medical-information/prof-joan-blade-or-ebmt-2018-or-optimal-induction-in-the-transplant-setting monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ebmt-2018-or-cd229-is-a-promising-target-for-mm monthly 0.9 2021-04-07T15:27:00.000Z https://multiplemyelomahub.com/medical-information/validation-of-liquid-biopsy-using-circulating-tumor-dna-to-monitor-mm monthly 0.9 2021-04-07T15:27:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-enhances-nk-cell-cytotoxicity monthly 0.9 2021-04-07T15:27:00.000Z https://multiplemyelomahub.com/medical-information/denosumab-is-cost-effective-for-the-prevention-of-sres monthly 0.9 2021-04-07T15:28:00.000Z https://multiplemyelomahub.com/medical-information/ixazomib-pomalidomide-and-dexamethasone-in-lenalidomide-refractory-rrmm-patients monthly 0.9 2021-04-07T15:28:00.000Z https://multiplemyelomahub.com/medical-information/case-study-or-triple-refractory-mm-patient-with-sustained-response-to-daratumumab-monotherapy monthly 0.9 2021-04-07T15:28:00.000Z https://multiplemyelomahub.com/medical-information/revlimid-lenalidomide-approved-in-china-for-treatment-of-transplant-ineligible-mm-patients monthly 0.9 2022-10-31T11:38:00.000Z https://multiplemyelomahub.com/medical-information/denosumab-xgeva-edges-towards-eu-approval-for-mm-related-sres monthly 0.9 2022-10-31T11:39:00.000Z https://multiplemyelomahub.com/medical-information/efficacy-and-safety-of-ibrutinib-in-rrmm monthly 0.9 2021-04-07T15:29:00.000Z https://multiplemyelomahub.com/medical-information/denosumab-vs-zoledronic-acid-phase-iii-study-in-ndmm-patients monthly 0.9 2021-04-07T15:29:00.000Z https://multiplemyelomahub.com/medical-information/the-23rd-congress-of-the-european-hematology-association-eha-abstract-deadline monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/clinical-advances-in-myeloma-2018-or-stem-cell-therapy-and-immunotherapy monthly 0.9 2021-04-07T15:30:00.000Z https://multiplemyelomahub.com/medical-information/clinical-advances-in-myeloma-2018-or-treatments-for-newly-diagnosed-and-relapsed-patients monthly 0.9 2021-04-07T15:30:00.000Z https://multiplemyelomahub.com/medical-information/subgroup-analysis-of-aspire-and-endeavor-trials-carfilzomib-in-rrmm monthly 0.9 2021-03-23T16:25:00.000Z https://multiplemyelomahub.com/medical-information/phase-ii-trial-of-pomalidomide-plus-low-dose-dexamethasone-in-rrmm-patients-with-renal-impairment monthly 0.9 2021-04-07T15:30:00.000Z https://multiplemyelomahub.com/medical-information/orphan-drug-designation-granted-to-pt-112 monthly 0.9 2021-04-07T15:31:00.000Z https://multiplemyelomahub.com/medical-information/clinical-advances-in-myeloma-2018-or-multidisciplinary-perspectives-on-myeloma-management monthly 0.9 2021-04-07T15:31:00.000Z https://multiplemyelomahub.com/medical-information/phase-ii-trial-of-selinexor-plus-dexamethasone-in-rrmm-patients monthly 0.9 2021-04-07T15:31:00.000Z https://multiplemyelomahub.com/medical-information/serum-free-light-chain-tests-for-the-diagnosis-and-monitoring-of-mm monthly 0.9 2021-04-07T15:31:00.000Z https://multiplemyelomahub.com/medical-information/clinical-advances-in-myeloma-2018-or-an-overview monthly 0.9 2021-04-07T15:32:00.000Z https://multiplemyelomahub.com/medical-information/fda-clearance-granted-for-hydrashift-24-daratumumab-assay monthly 0.9 2021-04-07T15:32:00.000Z https://multiplemyelomahub.com/medical-information/final-analysis-of-phase-iii-first-trial-in-transplant-ineligible-patients monthly 0.9 2021-04-07T15:32:00.000Z https://multiplemyelomahub.com/medical-information/review-and-meta-analysis-of-phase-iii-rcts-assessing-the-role-of-hdtasct-in-ndmm monthly 0.9 2021-04-07T15:32:00.000Z https://multiplemyelomahub.com/medical-information/mm-induced-bone-disease-an-overview-and-updated-asco-guidelines monthly 0.9 2021-04-07T15:33:00.000Z https://multiplemyelomahub.com/medical-information/cytogenetic-heterogeneity-has-prognostic-significance-in-ndmm monthly 0.9 2021-04-07T15:33:00.000Z https://multiplemyelomahub.com/medical-information/low-incidence-of-spms-after-asct-with-novel-agents monthly 0.9 2021-04-07T15:34:00.000Z https://multiplemyelomahub.com/medical-information/april-car-t-cells-for-dual-targeting-of-bcma-and-taci monthly 0.9 2021-04-07T15:34:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-darzalex-granted-priority-review-as-a-frontline-regimen monthly 0.9 2022-10-31T11:38:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-all-wrapped-up monthly 0.9 2021-03-23T16:28:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-darzalex-approved-for-use-in-england-and-wales monthly 0.9 2022-10-31T11:39:00.000Z https://multiplemyelomahub.com/medical-information/safety-and-efficacy-of-pomalidomide-dexamethasone-and-pegylated-liposomal-doxorubicin-in-patients-with-rrmm monthly 0.9 2021-04-07T15:35:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-genomics-and-molecular-profiling-in-mm monthly 0.9 2021-04-07T15:35:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-bcma-as-a-target-for-mm monthly 0.9 2021-04-07T15:35:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-pre-clinical-studies-to-examine-immune-suppression-surveillance-and-homing-mechanisms-in-mm monthly 0.9 2021-04-07T15:36:00.000Z https://multiplemyelomahub.com/medical-information/re-vaccination-following-asct-in-mm-patients-receiving-lenalidomide-maintenance monthly 0.9 2021-04-07T15:36:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-geneticgenomic-studies-examine-progression-from-smm-to-mm monthly 0.9 2021-04-07T15:36:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-treatment-strategies-for-ndmm-patients-not-undergoing-transplant monthly 0.9 2021-04-07T15:36:00.000Z https://multiplemyelomahub.com/medical-information/denosumab-xgeva-fda-approved-for-the-prevention-of-mm-related-sres monthly 0.9 2022-10-31T11:40:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-bortezomib-and-lenalidomide-induction-regimens-for-high-risk-transplant-ineligible-ndmm-patients monthly 0.9 2021-04-07T15:37:00.000Z https://multiplemyelomahub.com/medical-information/dr-n-lehners-or-ash-2017-or-key-highlights-myeloma-pathophysiology-and-pre-clinical-studies monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-nina-shah-or-ash-2017-or-current-clinical-landscape-for-ndmm-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-rafael-fonseca-or-ash-2017-or-understanding-and-harnessing-normal-plasma-cell-biology monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-ixazomib-thalidomide-low-dose-dexamethasone-itd-induction-and-maintenance-with-ixazomib-in-ndmm-patients-not-eligible-for-transplant monthly 0.9 2021-04-07T15:37:00.000Z https://multiplemyelomahub.com/medical-information/ixazomib-ninlaro-now-available-to-patients-in-england-and-wales monthly 0.9 2022-10-31T11:40:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-phase-ii-study-of-ixazomib-with-lenalidomide-as-post-asct-maintenance-therapy monthly 0.9 2021-04-07T15:38:00.000Z https://multiplemyelomahub.com/medical-information/japanese-study-of-elotuzumab-plus-lenalidomidedexamethasone-in-ndmm-patients monthly 0.9 2021-04-07T15:38:00.000Z https://multiplemyelomahub.com/medical-information/cellprotect-receives-eu-orphan-drug-status-for-the-treatment-of-mm monthly 0.9 2021-04-07T15:38:00.000Z https://multiplemyelomahub.com/medical-information/prof-sonja-zweegman-or-ash-2017-or-updated-results-from-the-hovon-126-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-catherine-pellet-deceunynck-or-ash-2017-or-transcriptional-regulatory-circuitries-of-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-david-siegal-or-ash-2017-or-key-findings-from-the-final-analysis-of-aspire monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-hermann-einsele-or-ash-2017-or-rationale-for-combining-hdac-inhibitor-and-daratumumab monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-suzanne-lentzsch-or-ash-2017-or-new-antibody-targeting-the-amyloid monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-bruno-paiva-or-ash-2017-or-using-ngf-for-mrd-monitoring monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-carfilzomib-versus-bortezomib-phase-ii-muk-five-study monthly 0.9 2021-04-07T15:39:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-pomalidomide-after-lenalidomide-first-line-therapy-for-rrmm-patients monthly 0.9 2021-04-07T15:39:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-elotuzumab-maintenance-after-asct monthly 0.9 2021-04-07T15:39:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-genomic-predictors-of-response-to-carfilzomib-in-rrmm-patients-in-the-endeavor-trial monthly 0.9 2021-04-07T15:39:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-phase-iii-study-of-bortezomib-vcd-versus-lenalidomide-rcd-combos-in-first-relapse monthly 0.9 2021-04-07T15:40:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-subcutaneous-daratumumab-in-rrmm monthly 0.9 2021-04-07T15:40:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-final-analysis-of-the-phase-iii-aspire-clinical-trial monthly 0.9 2021-03-23T16:25:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-lba-4-phase-iii-alcyone-clinical-trial-daratumumab-plus-bortezomib-melphalan-and-prednisone-d-vmp-in-ndmm-patients-ineligible-for-transplant monthly 0.9 2021-04-07T15:40:00.000Z https://multiplemyelomahub.com/medical-information/prof-meletios-dimopoulos-or-ash-2017-or-updated-safety-and-efficacy-data-from-the-pollux-trial-drd-vs-rd-in-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-mechanisms-of-resistance-and-prognosis-the-role-of-crowdsourcing-genomic-characterization-and-a-seven-gene-signature-approach monthly 0.9 2021-04-09T12:27:00.000Z https://multiplemyelomahub.com/medical-information/dr-charlotte-pawlyn-or-ash-2017-or-pre-clinical-novel-immunotherapeutic-strategies-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-ola-landgren-or-ash-2017-or-key-controversies-in-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-updated-data-from-the-pollux-trial monthly 0.9 2021-04-07T15:41:00.000Z https://multiplemyelomahub.com/medical-information/prof-heinz-ludwig-or-ash-2017-or-have-novel-mm-agents-improved-qol-in-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-novel-oncogenes-and-tumor-suppressors-in-ndmm monthly 0.9 2021-04-07T15:41:00.000Z https://multiplemyelomahub.com/medical-information/prof-sagar-lonial-or-ash-2017-or-highlights-of-ash-in-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/assoc-prof-jonathan-kaufman-or-ash-2017-or-venetoclax-as-targeted-therapy-for-t-11-14-rrmm-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-two-flu-vaccines-are-better-than-one-for-most-patients-with-plasma-cell-disorders monthly 0.9 2021-04-07T15:42:00.000Z https://multiplemyelomahub.com/medical-information/dr-paola-neri-or-ash-2017-or-genomics-of-the-pathogenesis-and-progression-of-mm-session-highlights monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-irene-ghobrial-or-ash-2017-or-impact-of-ngs-in-the-management-of-smoldering-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-nikhil-munshi-or-ash-2017-or-genomic-landscape-of-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/ash-2017-or-the-role-of-the-immune-microenvironment-in-mm monthly 0.9 2021-04-07T16:21:00.000Z https://multiplemyelomahub.com/medical-information/prof-gareth-j-morgan-or-ash-2017-or-novel-oncogenes-and-tumor-suppressor-genes-in-ndmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-philip-mccarthy-or-ash-2017-or-take-home-messages-for-transplant-eligible-mm-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-mohamad-mohty-or-ash-2017-or-role-of-asct-in-mm-differences-between-us-and-europe monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/partial-hold-on-opdivo-r-nivolumab-trials-with-mm-combos-has-been-lifted monthly 0.9 2022-10-28T16:18:00.000Z https://multiplemyelomahub.com/medical-information/bcma-car-t-cell-bb2121-granted-both-breakthrough-therapy-designation-and-prime-status monthly 0.9 2021-04-07T16:22:00.000Z https://multiplemyelomahub.com/medical-information/significant-differences-in-gene-mutations-between-patients-of-african-american-and-caucasian-descent monthly 0.9 2021-04-07T16:22:00.000Z https://multiplemyelomahub.com/medical-information/janssen-seeks-an-extension-of-daratumumab-darzalex-marketing-authorization monthly 0.9 2022-10-31T11:45:00.000Z https://multiplemyelomahub.com/medical-information/obesity-shown-not-to-be-a-risk-factor-for-occurrence-of-mgus-but-does-affect-progression-from-mgus-to-mm monthly 0.9 2021-04-07T16:22:00.000Z https://multiplemyelomahub.com/medical-information/activated-conformation-of-integrin-b7-is-a-new-myeloma-specific-target-for-immunotherapy-and-car-t-cell-specificity monthly 0.9 2021-04-07T16:23:00.000Z https://multiplemyelomahub.com/medical-information/success-for-slamf7-directed-car-t-cells-mm-specific-pre-clinical-study monthly 0.9 2021-04-07T16:23:00.000Z https://multiplemyelomahub.com/medical-information/jam-a-as-a-prognostic-factor-and-new-therapeutic-target-in-mm monthly 0.9 2021-04-07T16:23:00.000Z https://multiplemyelomahub.com/medical-information/bcma-antibody-drug-conjugate-granted-breakthrough-therapy-designation monthly 0.9 2021-04-07T17:05:00.000Z https://multiplemyelomahub.com/medical-information/significant-pfs-benefit-with-ixazomib-in-all-oral-regimen-for-high-risk-rrmm-patients monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/driving-forward-with-car-t-therapy-what-does-this-mean-for-mm monthly 0.9 2021-04-07T17:05:00.000Z https://multiplemyelomahub.com/medical-information/venetoclax-monotherapy-for-rrmm-patients-with-t-1114 monthly 0.9 2021-04-07T16:23:00.000Z https://multiplemyelomahub.com/medical-information/treatment-responsive-biology-observed-in-high-risk-smoldering-myeloma monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-darzalex-approved-in-scotland monthly 0.9 2022-10-31T11:41:00.000Z https://multiplemyelomahub.com/medical-information/acupuncture-may-reduce-disease-symptoms-in-mm-patients-undergoing-transplant monthly 0.9 2021-04-07T16:24:00.000Z https://multiplemyelomahub.com/medical-information/case-study-or-relapsed-mm-with-intracranial-plasmacytoma-and-malignant-pericardial-effusion-post-transplant monthly 0.9 2021-04-09T12:27:00.000Z https://multiplemyelomahub.com/medical-information/cytogenetic-high-risk-abnormalities-reveal-poor-prognosis-in-newly-diagnosed-mm monthly 0.9 2021-04-09T12:27:00.000Z https://multiplemyelomahub.com/medical-information/translocation-t-1114-confers-an-inferior-prognosis-to-other-standard-risk-patients-with-mm monthly 0.9 2021-04-07T16:25:00.000Z https://multiplemyelomahub.com/medical-information/secondary-analysis-of-the-endeavor-study-carfilzomib-dexamethasone-vs-sc-or-iv-bortezomib-dexamethasone-in-rrmm monthly 0.9 2021-04-07T16:25:00.000Z https://multiplemyelomahub.com/medical-information/evidence-for-favourable-outcomes-following-outpatient-auto-hct-treatment-in-mm monthly 0.9 2021-04-07T16:25:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-darzalex-granted-approval-for-use-in-japan monthly 0.9 2022-10-31T11:42:00.000Z https://multiplemyelomahub.com/medical-information/nice-upset-for-ninlaro-r-ixazomib monthly 0.9 2022-10-28T16:18:00.000Z https://multiplemyelomahub.com/medical-information/descriptive-study-results-for-low-dose-cyclophosphamide-with-bortezomib-and-low-dose-dexamethasone-in-rrmm monthly 0.9 2021-04-07T16:26:00.000Z https://multiplemyelomahub.com/medical-information/fda-halts-mm-trials-with-tecentriq-r-atezolizumab monthly 0.9 2022-10-28T16:19:00.000Z https://multiplemyelomahub.com/medical-information/safety-and-efficacy-of-pomalidomide-bortezomib-and-dexamethasone-for-the-treatment-of-rrmm monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/the-tourmaline-mm1-study-subgroup-analysis-via-prior-therapy monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/asco-sitc-clinical-immuno-oncology-symposium-abstract-submission-deadline-3rd-october monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/whole-body-computed-tomography-wbct-shows-increased-benefit-over-conventional-skeletal-survey-css-for-the-identification-of-bone-lesions-in-mm monthly 0.9 2021-04-07T16:26:00.000Z https://multiplemyelomahub.com/medical-information/the-gene-signature-of-mm-patients-can-predict-response-to-imid-treatment monthly 0.9 2021-04-07T16:27:00.000Z https://multiplemyelomahub.com/medical-information/ixazomib-treatment-regimens-in-ndmm-patients-oral-abstracts-at-soho-2017 monthly 0.9 2021-04-07T16:27:00.000Z https://multiplemyelomahub.com/medical-information/independent-dosing-trials-need-to-be-established-less-can-be-more monthly 0.9 2021-04-07T16:28:00.000Z https://multiplemyelomahub.com/medical-information/targeted-therapy-using-venetoclax-with-bortezomibdexamethasone-preliminary-data-indicates-positive-results-for-rrmm monthly 0.9 2021-04-07T16:28:00.000Z https://multiplemyelomahub.com/medical-information/case-study-or-practical-management-of-cardiovascular-events-in-carfilzomib-therapy-in-rrmm monthly 0.9 2021-04-07T17:06:00.000Z https://multiplemyelomahub.com/medical-information/fda-calls-a-partial-halt-to-opdivo-r-nivolumab-trials-in-mm monthly 0.9 2022-10-28T16:20:00.000Z https://multiplemyelomahub.com/medical-information/carfilzomib-extends-survival-in-rrmm-os-analysis-of-the-endeavor-trial monthly 0.9 2021-04-07T16:29:00.000Z https://multiplemyelomahub.com/medical-information/high-sensitivity-of-mass-spectrometry-based-m-protein-detection monthly 0.9 2021-04-07T16:29:00.000Z https://multiplemyelomahub.com/medical-information/dr-aldo-roccaro-or-esh-clinical-updates-on-mm-2017-or-monoclonal-antibody-treatment-in-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/frailty-replaces-old-age-in-geriatric-assessments-for-mm monthly 0.9 2021-04-07T16:30:00.000Z https://multiplemyelomahub.com/medical-information/the-evolutionary-history-of-mm-correlates-with-outcome-and-could-help-tailor-therapy monthly 0.9 2021-04-07T16:30:00.000Z https://multiplemyelomahub.com/medical-information/phase-iii-study-finds-no-significant-benefit-with-bortezomib-retreatment-versus-standard-retreatment-therapy monthly 0.9 2021-04-07T16:30:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-the-calgb-alliance-100104-clinical-trial-to-assess-efficacy-of-lenalidomide-maintenance-treatment-post-asct monthly 0.9 2021-04-07T16:30:00.000Z https://multiplemyelomahub.com/medical-information/long-term-results-of-the-hovon-65gmmg-hd4-trial-bortezomib-before-and-after-high-dose-therapy monthly 0.9 2021-04-07T16:31:00.000Z https://multiplemyelomahub.com/medical-information/prof-san-miguel-or-esh-clinical-updates-on-mm-2017-or-how-to-make-a-decision-for-mm-patients-after-1-3-lines-of-prior-treatment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/efficacy-of-daratumumab-outside-the-clinical-trial-setting monthly 0.9 2021-04-07T16:31:00.000Z https://multiplemyelomahub.com/medical-information/edo-s101-first-alkylating-hdac-inhibitor-works-in-synergy-with-proteasome-inhibitors-for-mm monthly 0.9 2021-04-07T16:31:00.000Z https://multiplemyelomahub.com/medical-information/meta-analysis-of-lenalidomide-maintenance-after-autologous-stem-cell-transplantation monthly 0.9 2021-04-07T17:06:00.000Z https://multiplemyelomahub.com/medical-information/validation-of-sky92iss-as-a-prognostic-indicator-for-mm monthly 0.9 2021-04-07T16:32:00.000Z https://multiplemyelomahub.com/medical-information/china-continuation-study-a-regional-expansion-of-the-tourmaline-mm1-clinical-trial monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/qol-study-of-rrmm-patients-treated-with-second-or-third-line-lenalidomide-or-bortezomib monthly 0.9 2021-04-07T16:32:00.000Z https://multiplemyelomahub.com/medical-information/literature-and-network-meta-analysis-to-assess-efficacy-of-rrmm-treatment-options monthly 0.9 2021-04-07T16:32:00.000Z https://multiplemyelomahub.com/medical-information/telomere-length-is-a-prognostic-indicator-for-mm monthly 0.9 2021-04-07T16:32:00.000Z https://multiplemyelomahub.com/medical-information/59th-ash-annual-meeting-and-exposition-abstract-submission-deadline-2nd-august monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/xpo1-inhibition-can-reverse-hypoxia-induced-resistance-to-bortezomib monthly 0.9 2021-04-07T16:33:00.000Z https://multiplemyelomahub.com/medical-information/ultra-high-doses-of-vitamin-c-can-selectively-kill-mm-cells-and-lower-the-dose-of-melphalan monthly 0.9 2021-04-07T16:33:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-the-endeavor-study-by-cytogenetic-risk-status monthly 0.9 2021-04-07T16:33:00.000Z https://multiplemyelomahub.com/medical-information/csf1r-blocking-antibodies-show-therapeutic-potential-in-mm monthly 0.9 2021-04-07T16:33:00.000Z https://multiplemyelomahub.com/medical-information/microfluidic-device-may-in-time-replace-bm-biopsy-for-mm-diagnosis-and-assessment monthly 0.9 2021-04-07T16:34:00.000Z https://multiplemyelomahub.com/medical-information/fda-calls-a-stop-to-merck-s-trials-of-pembrolizumab-in-mm monthly 0.9 2021-04-07T16:34:00.000Z https://multiplemyelomahub.com/medical-information/eha-22nd-congress-mm-education-session monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/eha-22nd-congress-clinical-debate-treatment-should-be-started-in-every-patient-with-high-risk-smoldering-multiple-myeloma monthly 0.9 2021-04-07T16:34:00.000Z https://multiplemyelomahub.com/medical-information/eha-22nd-congress-novel-developments-in-mm-and-related-diseases monthly 0.9 2021-04-09T12:36:00.000Z https://multiplemyelomahub.com/medical-information/prof-nikhil-munshi-or-eha-2017-or-impact-of-mrd-on-survival-in-mm-patients-in-cr monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-pieter-sonneveld-or-eha-2017-or-pom-lodex-in-rrmm-and-renal-impairment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-xavier-leleu-or-eha-2017-or-treatment-and-sequence-in-rrmm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/nice-news-for-kyprolis-r-carfilzomib monthly 0.9 2022-10-28T16:21:00.000Z https://multiplemyelomahub.com/medical-information/dr-elena-zamagni-or-eha-2017-or-should-imaging-be-part-of-mrd monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/eha-22nd-congress-navigating-the-complex-waters-in-rrmm monthly 0.9 2021-04-07T16:35:00.000Z https://multiplemyelomahub.com/medical-information/dr-monique-minnema-or-eha-2017-or-final-results-of-the-hovon-104-trial monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-avet-loiseau-or-eha-2017-or-the-implications-of-cytogenetics-on-personalized-treatment monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-charlotte-pawlyn-or-eha-2017-or-results-of-the-myeloma-xi-study monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-enrique-ocio-or-eha-2017-or-toxicity-of-novel-agents-in-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/pembrolizumab-pomalidomide-and-low-dose-dexamethasone-in-rrmm-patients monthly 0.9 2021-04-07T16:36:00.000Z https://multiplemyelomahub.com/medical-information/fda-approves-daratumumab-darzalex-in-combination-with-pomalidomide-and-dexamethasone monthly 0.9 2022-10-31T11:45:00.000Z https://multiplemyelomahub.com/medical-information/2017-asco-annual-meeting-daratumumab-continues-to-show-improved-results-for-rrmm-patients-and-those-with-high-risk-disease monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/2017-asco-annual-meeting-immunotherapy-in-mm monthly 0.9 2021-04-07T16:37:00.000Z https://multiplemyelomahub.com/medical-information/external-monitors-press-pause-on-keynote-phase-iii-clinical-trials-of-keytruda-r-pembrolizumab monthly 0.9 2022-10-28T16:21:00.000Z https://multiplemyelomahub.com/medical-information/2017-asco-annual-meeting-bcma-is-a-promising-target-for-directed-treatment-of-mm monthly 0.9 2021-04-07T16:38:00.000Z https://multiplemyelomahub.com/medical-information/prof-andrzej-jakubowiack-or-2017-asco-annual-meeting-or-dara-in-combination-with-krd-in-patients-with-nd-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-nina-shah-or-2017-asco-annual-meeting-or-are-all-relapses-the-same monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/2017-asco-annual-meeting-impact-of-denosumab-compared-with-zoledronic-acid-on-renal-function-for-the-treatment-of-bone-disease-in-mm monthly 0.9 2021-04-07T16:39:00.000Z https://multiplemyelomahub.com/medical-information/fda-clears-cd38cd3-bi-specific-antibody-for-treatment-of-mm-in-phase-i-clinical-trials monthly 0.9 2021-04-07T16:39:00.000Z https://multiplemyelomahub.com/medical-information/2017-asco-annual-meeting-are-we-integrating-biologic-advances-in-mm-into-clinical-practice monthly 0.9 2021-04-07T16:39:00.000Z https://multiplemyelomahub.com/medical-information/prof-noopur-s-raje-or-2017-asco-annual-meeting-or-impact-of-denosumab-dmb-compared-with-zoledronic-acid-za-on-renal-function-in-the-treatment-of-myeloma-bone-disease monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/2017-asco-annual-meeting-carfilzomib-frontline-in-newly-diagnosed-mm monthly 0.9 2021-04-07T16:40:00.000Z https://multiplemyelomahub.com/medical-information/2017-asco-annual-meeting-results-from-the-biomarker-driven-basket-trial-of-ro51267-ch5126766-a-potent-rafmek-inhibitor-in-ras-or-raf-mutated-malignancies-including-multiple-myeloma-abstract-2506 monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/nice-draft-guidance-rejects-ninlaro-for-treatment-of-mm monthly 0.9 2021-04-07T16:41:00.000Z https://multiplemyelomahub.com/medical-information/prof-philip-mccarthy-or-2017-asco-annual-meeting-or-lenalidomide-versus-placebo-maintenance-after-stem-cell-transplant monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/assist-prof-binod-dhakal-or-2017-asco-annual-meeting-or-asct-for-ndmm-a-meta-analysis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-sagar-lonial-or-2017-asco-annual-meeting-or-mrd-assessment-not-relevant-for-clinical-practice-yet monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-xavier-leleu-or-2017-asco-annual-meeting-or-carfilzomib-hebdomadaire-en-association-avec-mp-en-traitement-des-patients-ages-atteints-de-mm-non-pre-traites monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/2017-asco-annual-meeting-treatment-of-relapsed-mm-in-the-era-of-novel-drugs monthly 0.9 2021-04-07T16:44:00.000Z https://multiplemyelomahub.com/medical-information/assist-prof-laurent-garderet-or-2017-asco-annual-meeting-or-doublets-versus-triplets-at-relapse monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-katja-weisel-or-2017-asco-annual-meeting-or-drd-versus-dvd-in-rr-mm-based-on-cytogenetic-risk-status monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-francesca-gay-or-2017-asco-annual-meeting-or-krd-versus-kcd-induction-forte-trial-in-nd-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-xavier-leleu-or-2017-asco-annual-meeting-or-carfilzomib-weekly-melphalan-prednisone-in-untreated-elderly-multiple-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/dr-ashley-rosko-or-2017-asco-annual-meeting-or-respecting-frailty-fragility-or-age monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-maria-victoria-mateos-or-2017-asco-annual-meeting-or-aiming-for-cr-irrespective-of-age monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-meletios-dimopoulos-or-esh-clinical-updates-on-mm-2017-or-novel-agents-for-refractory-mm-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-hermann-eisele-or-esh-clinical-updates-on-mm-2017-or-how-to-improve-the-post-asct-outcome monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-hermann-einsele-or-esh-clinical-updates-on-mm-2017-or-definition-of-transplant-eligible-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-hermann-einsele-or-esh-clinical-updates-on-mm-2017-or-soc-for-transplant-eligible-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-sonja-zweegman-or-esh-clinical-updates-on-mm-2017-or-first-line-treatment-for-transplant-non-eligible-patients monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-irene-ghobrial-or-esh-clinical-updates-on-mm-2017-or-non-smouldering-treatment-of-smouldering-myeloma monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-philippe-moreau-or-esh-clinical-updates-on-mm-2017-or-treatment-of-high-risk-mm monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/key-highlights-from-the-esh-clinical-updates-meeting-on-multiple-myeloma monthly 0.9 2021-04-07T16:46:00.000Z https://multiplemyelomahub.com/medical-information/prof-shaji-kumar-or-esh-clinical-updates-on-mm-2017-or-newly-diagnosed-mm-diagnosis monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/prof-c-ola-landgren-or-esh-clinical-updates-on-mm-2017-or-mrd-based-treatment-paradigms monthly 0.9 2022-07-04T13:13:00.000Z https://multiplemyelomahub.com/medical-information/hexokinase-2-expression-is-linked-to-false-negatives-in-fdg-pet-imaging-of-mm-patients monthly 0.9 2021-04-07T16:46:00.000Z https://multiplemyelomahub.com/medical-information/panobinostat-works-synergistically-with-daratumumab-by-up-regulating-cd38 monthly 0.9 2021-04-07T16:47:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-darzalex-granted-approval-in-eu-but-rejected-by-nice monthly 0.9 2022-10-31T11:43:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-treatment-leads-to-loss-of-cd38-on-red-blood-cells monthly 0.9 2021-04-07T16:47:00.000Z https://multiplemyelomahub.com/medical-information/prolonged-use-of-zoledronic-acid-reduces-skeletal-events-but-does-not-improve-os monthly 0.9 2021-04-07T16:47:00.000Z https://multiplemyelomahub.com/medical-information/updated-esmo-clinical-practice-guidelines monthly 0.9 2021-04-07T16:47:00.000Z https://multiplemyelomahub.com/medical-information/amgen-requests-approval-of-xgeva-r-to-treat-mm-in-both-usa-and-europe monthly 0.9 2022-10-28T16:22:00.000Z https://multiplemyelomahub.com/medical-information/fda-grants-orphan-drug-designation-status-for-tasquinimod-to-treat-mm monthly 0.9 2021-04-07T16:48:00.000Z https://multiplemyelomahub.com/medical-information/inherited-susceptibility-to-mm-evidence-for-a-polygenic-etiology monthly 0.9 2021-04-07T16:48:00.000Z https://multiplemyelomahub.com/medical-information/the-bone-marrow-microenvironment-drives-mcl-1-dependence monthly 0.9 2021-04-07T16:49:00.000Z https://multiplemyelomahub.com/medical-information/transplantation-and-inductionconsolidation-therapy-lenalidomide-bortezomib-and-dexamethasone monthly 0.9 2020-12-11T01:13:00.000Z https://multiplemyelomahub.com/medical-information/age-should-not-be-a-limiting-factor-in-choosing-asct monthly 0.9 2021-04-07T16:50:00.000Z https://multiplemyelomahub.com/medical-information/bortezomib-consolidation-therapy-confers-distinct-pfs-benefit-in-newly-diagnosed-mm-patients monthly 0.9 2021-04-07T16:50:00.000Z https://multiplemyelomahub.com/medical-information/a-meta-analysis-of-phase-iii-trials-favors-the-use-of-a-triplet-drug-regimen-for-patients-with-rrmm monthly 0.9 2021-04-07T16:50:00.000Z https://multiplemyelomahub.com/medical-information/daratumumab-darzalex-r-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-mm-patients-who-have-received-at-least-one-prior-therapy monthly 0.9 2022-10-28T16:24:00.000Z https://multiplemyelomahub.com/medical-information/molecular-lesions-in-mm monthly 0.9 2021-04-09T12:36:00.000Z https://multiplemyelomahub.com/medical-information/an-assessment-of-the-revised-international-staging-system-using-unselected-patients-with-newly-diagnosed-and-relapsed-mm monthly 0.9 2021-04-07T16:51:00.000Z https://multiplemyelomahub.com/medical-information/the-impact-on-revised-imwg-diagnostic-criteria-of-new-findings-regarding-bm-aspiration-and-bm-biopsy monthly 0.9 2021-04-07T16:51:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-the-panorama-1-trial-os-of-patients-with-relapsed-mm-treated-with-panobinostat-plus-bortezomib-and-dexamethasone monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/humanized-mouse-model-for-the-study-of-mm monthly 0.9 2021-04-07T16:51:00.000Z https://multiplemyelomahub.com/medical-information/the-revised-international-staging-system-r-iss-is-a-powerful-tool-for-risk-stratification-of-newly-diagnosed-mm-patients monthly 0.9 2021-04-07T16:51:00.000Z https://multiplemyelomahub.com/medical-information/the-pollux-clinical-trial-to-assess-the-efficacy-of-daratumumab-in-combination-with-lenalidomide-and-dexamethasone monthly 0.9 2021-04-07T16:56:00.000Z https://multiplemyelomahub.com/medical-information/sub-group-analysis-of-the-aspire-clinical-trial-carfilzomib-significantly-improves-pfs-of-high-risk-patients-with-mm monthly 0.9 2021-03-23T16:26:00.000Z https://multiplemyelomahub.com/medical-information/the-castor-clinical-trial-for-daratumumab-in-combination-with-bortezomib-and-dexamethasone monthly 0.9 2021-04-07T16:57:00.000Z https://multiplemyelomahub.com/medical-information/stratus-mm-010-trial-to-assess-pomalidomide-plus-low-dose-dexamethasone-in-refractory-mm monthly 0.9 2021-04-07T16:57:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-the-first-clinical-trial-to-compare-lenalidomide-dexamethasone-with-mpt monthly 0.9 2021-04-07T16:58:00.000Z https://multiplemyelomahub.com/medical-information/the-effect-of-daratumumab-on-immune-cell-repertoire-depletion-of-cd38-immune-regulatory-cells-and-t-cell-expansion monthly 0.9 2021-04-07T16:58:00.000Z https://multiplemyelomahub.com/medical-information/bob1-intracellular-transcription-factor-is-a-target-for-tcr-based-therapy-in-mm monthly 0.9 2021-04-07T16:58:00.000Z https://multiplemyelomahub.com/medical-information/oral-ixazomib-lenalidomide-and-dexamethasone-for-mm monthly 0.9 2021-04-07T16:58:00.000Z https://multiplemyelomahub.com/medical-information/the-sirius-phase-ii-trial-daratumumab-monotherapy-in-patients-with-treatment-refractory-mm monthly 0.9 2021-04-07T16:58:00.000Z https://multiplemyelomahub.com/medical-information/nice-guidance-on-panobinostat-for-mm-patients-after-at-least-two-previous-treatments monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/comparison-of-vtd-with-vcd-for-the-treatment-of-patients-with-ndmm monthly 0.9 2021-04-07T16:59:00.000Z https://multiplemyelomahub.com/medical-information/the-endeavor-trial-to-compare-the-efficacy-of-carfilzomib-and-dexamethasone-with-bortezomib-and-dexamethasone-for-treatment-of-rrmm monthly 0.9 2021-04-07T16:59:00.000Z https://multiplemyelomahub.com/medical-information/sub-group-analysis-of-the-panorama-1-trial-panobinostat-plus-bortezomib-and-dexamethasone-by-prior-mm-treatment monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/eloquent-2-trial-to-assess-efficacy-of-elotuzumab-therapy-for-rrmm monthly 0.9 2021-04-07T17:00:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-mm-003-trial-of-pomalidomide-plus-low-dose-dexamethasone-cytogenetics-and-long-term-survival monthly 0.9 2021-04-07T17:00:00.000Z https://multiplemyelomahub.com/medical-information/the-us-fda-approves-revlimid-lenalidomide-as-post-asct-maintenance-therapy-for-mm monthly 0.9 2022-10-31T11:43:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-mm-003-trial-of-pomalidomide-plus-low-dose-dexamethasone-depth-of-response-analysis monthly 0.9 2021-04-07T17:00:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-mm-003-clinical-trial-health-related-quality-of-life monthly 0.9 2021-04-07T17:01:00.000Z https://multiplemyelomahub.com/medical-information/elotuzumab-therapy-for-relapsed-or-refractory-mm monthly 0.9 2021-04-07T17:02:00.000Z https://multiplemyelomahub.com/medical-information/panorama-1-study-to-assess-efficacy-of-panobinostat-in-combination-with-dexamethasone-and-bortezomib monthly 0.9 2020-11-06T13:17:00.000Z https://multiplemyelomahub.com/medical-information/aspire-clinical-trial-to-assess-carfilzomib-lenalidomide-and-dexamethasone-in-relapsed-mm monthly 0.9 2021-03-23T16:26:00.000Z https://multiplemyelomahub.com/medical-information/the-first-clinical-trial-to-assess-lenalidomide-and-dexamethasone-in-transplant-ineligible-mm-patients monthly 0.9 2021-04-07T17:03:00.000Z https://multiplemyelomahub.com/medical-information/pivotal-mm-003-trial-to-compare-pomalidomide-in-combination-with-high-or-low-dose-dexamethasone monthly 0.9 2021-04-07T17:03:00.000Z https://multiplemyelomahub.com/medical-information/lenalidomide-maintenance-therapy-for-newly-diagnosed-mm-patients monthly 0.9 2021-04-07T17:03:00.000Z https://multiplemyelomahub.com/medical-information/the-vista-clinical-trial-bortezomib-plus-melphalan-and-prednisone-for-treatment-of-transplant-ineligible-patients monthly 0.9 2021-04-07T17:03:00.000Z https://multiplemyelomahub.com/medical-information/updated-results-from-the-first-clinical-trial-health-related-quality-of-life monthly 0.9 2021-04-07T17:03:00.000Z https://multiplemyelomahub.com/about-us/louise-niven monthly 0.6 2026-03-10T10:33:00.000Z https://multiplemyelomahub.com/about-us/helen-croxall-1 monthly 0.6 2026-03-10T10:33:00.000Z https://multiplemyelomahub.com/about-us/jen-wilkinson monthly 0.6 2026-03-10T10:33:00.000Z https://multiplemyelomahub.com/about-us/amelia-campbell-warner monthly 0.6 2026-03-10T10:33:00.000Z https://multiplemyelomahub.com/about-us/jennifer-higgins monthly 0.6 2026-02-25T15:02:00.000Z https://multiplemyelomahub.com/about-us/haimanti-mandal monthly 0.6 2026-02-25T15:02:00.000Z https://multiplemyelomahub.com/about-us/beth-campbell monthly 0.6 2026-03-10T10:33:00.000Z https://multiplemyelomahub.com/about-us/dylan-barrett monthly 0.6 2026-03-10T10:33:00.000Z https://multiplemyelomahub.com/about-us/sari-cumming monthly 0.6 2026-03-10T10:33:00.000Z https://multiplemyelomahub.com/about-us/devon-else monthly 0.6 2026-02-25T15:02:00.000Z https://multiplemyelomahub.com/about-us/nathan-fisher monthly 0.6 2026-02-25T15:02:00.000Z https://multiplemyelomahub.com/about-us/amy-hopkins monthly 0.6 2026-02-25T15:02:00.000Z https://multiplemyelomahub.com/about-us/becky-gribbell monthly 0.6 2026-03-20T13:13:00.000Z https://multiplemyelomahub.com/about-us/natasha-fort monthly 0.6 2026-02-25T15:02:00.000Z https://multiplemyelomahub.com/about-us/addy-dullaghan monthly 0.6 2026-02-25T15:02:00.000Z https://multiplemyelomahub.com/about-us/alison-roddam monthly 0.6 2026-02-25T15:02:00.000Z https://multiplemyelomahub.com/about-us/monty-morris monthly 0.6 2026-04-02T14:45:00.000Z https://multiplemyelomahub.com/about-us/abbie-mckillop monthly 0.6 2026-04-02T14:45:00.000Z https://multiplemyelomahub.com/about-us/nathalie-tipler monthly 0.6 2026-04-02T14:45:00.000Z https://multiplemyelomahub.com/about-us/suzanna-de-barra monthly 0.6 2026-04-02T14:45:00.000Z https://multiplemyelomahub.com/about-us/chris-barnes monthly 0.6 2026-04-02T14:45:00.000Z https://multiplemyelomahub.com/contributors/sagar-lonial monthly 0.6 2025-04-24T08:59:00.000Z https://multiplemyelomahub.com/contributors/maria-victoria-mateos monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/elena-zamagni monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/heinz-ludwig monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/hermann-einsele monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/bruno-paiva monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/miles-prince monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/mohamad-mohty monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/morie-gertz monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/paul-richardson monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/shaji-kumar monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/sonja-zweegman monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/vania-tietsche-de-moraes-hungria monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/meral-beksac monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/hang-quach monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/rakesh-popat-1 monthly 0.6 2025-04-24T09:30:00.000Z https://multiplemyelomahub.com/contributors/chng-wee-joo monthly 0.6 2025-07-08T19:41:00.000Z https://multiplemyelomahub.com/steering-committees monthly 0.7 2026-04-05T04:07:26.181Z https://multiplemyelomahub.com/about-us monthly 0.7 2026-04-05T04:07:26.181Z https://multiplemyelomahub.com/newsletter monthly 0.7 2026-04-05T04:07:26.181Z https://multiplemyelomahub.com/our-hubs monthly 0.7 2026-04-05T04:07:26.181Z https://multiplemyelomahub.com/contact monthly 0.7 2026-04-05T04:07:26.181Z